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ABSTACT. 
Drug hypersensitivity reactions are unpredictable adverse drug reactions. They represent a 
considerable clinical problem and an obstruction to drug development. Delayed-type drug 
hypersensitivity reactions targeting skin and/or liver are thought to have an immune 
pathogenesis with drug-specific T-cells believed to play an important role in the initiation 
and regulation of tissue injury. The objective of this thesis was to explore the cellular basis 
of three forms of drug hypersensitivity reaction, namely, dapsone hypersensitivity syndrome, 
tolvaptan-induced liver injury and telaprevir-induced severe skin injury. The availability of 
patient and healthy donor PBMC allowed us to (1) clone drug-specific T-cells, (2) explore 
the phenotype of T-cells involved in different forms of hypersensitivity and (3) characterize 
mechanisms of drug antigen presentation.   
Drug hypersensitivity associated with expression of specific HLA alleles has focussed on 
the interaction between parent drug and the HLA with no attention given to reactive 
metabolites. For this reason, we studied HLA-B*13:01-linked dapsone hypersensitivity. 
PBMC from 6 patients and cloned T-cells proliferated and secreted Th1/2/22 cytokines when 
stimulated with dapsone (clones: n=395; 80% CD4+ CXCR3hiCCR4hi, 20% 
CD8+CXCR3hiCCR4hiCCR6hiCCR9hiCCR10hi) and nitroso dapsone (clones: n=399; 78% 
CD4+, 22% CD8+ with same chemokine receptor profile). CD4+ and CD8+ clones were HLA-
class II and class I restricted, respectively, and displayed three patterns of reactivity: 
compound-specific, weakly crossreactive and strongly cross reactive. Nitroso dapsone 
formed dimers in culture and was reduced to dapsone, providing a rationale for the 
crossreactivity. T-cell responses to nitroso dapsone were dependent on the formation of a 
cysteine-modified protein adduct, while dapsone interacted in a labile manner with antigen 
presenting cells. CD8+ clones displayed an HLA-B*13:01-restricted pattern of activation.  
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Telaprevir, a protease inhibitor, was used alongside PEGylated interferon- and ribavirin to 
treat hepatitis C viral infections. The triple regimen proved successful; however, the 
appearance of severe skin reactions alongside competition from newer drugs restricted its 
use. Thus, we used PBMC from healthy donors to investigated whether telaprevir and/or its 
diastereomer, which is generated in humans, activates T-cells. Drug-specific CD4+ and CD8+ 
T-cell clones responsive to telaprevir and the R-diastereomer were generated and 
characterised in terms of phenotype and function. The clones proliferated in a dose-
dependent manner and secreted IFN-γ, IL-13, and granzyme B in response to culture with 
telaprevir and the diastereomer at the same concentrations. The T-cell response was MHC I-
restricted and dependent on the presence of soluble drug. Flow cytometric analysis showed 
that clones expressed chemokine receptors CCR4 (skin homing) and CXCR3 (migration to 
peripheral tissue) and one of three distinct TCR Vβs; TCR Vβ 2, 5.1, or 22. 
Use of the selective arginine vasopressin V2 receptor blocker tolvaptan is associated with 
the development of liver injury. We recruited PBMC from patients with liver injury to 
explore whether tolvaptan and/or its two metabolites DM-4103 and DM-4107 activate T-
cells. Drug-specific T-cells were detected infrequently and only in a small number of 
patients. The majority of clones were stimulated to proliferate and secrete cytokines with the 
metabolite DM-4107 and not the parent drug.   
Collectively, these studies have identified drug and drug metabolite-responsive CD4+ and 
CD8+ T-cells in healthy donors and patients with skin and liver injury. Through the 
generation of T-cell clones we were able to characterize mechanisms of T-cell activation 
with parent compounds and synthetic stable and reactive metabolites. Furthermore, we have 
shown that drugs and reactive metabolites participate in HLA allele linked forms of 
hypersensitivity.   
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1 General introduction: 
In the modern era, the encumbrance from drug problems became equal to disease problems, 
especially with an increase in unexpected cases of severe adverse reactions to drugs. 
Researchers continue to study the mechanisms of drug hypersensitivity, and the reasons why 
certain individuals are susceptible. To do this, researchers explore the interaction between 
the human body (especially the immune system) and drugs. In the long term, these specific 
studies will help to control and prevent more cases of drug hypersensitivity diagnosis.  The 
aim of this introductory section is to explain the basic topics of immunology and 
pharmacology, and some cases the interaction of drugs in the human body. This provides the 
framework for my investigation into the cellular basis of drug hypersensitivity. 
1.1 Immunology. 
Immunology is the study of the body’s defence against infection. This science started when 
Edward Jenner in the 18th century observed that the mild disease of cowpox or vaccinia 
could confer a protection from the fatal version of the disease. Although Jenner introduced 
vaccination, he knew nothing about the causative agent. That became known only in the late 
19th century, when Robert Koch demonstrated that the disease was caused by specific 
microorganisms (Murphy, 2012). 
1.2. Immune system.  
Is a complex network consisting of organs, cells and molecules spread through the body to 
deal with pathogens, viruses, bacteria and parasites (Chaplin, 2010). The main function of 
the immune system is a defence against pathogens and prevention of these pathogens from 
entering the body (Chaplin, 2006). Furthermore, if these pathogens succeed in penetrating 
the external defence of the body, the immune system will determine which type of response 
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will occur. The immune response is classified into two areas based on the nature of the 
pathogen. 
 An intracellular pathogen (invades the body cells to reproduce). 
 An extracellular pathogen (does not enter the inside of host cells)  
1.2.1. Innate and Adaptive Immunity. 
The immune system deals with pathogens in different ways, and this response is determined 
by two components of the immune system: 
 Innate immune response (natural or native immunity or non-adaptive immune 
system). In order for the immune system to respond to an invading pathogen, it needs 
to first identify the threat as “non-self” pathogen. The immune system can distinguish 
and respond to foreign patterns. (Gallucci and Matzinger, 2001, Maverakis et al., 
2015). The innate immune system depends on a limited number of germ line-encoded 
pattern recognition receptors (PRRs), which detect various structures on pathogens, 
these structures are termed pathogen-associated molecular patterns (PAMPs). Toll-
like receptors are the more important receptors among all the PRRs (Suresh and 
Mosser, 2013, Mogensen, 2009). The response is rapid as this system does not have 
to learn /adapt to the variability of the environment. Thus, the innate system responds 
in the same way when exposed to the same pathogen twice.  
 Adaptive immune response (antigen-specific adaptive immune response). It is 
characterised by a slow response, because initial antigen exposure leads to the 
activation of naïve lymphocytes (Danilova, 2006, Koenderman et al., 2014). After 
the initial immune response recedes, a small population of long-lived memory T-cells 
ensure that the host is never infected again by the same pathogen. 
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Both the innate and adaptive immune responses are involved in the secretion of soluble 
proteins, receptor-mediated signalling, and intricate cell-to-cell communication. The two 
components act together to eliminate the pathogen.   
1.2.2 The main components of the innate system are: 
 Physical and chemical barriers:  
These include the skin and its layers including mucous membranes. In addition to being a 
physical barrier, the skin provides low pH. The epithelial tissue can secrete substances to kill 
the pathogen or weaken its activity (Clark et al., 2007). Chemical barriers include 
endogenous chemicals substances such as the hydrolytic enzymes within saliva or the low 
pH of the stomach and the vagina (Parham and Janeway, 2009, Davies, 1997, Kenneth 
Murphy, 2017). 
  Cellular barriers. 
Natural killer cells, macrophages, monocytes, granulocytes (which include neutrophils, 
eosinophils and basophils) and dendritic cells are responsible for combatting the invading 
microorganisms, they can engulf and digest invading pathogens. These cells gulp the 
pathogens by the mechanisms of pinocytosis, receptor mediated endocytosis, and 
phagocytosis. Endocytosis is not cell specific and is perhaps carried out by all cells. 
However, phagocytosis is more cell-specific and results in the ingestion of the particulate as 
well as the whole microorganism (Murphy and Weaver, 2017). 
 Blood proteins. 
 The blood contains members of the complement system and other mediators of 
inflammation (Abbas et al., 2018, David et al., 2013). The complement system plays an 
enormous role in fighting infections through several mechanisms which include: 
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opsonisation, chemotaxis, cell lysis and clumping of antigen-bearing agents (Parham and 
Janeway, 2009). 
 Innate mechanisms. 
 Innate immunity works jointly in inhibiting the invasion of a pathogen or eliminating it, 
preventing infection. Furthermore, innate immunity fights the pathogen until the slower 
adaptive immune response can be activated (Mak et al., 2014). The innate immune system 
recognises pathogens by patterns. These include lipopolysaccharides (LPS), mannose, 
fructose, teichoic acid and N-formyl peptides. These common microbial patterns are called 
Pathogen-Associated Molecular Patterns (PAMPs) (Khan, 2016). In contrast, there are 
special molecules known as Toll like receptors (TLRs) that are expressed by the cells of the 
innate immune system. These receptors are responsible for recognising PAMPs (Alegre et 
al., 2008). Gamma Interferon (IFN-γ) and Tumour Necrosis Factor-alpha (TNF-α) are 
important molecules which are secreted from innate cells such as Natural Killer (NK) Cells. 
They provide a  connection between the innate and adaptive responses (Eagar and Miller, 
2008, Abul K Abbas, 2015). Moreover, the recognition of the pathogen by the Toll-like 
receptors (TLRs) expressed on cells residing close to the infection site leads to secretion of 
chemokines, which are soluble proteins that have a special chemotactic role for immune cells 
(Bachmann et al., 2006).  
1.2.3 Adaptive immune system. 
The adaptive immune system seeks to protect humans from death by pathogens. The major 
difference between the innate immune system and the adaptive immune system is that 
adaptive responses are highly specific and provide long-lasting protection (Alberts et al., 
2002). The adaptive immune response is so called because it adapts to the first exposure to 
foreign antigen. This is often referred to as the primary response to antigens. When the body 
is exposed to the same pathogen, the exposure will reproduce another type of response 
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known as the secondary response. Adaptive immune responses are achieved by the white 
blood cells, which are also called B and T lymphocytes. These mediate cells humoral and 
cellular components of the adaptive immune response, respectively. These mechanisms are 
highly specific and are only activated in the presence of a single antigen (Khan, 2016, 
Alberts, 2002, Kutteh et al., 2014). 
 Humeral mechanisms (antibodies).  
Antibodies (also known as immunoglobulins) are glycoproteins produced by activated B-
cells during the immune response. Before maturation, B-cells express special receptors on 
their surface, which are specific for antigens (immunoglobulin molecules). After the B-cell 
becomes activated, it matures, and then it differentiates into a plasma cell which secretes a 
large number of soluble immunoglobulins into the extracellular fluid. This type of secretory 
molecule in a soluble form is known as an antibody. This antibody will be specific for the 
same antigen that initially activated the B-cell. However, these antibodies will support 
phagocytes and remove the pathogen in a process known as opsonisation. The antibody 
molecule is a Y-shaped structure, consisting of two heavy (H) and two light (L) chains. 
Depending on the function of these structures, it is divided into variable (V) domains which 
are specific to antigens and constant (C) domains which designate effector functions (Male 
et al., 2012). Moreover, there are five general classes of heavy chain C domains, each class 
gives a definition of the immunoglobulin isotypes such as; IgM, IgG, IgA, IgD, and IgE.  
Each one of these isotypes is divided into subclasses. For example, IgG divides into four 
subclasses, IgG1, IgG2, IgG3, and IgG4 (Leder, 1982, Tonegawa, 1983, Schroeder and 
Cavacini, 2010). Each antibody has an individual specificity.  
 Cellular mechanisms.  
The main cells involved in cellular immune responses are B and T lymphocytes. The 
classification and function of B and T lymphocytes are discussed below. 
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1.2.4 The immune system cells. 
All the cellular elements of blood, including the red blood cells, platelets and the white blood 
cells, derive from the same progenitor or precursor cells which are known as hematopoietic 
stem cells, that are found in the bone marrow (Janeway, 2001, Lai and Kondo, 2008). These 
various cell types have specific roles (Khan, 2008), which are explained in the following 
paragraphs. 
1.2.4.1 The lymphoid lineage. 
Lymphocytes are highly discriminatory white blood cells and they are the main defenders in 
adaptive immune response. They achieve their role through two broad types of immune 
responses, either antibody responses or cell-mediated immune responses (Kutteh et al., 2014, 
Alberts et al., 2002). 
1.2.4.1.1 B-cell: 
B lymphocytes constitutes 20-25% of total lymphocytes in the blood (Tomasek et al., 2011). 
B-cells distinguishe the foreign antigen directly by a molecule called the B-cell receptor (Zou 
et al., 2017). B-cell defence against pathogens occurs by various mechanisms, all of these 
mechanisms depend on antibodies. During the development period, the immature B-cells 
express Cluster of Differentiation (CD) 20. These cells have the unique function to generate 
antibodies, which take place after binding to antigens. The B-cell then converts into a plasma 
cell or memory cell depending on the signals it recieves (Hoffman et al., 2016). 
 There are two pathways for B-cell activation (Baumgarth, 2003, Bretscher and Cohn, 
1970); 
 T-independent B-cell activation. 
When the antigens such as bacterial lipopolysaccharides, interact with B-cells, they require 
a second signal which triggers TLRs for full activation. These signals stimulate B-cells to 
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proliferate and produce IgM antibodies. Generally in this activation pathway, the IgM 
antibodies have a low affinity, hence it is an innate immune stereotyped weak response. As 
it is demonstrated in the next section, T-cells play a crucial role in the B-cell activation 
process (Figure 1.1 A) (Baumgarth, 2003, Vos et al., 2000). 
 T-dependent B-cell activation.  
In this pathway, antigens will bind to B-cells with B-cell receptors (BCRs), providing the 1st 
signal to the inactive B-cells. Full activation depends on various other immune cells such as 
antigen presenting cells (APCs), dendritic cells (DCs) or macrophages which present the 
antigen to a special type of T-cell known as Th2 secreting T-cells. These cells secrete 
cytokines such as Interleukin (IL) 4, 5 and 13, which provide the 2nd signal for B-cell 
activation (Fazilleau et al., 2007). After activation the B-cell, will be converted into plasma 
or memory cells. The plasma cells have the potential to produce IgG, IgA and IgE antibodies. 
This process is referred to as class switching because it will change the characteristics of the 
humoral response. These antibodies are highly specific and exert different functions (Allen 
et al., 2007). The role of T-cells in B-cells activation is summarized in  Figure 1.1 B (Male 
et al., 2012). 
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Figure 1-1 (A) T-independent B-cell activation: B-cell stimulation by antigens (bacterial antigens like the 
polysaccharides) directly through antigen mediated cross-linking of BCRs (1st signal). Also, antigens bind with 
TLRs (2nd signal). This activation leads to maturation to the plasma cell, and then these cells will continue to 
produce IgM antibodies. 
(B) T-dependent B-cell activation: B-cells receive a 1st signal from antigen mediated cross-linking of BCRs. 
Furthermore, T-cells are activated by the antigen presenting cells that express CD28, CD40L and secrete Th2 
cytokines (2nd signal). This will lead to B-cell maturation and the generation of plasma cell or memory cells. 
 
1.2.4.1.2 Natural Killer cells (NK cells). 
NK cells are lymphocytes of the innate immune system. NK cells represent 15% of blood 
lymphocytes. NK cells develop in the bone marrow, similar to B-cells. However,  NK cells 
can also develop in lymph nodes and the liver (David et al., 2012, Mandal and Viswanathan, 
2015). NK cells depend on the cytokine IL-15 for their normal development and maintenance 
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(Khan, 2008). Their main biological function is recognising and killing virally-infected and 
neoplastic cells but these cells are also able to respond to protozoa and bacteria (Yokoyama 
et al., 2004, Mandal and Viswanathan, 2015). The NK cells are part of the innate response, 
and respond rapidly. The response is not previous sensitisation. (Vivier et al., 2008, Vivier 
et al., 2011). NK cells mainly express CD56+ (CD3- cells); however, the expression of this 
molecule differs on the individual cells. Among the NK cells in blood, 90% of the NK cells 
are CD56 low (CD56 low). These cells contain granules and are efficient killers. The other 
10% of blood NK cells are CD 56 high. The CD56 high NK cells do not have granules to 
complete their function as killer cells. But they respond to target cells by producing important 
substances in immune response like Th1 cytokines (Rebuli et al., 2018, David et al., 2012, 
Burleson et al., 2015, Van Acker et al., 2017). These cells are not restricted to MHC-
dependent antigen presentation. They are activated by glycolipid antigens that interact with 
CD1d (Godfrey et al., 2005). The CD1d is a major-histocompatibility-complex (MHC) 
class-I-like molecule, which is responsible for presenting self-lipid and non-self-lipid 
antigens to NK cells (Oleinika et al., 2018, Godfrey et al., 2005). To complete the protection 
role NK cells have the ability to detect the foreign cells in non-MHC self-molecules. NK 
cells use inhibitory receptors to measure the loss of constitutively expressed self-molecules 
on the surface of target cells. When NK cells are facing target cells, the NK cells recognise 
missing self-MHC molecule on the target cells (Karre et al., 1986, Bix et al., 1991). That 
means in case of down regulated or absent self-MHC, the NK cells become active and kills 
the target cells due to loss of the inhibitory signals (Medzhitov and Janeway, 2002, Storkus 
et al., 1987, Vivier et al., 2008). The NK cells have important TLRs (Lemaitre et al., 1996), 
which upon activation will encourage NK cells to secrete IFN-γ and will enhance 
cytotoxicity (Vivier et al., 2008, Souza-Fonseca-Guimaraes et al., 2012). This provides a 
strong link between the innate and adaptive responses, because IFN-γ works on the activation 
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of the T-box transcription factor (T-bet) which is an important factor to T-cell development 
(Larosa and Orange, 2008). 
1.2.4.1.3 T lymphocytes. 
T-cells play a crucial role in the response to pathogens that takes place inside host tissues. 
They constitute 75-80% of the total lymphocytes in the blood (Tomasek et al., 2011). The 
development process for T-cells starts in the fetal liver during the period of early 
embryogenesis and later continues within a specialised primary lymphoid organ, the thymus 
(Swainson et al., 2013). T-cells are generated in the thymus; however, their precursors are 
found in the bone marrow. The cells in this stage do not mature fully and they do not express 
CD4 or CD8 receptors (double negative T-cells) (Murphy and Weaver, 2017, Gargani and 
Kitchen, 2012). T-cells pass several stages in the thymus to become mature cells with the 
ability to differentiate between self and non-self antigens. This process in the thymus will 
select the TCR that can bind to major histocompatibility complex (MHC) class I or class II 
proteins encoded by the MHC group of genes are found on the surfaces of cells that help the 
immune system recognise foreign substances. The MHC molecules are responsible for 
presenting antigens to T-cells (Murphy, 2012). The cells, which do not bind to the MHC-
antigen complexes weakly, die by apoptosis so the rest of the cells will undergo positive 
selection. The positive selection indicates that the T-cell has the ability to interact with self-
peptide-MHC complexes expressed by the cortical epithelial cells of the thymus (Figure1.2 
A) (Harrington, 2019, Male et al., 2012).  
In the same time, cells that respond to the MHC class II will keep the CD4 receptor and lose 
the type CD8 receptor so turn into T helper cells. The cells which respond to the MHC class 
I receptor will keep the CD8 receptor and lose the CD4 receptors and consequently become 
cytotoxic T-cells. After this stage, they will suffer the process of negative selection, in which 
the cells that bind strongly to the MHC/self-peptide will undergo apoptosis. This means that 
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an immature T-cell clone encoding a self-reactive T-cell is eliminated from the host (Figure 
1.2 B) (Rhoades and Bell, 2009, Harrington, 2019). The cells are now ready to leave the 
thymus into the bloodstream. The product cells are considered to be immunologically naïve 
T-cells (Th0). Naïve T-cells are structurally mature but different from the activated or 
memory T-cells. That difference is because the effector and memory T-cells have previously 
encountered specific antigens (Punt, 2013, Berard and Tough, 2002). Naïve T-cells are 
characterized by the expression of L-selectin (CD62L), the absence of the markers of 
activation CD25, CD44 or CD69; and the absence of the memory CD45RO marker (De Rosa 
et al., 2001, Berard and Tough, 2002). T-cells are classified into two broad subtypes 
according to the structure of the T-cell receptor (TCR) molecules. 
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Figure 1-2 CD4 T-cell maturation in the thymus (positive and negative selection). A. positive selection for 
T lymphocytes bound weakly to self-peptide-MHC complexes. If a T-cell has the ability to bind to MHC class 
I, it will become a CD8+ T-cell, while cells that bind to MHC class II will become CD4+ T-cells. Apoptosis 
occurrs with the unbound cells. B. negative selection, cells that bind strongly to the self-peptide-MHC will 
undergo apoptosis. This means that an immature T-cell clone encoding a self-reactive T-cell is eliminated from 
the host. Only the T-cells that have not recognised the self-peptide will survive. 
 
 1.2.4.1.3.1 TCR-1 (γδ cells).  
TCR-1 (γδ cells) TCR surface membrane molecules are composed of γ and δ polypeptides. 
These cells constitute 5% of the T-cells in general, and 10% of intraepithelial T-cells. They 
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are not limited to binding to antigens presented by the MHC molecules and their role in the 
immune response is less well defined compared to that of the αβ cells discussed below 
(Parham and Janeway, 2009, Hayday and Pao, 1998). The γδ T-cells recognize target cells 
in an MHC-independent model, harmonic with a lack of surface CD4/CD8 co-receptor 
expression (Davey et al., 2017). Functional and molecular analyses show that following 
infection with various pathogens, γδ T-cells respond earlier than αβ T-cells, also they emerge 
late, after the pathogen numbers start to decline, which means these cells may be involved 
in both establishing and coordinating inflammatory response (Chien et al., 2014). The γδ T-
cells have been identified as the major initial producers of IL-17, and γδ T-cells are also early 
sources of IFN-γ and TNF-α (Chien et al., 2014, Cai et al., 2011, Stark et al., 2005, Zhao et 
al., 2018). The γδ T-cells activation model still is not fully defined (Chien et al., 2014). 
 1.2.4.1.3.2 TCR-2 (αβ cells). 
The TCR consists of α and β polypeptides and constitutes 95% of T-cells. They are sub-
classified into two groups of cells: Th (T-helper cells) that are CD4+ and Tc (cytotoxic T-
cells) that are CD8+. Th cells detect the antigens that are expressed on MHC class II, while 
the Tc cells detect antigens expressed on MHC class I (Murphy, 2012). Th cells can be 
classified more through subdivision into Th1, Th2, Th9, Th17, Th22, T follicular helper cells 
(Tfh) and T regulatory (Tregs). These cell populations are classified according to the 
cytokines they secrete (Figure 1.3) (Murphy, 2012, Eyerich et al., 2009, Brownlie and 
Zamoyska, 2013).  
 Th 1 cell. 
Th1 cells play an important role in the immune response against bacteria enclosed inside 
macrophages. Antigen uptake results in activation of macrophages and an increase in their 
intracellular killing capacity. Intracellular pathogens stimulate DCs and macrophages to 
produce cytokines favouring Th1 development, which are derived from an antigen-activated 
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CD4+ T-cells, such as IFN-γ and IL-12. The prevalence of certain type of APCs plays a 
crucial role in developing specific types of Th cells and can influence whether a shift from 
the Th1 to the Th2 phenotype occurs. Macrophages express antigen most efficiently to Th1 
cells and this cell specific expression will produce cytokines stimulating Th1 proliferation 
and increasing  the dominance of this subset (Mak and Saunders, 2006). Th1 cells secrete 
IL-2, IL-3, IFN-γ, TNF-α, TNF-β and GM-CSF. Th1 cells play an important role in 
inflammation, cytotoxicity and delayed-type hypersensitivity (Murphy, 2012, Abbas et al., 
2017). 
 Th2 cells: 
The infection with extracellular pathogens most often promotes the development of Th2 
cells. Antigen-specific B cells play a more important role in antigen presentation to Th2 
cells. IL-4 promotes Th2 proliferation and development (Mak and Saunders, 2006). Th2 cells 
secrete cytokines such as IL-4, IL-5, IL-6, IL-10, IL-13, TNF-β and GM-CSF when they are 
activated. Moreover, these cells support the activation of B-cells and encourage B-cells to 
generate different types of antibodies, such as IgE and some subclasses of IgG antibodies. 
Eyerich et al confirmed that Th2 cells can be found in the skin of patients with atopic eczema, 
psoriasis, or allergic contact dermatitis (ACD) (Eyerich et al., 2009). Thus, Th2 are also 
implicated in the pathogenesis of certain skin diseases (Duhen et al., 2009, Kagami et al., 
2010).  
 Th17. 
In the 1990s the cytokine IL-17 was detected and new cloned forms of a CD4+ T-cell was 
added to this family. The new member of helper T-cells was named Th17 cells (Tesmer et 
al., 2008, Sutton et al., 2009). When the DCs secrete IL-23 in response to antigens, IL-23 
supports the conversion of CD4+ T-cells to Th17 cells (Zhou et al., 2007). Moreover, it has 
been shown that IL-6, TGF-β and IL-1 are important cytokines in Th17 differentiation (Zhou 
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et al., 2007, Kurts, 2008). There are six subtypes of the IL-17 cytokines (A-F), however only 
IL-17A and IL-17F are secreted by Th17 cells (Wu et al., 2018). Th17 cells also produce 
other cytokines including IL-16, IL-17, IL-21, IL-22, IL-26 and TNF-α, in response to 
antigens (Eagar and Miller, 2008, Abul K Abbas, 2015, Shuttleworth et al., 2011). Th17 cells 
have been divided into two subtypes depending upon the cytokine milieu present during the 
differentiation process, pathogenic Th17 (that have been activated in the presence of IL-1β 
and IL-23) (Singh et al., 2013, Wu et al., 2018), and non-pathogenic Th17 cells (activated in 
the presence of TGF-β and IL-6) (Lee et al., 2012). Th17 cells participate in various 
autoimmune diseases such as systemic lupus erythematosus and the cytokine itself is defined 
as proinflammatory (Bettelli et al., 2007, Koshy et al., 2002, Kurts, 2008). 
 Th22. 
Th22 cells develop from naïve CD4+ T-cells under specific conditions, which are determined 
by lineage-specific cytokines. Th22 cells are identified by the production of interleukin IL-
22 (Jia and Wu, 2014). Naïve CD4+ T-cells are converted to a Th22 cell phenotype in the 
presence of IL-6 and TNF-α, and this process is promoted by IL-1β (Duhen et al., 2009). 
Th22 cells secrete IL-22 and TNF-α, but not IFN-γ, IL-4, or IL-17 (Th1, Th2 and Th17 
markers, respectively) (Eyerich et al., 2009, Jia and Wu, 2014). These cells have a profile 
that is clearly different from that of Th1, Th2, and Th17 cells (Eyerich et al., 2009). They 
express functional chemokine receptors that help them to reside in the skin. These include 
CCR4, CCR6, and CCR10 indicating their crucial roles in skin diseases (Duhen et al., 2009). 
Th22 cells are implicated in skin diseases such as psoriasis, atopic eczema, and allergic 
contact dermatitis. Moreover, Th22 cells are associated with different diseases, for example 
infections, autoimmune diseases, hepatitis and pancreatitis (Jia and Wu, 2014). 
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 T follicular helper cells (Tfh). 
T follicular helper cells (Tfh) are specific subset of CD4+ T-cells. These cells were first 
identified in the human tonsils (Breitfeld et al., 2000). Tfh cells are found in secondary 
lymphoid organs such as tonsils, spleen and lymph nodes, however, they can also be found 
in the blood circulation. Tfh cell differentiation is a very complex process that starts when 
DC prime naïve CD4+ T-cells. Cytokines such as IL-6/IL-21 increase the ability for Tfh 
differentiation (Baumjohann et al., 2013).The transcription factor Bcl6 (B-Cell Lymphoma 
6) is the master regulator for Tfh cell differentiation and development (Johnston et al., 2009, 
Nurieva et al., 2009, Crotty, 2014). Bcl6 induces CXCR5 molecules, which are a 
characteristic feature of Tfh cells (Choi et al., 2011). The chemokine receptor CXCR5 (B-
cell follicle homing receptor) is a transmembrane protein that binds to the chemokine 
CXCL13 (Schaerli et al., 2000, Kim et al., 2001b, Fazilleau et al., 2009, Choi et al., 2011, 
Good et al., 2017). Tfh cells provide help to B-cells for germinal centre reactions. This 
reaction produces high-affinity antibodies through secretion of effector cytokines, such as 
IL-21 and IL-4, and through cell-to-cell interactions. Furthermore, Tfh cells support the 
generation of memory B-cells and long-lived plasma cells (Baumjohann et al., 2013, Crotty, 
2011, King, 2009, McHeyzer-Williams et al., 2011, Jandl et al., 2017). 
 Th9. 
Th 9 cells are a group of CD4+ helper T-cells produced after activation of naïve CD4+ T-
cells. The presence of TGF-beta and IL-4 are very important for this process. Th9 cells are 
characterised by secretion IL-9, IL-10, IL-21, CCL17, and CCL22, but not IL-4, IL-5, or IL-
13 (Wilson and Wynn, 2009). Th9 cells play an important role in mucosal immunogenicity 
especially with allergic diseases such as asthma-induced allergic responses, airway 
inflammation, and allergic rhinitis through the secretion IL-9 (Neurath and Finotto, 2016). 
Th9 cells also play an important role in helminthic infections. They may produce harmful 
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effects due to development of chronic allergic inflammation and generaion of autoimmune 
disease (Kaplan et al., 2015, Matusiewicz et al., 2018). 
 Regulatory cells (Treg cells).  
Treg cells are known as CD4+ T-cells with a liability to suppress potentially unwholesome 
activities of Th cells. Tregs cells are classified into two types; naturally occurring Treg (n 
Treg), which are generated in the thymus and induced Treg (I Treg) cells, which are created 
in the periphery through the action of TGFβ on naïve CD4+ T-cells (Yadav et al., 2012, Hori 
et al., 2003, Fontenot et al., 2003). Both nTregs and iTregs work through inhibition of the 
other T-cells. They express the cell surface receptor CD25 which is also found in activated 
T-cells (Francisco et al., 2009). Treg cells are also characterised by the unique surface 
molecules such as CD62L and specific CD45 isoforms. They also express the Forkhead box 
P3 (Foxp3) transcription factor (Sakaguchi et al., 1995, Herbelin et al., 1998). Foxp3 is also 
called ‘master regulator’ or ‘lineage-specification factor’ which is responsible for the 
development of Treg cells (Hori et al., 2003, Fontenot et al., 2003). Tregs act either directly 
or indirectly to produce a regulatory and balanced environment, their action extends to 
various types of cells such as NK, NKT, B-cells, monocytes and dendritic cells. This includes 
the production of immunosuppressive cytokines (IL-10, TGF-β, IL-35), and interaction with 
costimulatory molecules on APCs (such as DCs) through cytotoxic T-lymphocytes 
associated protein-4 (CTLA4) (co-inhibitory molecule) (Thornton and Shevach, 1998, 
Schmidt et al., 2012).  
 Memory T-Cells. 
Immunological memory is a fundamental characteristic of adaptive immunity and the main 
aim of vaccination strategies (Chang et al., 2014). Naïve T-cells, which are CD45RO- when 
activated divide, multiply and express molecules especially cytokine proteins that will help 
in fighting pathogens. These cells have the ability to migrate to different tissues and convert 
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to memory T-cells. Long-lived memory cells are distinguished by expression of the 
characteristic receptor CD45RO (Murphy, 2012). Memory T-cells mainly aggregate in the 
memory T-cell pool (Kaech and Cui, 2012). IL-7 and IL-15 are important for memory T-cell 
survival (Surh and Sprent, 2008, Mazzucchelli and Durum, 2007, Raeber Miro et al., 2018). 
Memory T-cells are heterogeneous in phenotype and functional characteristics such as 
expression of surface-receptor molecules, location and trafficking properties (Willinger et 
al., 2005, Sallusto et al., 1999, Hamann et al., 1997). To survive memory T-cells are required 
to interact with self-peptides to maintain proliferation. Furthermore, memory T-cells are 
divided into two types; the central and the effector memory T-cells. Central memory T-cells 
express CCR7 and secrete IL-2, they remain in peripheral lymphoid tissues after re-
stimulation. In contrast, effector memory T-cells settle down in tissues; they lack ability to  
express CCR7 but they express CCR3 and CCR5 (Murphy, 2012). 
 CD8+ cytotoxic T lymphocytes (CD8+ CTLs). 
CD8+ CTLs react with antigens presented on MHC-I expressed on all nucleated cells. CD8+ 
T-cells are also subdivided into Tc1, Tc2, Tc17, regulatory, and memory cells (Betts and 
Kemeny, 2009). This classification depends on patterns of cytokine production. CD8+ CTLs 
are very specific towards a variety of antigens. Tc1 cells migrate to sites of inflammation 
and they are involved in viral clearance via general cytotoxic abilities and secretion of IFN-
γ, IL-2, and TNF-β. While Tc2 cells are characterized by secretion of the cytokines IL-4, IL-
5, IL-10, and TGF-β. The Tc2 cells are associated with other forms of pathologic conditions 
including various form of autoimmune disease (Burleson et al., 2015, Iezzi et al., 2006, 
Flaherty, 2012a). Tc17 cells produce IL-17 that participates in various conditions, such as 
infections, cancers, and autoimmune inflammation (Yen et al., 2009). 
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Figure 1-3 CD4+ T-cell differentiation. In the peripheral bloodstream when naïve cells encounter specific 
antigens, they will convert into several mature types of T-cell depending on stimulation signals and the cytokine 
environment. Each activated cell secretes specific types of cytokines.   
 
 
Chapter one                                                                        Introduction and Literature review 
21 
 
1.2.4.2 Granulocytes. 
1.2.4.2.1 Neutrophils. 
Neutrophils (neutrophilic polymorphonuclear leukocytes) are one of the most important 
white blood cells in the human peripheral blood. They are characterised by a multi-lobed 
nucleus and neutrophilic granules. They exert an important function the engulfment and 
killing of extracellular pathogens (Frederick, 2000). Neutrophils are the most widespread 
leukocytes in the bloodstream. In normal conditions they constitute more than 50% of all 
bloodstream leukocytes. The percentage of neutrophils in the bloodstream will increase to 
80% or more during bacterial infection (Shah et al., 2017). Neutrophils play an influential 
role in inflammatory reactions, and elimination of microorganisms and damaged cells. 
Furthermore, neutrophils perform an important role in the generation of inflammatory agents 
(chemotactic peptides, cytokines, leukotrienes and other lipid mediators) (Roos, 1998). 
Neutrophil cytoplasm is characterised by the granules which contain substances like 
myeloperoxidase, defensins, cathepsin-G and bactericidal/permeability-increasing protein, 
lactoferrin, cathelicidin and gelatinase. Neutrophils have the ability to regulate the function 
of monocytes and other lymphoid cells by secreting various types of cytokines such as IL-
1β, IL-1ra, IL-8, TGF-β, and TNF-α (Khan, 2008). 
1.2.4.2.2 Eosinophils. 
Eosinophils are granulocytic leukocytes generated like other blood cells in bone marrow. 
They are important cells in innate immunity. They comprise 2% of the blood leukocytes in 
non-atopic individuals. Eosinophils participate in the pathogenesis of multiple inflammatory 
processes, including parasitic helminth infections and allergic diseases. Eosinophils also 
have phagocytotic ability and they kill ingested microorganisms (Rothenberg, 1998, Gleich 
and Loegering, 1984). They have granules that contain different types of enzymes and a toxic 
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protein. These granules are released during the activation of eosinophils (Logan et al., 2003). 
Eosinophils contribute to the inflammatory process by releasing a group of proinflammatory 
cytokines including TGF-α/β, IL-2, IL-4, IL-5, IL-10, IL-12, IL-13, IL-16 and IL-18, and 
they also produce chemokines such as RANTES and eotaxin-1 (Rothenberg and Hogan, 
2006, Kita, 1996, Lim et al., 1995, Moller et al., 1996). Chemokines affect leukocytes 
through their specific selective receptors and are now known to attract material involved in 
leukocyte maturation, trafficking, and homing of cells. RANTES and eotaxin are very 
important chemoattractants for eosinophils. Eosinophils play a critical role in the process of 
allergic inflammation (Graziano et al., 1999, Khan, 2008). 
1.2.4.2.3 Basophils and Mast cells. 
Paul Ehrlich discovered and detected the basophils in 1879 based on their individual shape 
(Falcone et al., 2000). Basophils represent very small population of the white blood cells in 
the blood stream. They constitute 0.01- 0.3% of all leukocytes. They have large dark purple 
granules and a bilobed nucleus (Cawley and Hayhoe, 1973). They develop in bone marrow 
similar to mast cells but they generate from different precursor cells (Khan, 2008). Basophil 
maturation occurs in the bone marrow. They then circulate in the peripheral blood before 
moving to specific tissues. In contrast, mature mast cells take another path. They do not 
circulate in the blood but their maturation and differentiation processes occur in vascularised 
tissues (Galli, 1999). Basophils are non-phagocytic granulocytes. They exert their function 
by releasing pharmacologically active substances from their granules (Goldsby and Richard, 
2003). Both mast cells and basophils release heparin. They also both release histamine and 
cytokines. They play an important role in mediating type I hypersensitivity reactions due to 
the IgE antibody that is attached to their cell membrane. The IgE antibody will stimulate the 
release of large quantities of mediators which yield local inflammatory process that result in 
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vascular and tissue reactions and the various allergic manifestations (Bain, 2017, 
Wedemeyer et al., 2000).  
1.2.4.3 Antigen presenting cells. 
1.2.4.3.1 Macrophages.  
Macrophages are a family of mononuclear leukocytes. Macrophages are widely distributed 
throughout most tissues. Monocytes are differentiated into either tissue macrophages or DCs 
and the process is dependent on the local cytokine milieu and inflammatory stimuli (Yang et 
al., 2014, Tacke et al., 2007). Monocytes differentiate to macrophages in the intestine and 
the dermis during acute inflammation (Das et al., 2015). Macrophages are widely distributed 
throughout most tissues. The main role of the macrophage is the scavenging of dying cells, 
pathogens, and molecules through phagocytosis and endocytosis (Toews, 2009). They are 
large cells that differentiate from circulating monocytes after they enter tissues. There are 
several steps for generation and differentiation of macrophages. The interleukin-3 (IL-3), 
granulocyte-macrophage colony stimulating factor (GM-CSF), and macrophage colony 
stimulating factor (M-CSF) bind to specific receptors on progenitor cells to activate a 
sequence of differentiation steps essential in the monocyte development. Cytokines secreted 
from inflammatory cells during acute inflammatory responses play a vital role in regulating 
macrophage differentiation. Interleukin-1 (IL-1) and tumor necrosis factor (TNF-α) promote 
M-CSF and GM-CSF production (Kinne et al., 2009, Toews, 2009, Cole et al., 2014). 
Macrophages kill invading microorganisms by generating a respiratory burst and through 
activation of proteolytic enzymes. Furthermore, macrophages secrete a group of cytokines 
that attract leukocytes to the area of inflammation and trigger an acute inflammatory 
response. If macrophages receive inflammatory stimuli, they secrete cytokines such TNF, 
IL-1, IL-6, IL-8, and IL-12. Additionally, macrophages secrete chemokines, leukotrienes, 
prostaglandins, and complement. All of these molecules work together to induce increased 
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vascular permeability and recruitment of inflammatory cells (Arango Duque and 
Descoteaux, 2014). The most significant role of macrophages is that they act as antigen 
presenting cells; presenting antigens to T-cells. Thus, the macrophage is considered a bridge 
between the innate and adaptive immunity (Rhoades and Bell, 2013).  
1.2.4.3.2 Dendritic cells. 
Dendritic cells (DCs) are involved in both the priming of adaptive immune responses and 
induction of self-tolerance (Steinman, 1991, Steinman and Nussenzweig, 2002). They are 
distributed in small numbers in tissues that encounter various antigenic stimuli like the skin, 
the lining of the nose, the lungs and the stomach. DCs collect antigens from various tissues 
and transfer them to the lymph nodes. Following activation, the DCs initiate acquired 
immune responses through an interaction with the B and T-cells. The DCs can be classified 
into myeloid DCs and lymphoid DCs and they look similar to the plasma cells. These cells 
are also called plasmacytoid DCs (Murphy, 2012).  Myeloid dendritic cells (MDCs) secrete 
IL-12 and are divided into two subsets; MDC1 and MDC2. MDC1 cells play a role in 
stimulating T-cells, while the MDC2 cells have a role in fighting wound infections. 
Lymphoid dendritic produce large amounts of IFN-α (Khan, 2008). 
1.2.5 Antigen presentation and presenters. 
The major histocompatibility complex (MHC) is a set of cell surface proteins essential for 
presenting antigens on the cell surface of APCs for recognition by T-cells. They perform this 
role through several biochemical modifications (Neefjes et al., 2011). The binding between 
TCRs and MHC molecules depends on the specific molecules on the T-cell surface known 
as cluster of differentiation (CD) CD4+, and CD8+. If the T-cell is a CD4+ cell it will 
recognise antigens expressed on the MHC class II molecules, but if the T-cell is a CD8+ cell, 
it will recognise antigens expressed on the MHC class I molecules. Furthermore, there are a 
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minority of T-cells that have gamma and delta receptors. They express alpha and beta chains, 
but they do not have CD4 or CD8. These cells require more than one signal to be activated 
(Dasgupta and Wahed, 2014). (See section 1.2.4.1.3.2). 
1.2.5.1 MHC molecules structure. (Antigen presenters). 
 MHC class I molecule.   
MHC class I molecules are found on the all nucleated cells and express protein fragments of 
cytosolic and nuclear origin for cytotoxic CD8+ T-cells. These antigens are degraded by 
cytosolic and nuclear proteasomes. MHC I is composed of a single polypeptide heavy α-
chain of the binding platform which requires support by β-2-microglobulin protein. The 
heavy α-chain consists of 3 domains, α1, α2 and α3 (Figure 1.4 A). The long alpha chain 
possesses the entire peptide binding groove (Neefjes et al., 2011, Mosaad, 2015, Cresswell, 
2012, Wieczorek et al., 2017, Coico and Sunshine, 2015). The long alpha chain of the MHC 
I is encoded by three genes on a specific region of chromosome 6, the genes are distinct but 
adjacent and are nominated A, B, and C genes. Moreover, β-2 microglobulin is encoded from 
a single gene on chromosome 15 (Figure 1.5) (Dasgupta and Wahed, 2014, Choo, 2007). ) 
(See section 1.5.1). The position of HLA-A, B, and C genes are towards the telomere on 
chromosome 6  (Toews, 2009). 
 MHC class II molecule.  
The expression by the MHC class II molecules differs from class I, the MHC II is found on 
APCs only such as dendritic cells, macrophages, and B-cells. MHC II bound peptide antigens 
are recognised by CD4+ T-cells. This molecule expresses peptides derived from the 
degradation of extracellular proteins after the APCs have internalised them. The MHC class 
II molecule consist of two separate polypeptide chains of equivalent length. These two chains 
known as α and β dimerise, and when they bind together form a peptide binding groove, α1 
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pairs with β1 on the exterior surface α2 pairs with β2 on the interior surface(Choo, 2007, 
Wieczorek et al., 2017, Coico and Sunshine, 2015). Furthermore, MHC II differs from MHC 
I, because both α and β chains have cytoplasmic tails (Figure 1.4 B) (Coico and Sunshine, 
2015, Choo, 2007). The map of MHC genes is constantly being revised as new information 
is added (see figure 1.5). The MHC II is encoded by three distinct but adjacent genetic 
clusters on the specific region of chromosome 6. These groups of genes are called DP, DQ, 
and DR (Figure 1.5) (Coico and Sunshine, 2015). (See section 1.5.1). The position of HLA-
D is towards the centromere. In sequence, they are separated from the class I genes by the 
complement protein genes. Each part of these regions is known to contain multiple genes 
(Toews, 2009).  
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Figure 1-4 Figure MHC class I and II structures. A. MHC class I has heavy α-chain consisting of 3 
domains, α1, α2 and α3. These bind with Beta-2 microglobulin and this expresses one cytoplasmic tail. MHC 
I presents antigen to CD8+ T-cells. B. MHC class II consists of two separate polypeptide chains of equivalent 
length. α and β chains dimerise; α1 pairs with β1 on the exterior, and α2 pairs with β2 on the interior. This 
class expresses two cytoplasmic tails. MHC II presents  the antigens to CD4+ T-cells. 
 
********************************************************************************** 
          
Figure 1-5 Human HLA on the chromosome 6, MHC II is encoded by three distinct genetic clusters HLA-
DR, DP, and DQ. MHC class I is encoded by A, B and C genes. Class III cluster of genes is encoded by TNF 
and C' (complement genes), which is primarily influential in inflammatory factors, but it is not involved in 
antigen presentation. 
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1.2.5.2 MHC class I antigen presentation. 
The MHC class I molecules express peptide fragments of cytosolic and nuclear 
(intracellular) proteins such as viral proteins, at the cell surface. These intracellular proteins 
are degraded by cytosolic and nuclear proteasomes. The derived peptides are translocated 
into the endoplasmic reticulum (ER) by carrier or transporter associated with antigen 
presentation (TAP) to the MHC class I molecules. In the ER, the MHC class I molecules are 
not stable until they bind to peptides deep in the MHC class I peptide-binding groove. The 
binding groove mainly accommodates peptides of 8-9 amino acids (Neefjes et al., 2011, 
Mosaad, 2015, Cresswell, 2012). MHC class I-peptide complexes will liberate from the ER 
and then the MHC I-peptide complex traffics through the Golgi apparatus to the plasma 
membrane to express the processed peptide on the cell surface for CD8+ T-cells (Figure 1.6) 
(Neefjes et al., 2011, Zarling et al., 2003, Hewitt, 2003). 
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1.2.5.2 MHC class II antigen presentation. 
Peptide presentation by MHC class II molecules differs from MHC class I, because of the 
site and mechanism of processing. MHC class II binding only occurs in professional APCs, 
such as DCs, macrophages and B cells. The α- and β-chains of MHC class II are composed 
in the ER, and confederate with the invariant chain (Ii). This complex called Ii-MHC class 
II complex, leaves the ER, travels through the Golgi apparatus, where it will be transported 
to a late endosomal compartment. In this loci, Ii is digested due to the environment which is 
proteases rich and acidic. After digestion of Ii peptide, the remaining structure is MHC class 
II-CLIP. CLIP binds to a specific place in the peptide-binding groove of the MHC class II 
heterodimer. MHC class II molecules utilise HLA-DM to simplify the exchange of the CLIP 
fragment to a specific peptide derived from a protein degraded in endosomes or lysosomes. 
The MHC class II molecules then move to the plasma membrane to present their peptide 
cargo to CD4+ T-cells (Figure 1.7) (Denzin Lisa et al., 2005, Neefjes et al., 2011, 
Guermonprez et al., 2002). 
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Figure 1-6 MHC class I presentation. The endogenous peptides enter the proteasome and are degraded by 
proteases. They are derived from the ER by the Transporter associated with Antigen presenter (TAP), where 
they bind to MHC I. This complex then moves to the Golgi apparatus and finally to the cytoplasmic membrane 
to encounter CD8+T-cells. 
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Figure 1-7 MHC class II presentation. The exogenous peptides enter the cell and are degraded by protease 
enzymes. They then move to bind with MHC II in the endosomal compartment, where the exchange of the 
CLIP fragment with a specific peptide occurs, with the help of HLA-DM. Then, the MHC II-peptide complex 
moves to the cytoplasmic membrane to express the antigen to CD4+ T-cells. 
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1.2.6 The role of the T-cell receptor (TCR) in mediating an immune 
response. 
 1.2.6.1 TCR structure and diversity. 
The T-cell receptor (TCR) is a dimeric (αβ or γδ) and highly variable membrane protein 
existing on the surface of the T-cells. It is responsible for the discrimination of the antigen-
major histocompatibility complexes. A binding interaction may trigger an immune response 
(Lee, 2016, Stauss and Xue, 2014, Bassing et al., 2002). Each chain of the TCR consists of 
two extracellular domains: a Variable (V) region and a Constant (C) region. These two parts 
belong to the immunoglobulin superfamily. A transmembrane/cell membrane-spanning 
region binds to the constant region and expresses short cytoplasmic tail at the C-terminal end 
(Figure 1.8). The pairs of α/β or γ/δ evolve from the somatic DNA recombinations of 
germline gene segments through T-cell development. TCR genes for α and δ are on 
chromosome 14 while β chain and γ chain gene loci are on chromosome 7 (Boehm and 
Rabbitts, 1989). The capability of the TCR to bind with an enormous number of antigens 
both foreign and self is due to the antigen recognition site (or variable region). The region is 
created by a unique process of somatic recombination.  The presence of a pool of multiple 
V(D)J gene segments in the DNA produces a highly diverse TCR composition. Moreover, 
the addition or removal of genes is important for T-cell antigen recognition (Setton et al., 
2016, Lee, 2016, Freeman et al., 2009). Site-specific V(D)J recombination subgenic 
elements are classified as V (Variable), D (diversity), and J (joining) families (Schwarz and 
Bartram, 1996). Genes encoded for variable domain of both the TCR α-chain and β-chain 
are characterised by three hypervariable or complementarity regions (CDRs); (CDR1, 2, and 
3). CDR3 is the main CDR in charge of recognising the peptide antigen. However, CDR1 of 
the alpha chain has also been shown to interact with the N-terminal site of the antigenic 
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peptide, while, the same CDR1 of the beta chain interacts with the C-terminal part of the 
peptide. CDR2 is believed to interact with the MHC molecule (Figure 1.8) (Stauss and Xue, 
2014). TCRs are very similar to immunoglobulins in many aspects, but the TCRs are stably 
expressed on the cell surface and are  never secreted (David et al., 2012). 
 
Figure 1-8 T-cells receptor (TCR) with CD3 and CD4/CD8 structures. The T-cell receptor consists of α 
and β chains in αβ T-cells, and it is composed of γ and δ chains in γδ T-cells. Antigen binding site is at the end 
of the variable region, which has the complementarity determining regions (CDRs). The CD3 receptor is 
composed of two couples of chains ε and γ, ε and δ. Further, there are two ζ chains. CD4 molecule in CD4+ T-
cell (responsible for recognising the antigens on MHC II) and CD8 molecules in CD8+ T-cell (responsible for 
recognising the antigens on MHC I) are attached to p56lck, which is a tyrosine kinase and it participates in T-
cell signalling. 
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1.2.6.2 The CD3 receptor complex. 
The T-cell receptor-CD3 complex (TCR-CD3) play an essential role in the differentiation, 
survival, and function of T-cells. The CD3 complex of polypeptides is expressed on the T-
cell surface (Call et al., 2002). CD3 is composed of six different chains responsible for ligand 
recognition, (Ley et al., 1989). These chains form two heterodimers CD3γε, CD3δε, as well 
as the CD3ζζ homodimers (Figure 1.8) (Bettini et al., 2017). A T‐cell response to foreign 
antigen is initiated by the binding of the T‐cell receptor (TCR)-CD3 complex to a foreign 
peptide express to an MHC molecule on an antigen‐presenting cell. The signal deriving from 
this binding is transmitted into the cytosol to stimulate many signalling proteins. The 
question here is how the signals are transferred from outside the cell to inside? The 
cytoplasmic tail of the CD3 complex contains an immunoreceptor tyrosine‐based activation 
motif; CD3ε, CDδ, and CD3γ each contain one immunoreceptor tyrosine‐based activation 
motif (ITAM) and that of CD3ζ contains three ITAMs, as shawn in figure 1.8. Therefore, 
TCR-CD3 complex comprises 10 ITAMs. The binding betweenTCR‐CD3 complex and an 
antigen leads to phosphorylation of the ITAM residues, this process will produce recruitment 
and activation of multiple downstream signalling molecules including enzymes and adaptor 
proteins (Ngoenkam et al., 2017).  
1.2.6.3 Stabilizing molecules. 
The TCR binds to the MHC molecules with low affinity. Therefore, additional molecules 
are necessary to support the complex. CD4 and CD8 both play a role in stabilizing the T-cell 
interaction the APCs. These stabilising molecules have a transmembrane region which binds 
to APCs and a cytoplasmic tail. CD4 binds to the MHC class II molecule and CD8 to the 
MHC class I molecule. The tail of CD4 and CD8 plays a role in signal transduction also to 
the nucleus by phosphorylation of serine residues in the cytoplasmic tail. This process will 
trigger p56lck kinase activation (Figure1.8) (Flaherty, 2012b, Artyomov et al., 2010). CD4 
Chapter one                                                                        Introduction and Literature review 
35 
 
is a single-chain consisting of four immunoglobulin-like domains (D1, D2, D3, and D4) 
(Figure 1.8). The binding between CD4 and MHC II molecules occurs through the lateral 
face of the first domain, D1 binds to a site on the β2 domain of the MHC class II molecule.  
This connection is away from the site where the T-cell receptor binds to MHC-peptide 
complex. The binding of the CD4 molecule to the T-cell receptor enhances the transfer of 
signalling complexes.  CD4 interacts strongly with a cytoplasmic tyrosine kinase called Lck. 
The tyrosine kinase Lck molecule associates most strongly to the cytoplasmic tails of CD4 
and CD8 coreceptors. Lck plays crucial role in signal transduction and activation of the T-
cell receptor. When CD4 molecule and the T-cell receptor simultaneously bind to the same 
MHC class II-peptide complex, T-cell sensitivity to this antigen is increased and T-cells 
could requires 100-fold less antigen for activation. The CD8 molecule consists of an α and a 
β chain, and each one contains a single immunoglobulin-like domain connecting to the cell 
membrane by a segment of extended polypeptide chain. CD8 binds to the α3 domain of an 
MHC class I molecule (Figure 1.8). CD8α and β chains interact with α2 and α3 domain of 
the MHC class I molecule. Similar to CD4, CD8 also binds Lck through the cytoplasmic tail, 
resulting in the same action. Furthermore, CD8 participate in the response to antigen 
increases the sensitivity of T-cells to antigen presented by MHC class I molecules by about 
100-fold (Janeway et al., 2001). 
1.2.6.4 Co-stimulatory and co-inhibitory molecules.  
There are two signals needed for T-cell activation. The first signal for activation is formation 
of TCR MHC-peptide complex (Signal 1). This signal is not enough to stimulate a full 
immune response. There are co-stimulatory signals which occur through co-stimulatory 
receptors and their symmetric ligands on APCs (signal 2) (Mueller et al., 1989, Zhang and 
Vignali, 2016, Lafferty and Cunningham, 1975). For example, the more distinguished co-
stimulatory pathways are the interaction between the co-stimulatory receptor CD28 (on the 
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T-cells) with its ligands B7.1 (CD80) and B7.2 (CD86) on the APC. The CD28:B7 axis 
produces a strong stimulatory signal for TRC activation and IL2 production will lead to an 
increase the T-cell proliferation. To prevent an immune response, there is another 
mechanism dependent on co-inhibitory receptors, which dampens co-stimulatory signals 
(Zhang and Vignali, 2016). B7.1 also works as a co-inhibitory receptor. If this molecule 
interacts with the co-inhibitory receptor CTLA4 (CD152) on the T-cells it can prevent T-cell 
activation. Other important co-inhibitory receptors are listed in Table 1.1, Figure 1.9 (Zhang 
and Vignali, 2016, Goronzy and Weyand, 2008, Naisbitt et al., 2000). 
 
 
Figure 1-9 Co-stimulatory molecules. T-cell activation is triggered by a determined MHC-peptide complex 
presented by APCs to the TCR complex and T-cell costimulatory signals provided by the main CD28 
interactions with CD80 and CD86. There are many costimulatory molecules involved in the interaction. The 
red box represent signal 1 and the binding among the co-stimulatory molecules between T-cell and the APC 
represent signal 2. 
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Table 1-1 Co-stimulatory and co-inhibitory molecules. These are binding interaction 
between T-cells and antigen-presenting.  
Co-stimulation molecules Co-inhibition molecules 
T-cell Antigen-presenting 
cell 
T-cell Antigen-presenting 
cell 
CD40-L CD4 PD-1 PD1-L 
ICOS ICOS-L CTLA-4 CD80/CD86 
CD28 CD80/CD86 BTLA HVEM 
CD27 CD70   
 
1.2.6.5 Cytokines. 
Cytokines are small polypeptides secreted by cells that have a specific influence on the 
interaction and communication between cells. The name cytokine is given to several groups 
of secretory proteins including lymphokines (cytokines secreted by lymphocytes), monokine 
(cytokines secreted by monocytes), chemokines (cytokines with chemotactic activities which 
attract other cells) and interleukins (this type of cytokine is made by one leukocyte and 
effects other leukocytes) (Zhang and An, 2007). Cytokines play a fundamental role in cell 
signalling, which means the communication within the immune system and they provide the 
immune system and host cells a mechanism to interchange information. Cytokines perform 
their role by binding to the particular receptors that deliver signals to recipient cells 
(McInnes, 2017). Cytokines may affect the same cells that secrete them (autocrine action), 
or act on nearby cells (paracrine action). Furthermore, some cytokines act on distant cells 
and tissue (endocrine action) (Zhang and An, 2007). Naive T-cell differentiation is promoted 
by cytokines, and their actions are controlled by various types of cytokines. Th1 cells 
produce interferon (IFN-γ) and interleukin (IL-2), and their differentiation is supported by 
IL-12 and IFN-γ. Th2 cells produce IL-4, IL-5, IL-9, IL-10, and IL-13, and their 
differentiation is supported by IL-4 (Eagar and Miller, 2008). This has been discussed in 
greater detail in section 1.2.4.1.3.  
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1.2.6.6 TCRs in drug hypersensitivity  
 TCR signalling. 
The interaction between TCR and a peptide-loaded major histocompatibility complex 
(pMHC), produces responses that differ in severity and duration (Varma, 2008). TCR-
peptide-MHC complexes will trigger the TCR and transduce signals across the plasma 
membrane (Choudhuri and van der Merwe, 2007, Kuhns et al., 2006). These signalling 
pathways mediate T-cell proliferation, differentiation and cytokine secretion (Choudhuri et 
al., 2005). TCR triggering has been classified into three categories aggregation, 
conformational change, and segregation, to initiate signal transduction (Figure 1-10) 
(Choudhuri et al., 2005, van der Merwe and Dushek, 2011, Choudhuri and van der Merwe, 
2007). TCR signalling is enriched by CD4+ and CD8+co-receptors via a mechanism called 
co-receptor heterodimerization. They bind to the peptide-MHC TCR complex (Locksley et 
al., 1993, Schilham et al., 1993, Choudhuri et al., 2005). The TCR-CD3 complexes can 
aggregate following TCR clashes with peptide-MHC complexes. This will promote 
phosphorylation processes. This aggregation could, increase the, closeness of associated 
Lck molecules (Figure 1.10 A) (Cooper and Qian, 2008). In the conformational change 
model has been proposed for triggering TCR at very low densities of agonist peptide-MHC 
molecules (van der Merwe and Dushek, 2011). This model of TCR triggering suggests that 
the TCR undergoes a conformational change during T-cell activation of lipid vesicles appear 
mimicking the lipid structure of the plasma membrane. This lipid vesicles promote the 
folding of the CD3ζ chain into a state where it is unable to be phosphorylated by Lck 
(Aivazian and Stern, 2000). After TCR-CD3 phosphorylation by Lck this process will 
produce a binding place for the action of another tyrosine kinase called ZAP-70 (zeta chain 
associated protein of 70 kDa) (Smith-Garvin et al., 2009). Sequentially ZAP-70 
phosphorylates another two molecules called SLP76 (SH2-domain containing leukocyte 
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protein of 76kDa) and LAT (linker for T-cells activation). These molecules work together to 
trigger Ca2
+ and diacylglycerol (DAG) release, which leads to T-cell activation (Figure 1.10 
B) (Li and Rudensky, 2016). The final triggering model is called segregation. This model 
suggests that there is a redistribution of the TCR-CD3 complex with respect to other cell 
membrane-associated proteins. New molecules such as CD45 prevent Lck from 
constitutively proceeding with the TCR signalling cascade (Figure 1.10 C) (van der Merwe 
and Dushek, 2011, Nika et al., 2010). 
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Figure 1-10 T-cell signalling A. binding T-cell to peptide-MHC complex (Signal 1), TCR-CD3 will aggregate 
together. The co-receptor will bind to the peptide–MHC complex as the T-cell receptor (TCR) brings co-
receptor-associated LCK into proximity with TCR-CD3 immunoreceptor tyrosine-based activation motifs 
(ITAMs). B. conformational change, when zap70 become active and produces phosphorylation for SLP76 and 
LAT, these molecules work to trigger Ca2+ and diacylglycerol (DAG) release that will lead to serial events of 
T-cell activation. C. Segregation, the TRC-CD3 complex will redistribute by CD45 molecules. (A and B figures 
in the previous page). 
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1.3 Adverse Drug Reaction (ADR). 
An adverse drug reaction (ADR) is defined as a response to a drug that is noxious, unintended 
or undesired, occurring at doses normally used for diagnosis or treatment of disease (World 
Health Organization, 1966, Edwards and Aronson, 2000). Although this definition has been 
used for a long period of time, several adaptations have been suggested. This is because some 
drugs are noxious but not really harmful, or just produce some irritation that combines with 
the treatment. For example, a persistent cough in patients using angiotensin-converting 
enzyme (ACE) inhibitors to treat hypertension and congestive heart failure (Cialdai et al., 
2010). An adverse drug event (ADE) occurs in patients during or after the treatment, as a 
result of the exposure to the drug but it is not necessarily caused by the drug itself or from 
the mechanism of drug action (Asscher et al., 1995, Pirmohamed et al., 1998). ADRs are 
always adverse events but not all ADEs are ADRs.  Finney was first to describe and 
distinguish the difference between the two terms (ADRs and ADEs) (Finney, 2006 ). 
Adverse drug events produce a significant patient morbidity and mortality; they are still 
underappreciated and sometimes not fully understood (Nebeker et al., 2004). 
1.3.1 Adverse drug reactions, health burden and epidemiology. 
ADRs are undesirable drug effects that have considerable economic as well as clinical costs. 
These reactions lead to hospital admission, prolongation of hospital stay and emergency 
department visits. Pharmacovigilance, which is defined as the science and activities relating 
to the detection, assessment, understanding and prevention of adverse effects or any other 
drug-related problem. ADRs are known to result in a high morbidity and mortality (Sultana 
et al., 2013, Formica et al., 2018). The burden on the health services and hospitals as a result 
of an ADRs is very high. ADRs are associated with losses in human life, reduced financial 
expenses and annual resources. Drug‐related hospitalisation, and the output losses, are 
related to the nature of the ADRs (Roughead, 2002, Pirmohamed et al., 2004). The annual 
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cost of ADRs in Canada is estimated to be about $35.7 million (Wu et al., 2012). 
Furthermore, in the Children's Hospital of Michigan the total Intensive Care Unit (ICU) cost 
was increased by 3.5 fold, and length of hospitalisation was increased by 3.8 fold due to 
various cases of ADR (Du et al., 2013). In Europe, it has been estimated that approximately 
5 % of all hospital admissions are caused by ADRs, and that ADRs cause 197,000 deaths 
per year throughout Europe (Bouvy et al., 2015). A prospective study in the UK estimated 
that of 18 820 patients who were admitted to hospital over a period of 6 months, 6.5% of 
admissions were due to ADRs. Further, the fatality rate was 0.15% and the annual cost to 
the National Health Service (NHS) was estimated at £466 million (Pirmohamed et al., 2004). 
Following all these studies, it has become extremely difficult to ignore the problem of ADRs  
and their effect on the health care system and human health (Bharadwaj et al., 2012).  
1.3.2 Drug Allergy. 
First use of the term "allergy” was in 1906 by Clemens von Pirquet to describe the reaction 
that occurs on second exposure to a substance termed as an "allergen” (foreign substance) 
(Shulman, 2017). The definition of allergy was updated by EAACI in 2001 and the World 
Allergy Organization (WAO) also advocated this term in 2003. Furthermore, they proposed 
the general definition as “a hypersensitivity reaction initiated by specific immunological 
mechanisms” (Johansson et al., 2004). Drugs can activate a spectrum of immunologically-
mediated hypersensitivity reactions via various mechanisms (Warrington et al., 2018). 
1.3.3 Classification of ADRs. 
There are two commonly used classification systems for ADRs. The original classification 
was known as the type A and type B classification (Figure 1.11) (Patton and Borshoff, 2018). 
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Figure 1-11Classification of adverse drug reactions (ADRs). 
 
1.3.3.1 Type A reactions (on-target). 
 Type A reactions are considered to be predictable pharmacological reactions (Rawlins MD 
and JW, 1991). Type A reactions constitute 80% of ADRs (Shah et al., 2005). These 
reactions are also called on-target, they are expected and common reactions, related to the 
drug dose, and they depend on the pharmacological actions of the drug. The majority of type 
A ADRs represent an exaggeration of the desired pharmacological actions of the drug. This 
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type of reaction mainly occurs due to some error in dosing or sometimes it occurs due to 
sensitivity of the patient or interactions among drugs in a patient who is treated with different 
types of drug (Gomes and Demoly, 2005, McDowell et al., 2011). 
Type A reactions can be further classified and subdivided according to Rawlins and 
Thompson classification (Rawlins and Thompson, 1991, Shah et al., 2005). 
1.3.3.1.1 Toxicity or overdose. 
Overdose is a serious, harmful, and sometimes fatal toxic reaction. Overdose means 
ingestion of more than a treatment dose of a drug by mistake or intention or due to an 
exaggeration of the drug’s primary pharmacological action (Bennett et al., 2012).  
1.3.3.1.2 Side effects. 
Side effects means that drug-specific effects or symptoms appear during the treatment, which 
are other than intentional actions, whether useful, neutral or hurtful (Ferner and Butt, 2008). 
Side effects could in the most extreme cases lead to death (Lazarou et al., 1998), or they 
could be one of the reasons for failure in treatment (Hay et al., 2014). The coumarins and 
heparins are used as anticoagulants for temporary or long-term use. These drugs may have 
very strong and devastating side-effects, including widespread skin necrosis. There is a case 
report of an elderly patient who developed severe skin lesions due to the use of heparin for 
a surgical procedure and after further investigation, they detected that the blood was forming 
circulating antibodies directed against heparin platelet factor 4 (Sanchez‐Politta et al., 2006). 
There has been a report of another case of sedation with antihistamine treatment (Ferner and 
Butt, 2008).  
1.3.3.1.3 Secondary effects. 
Secondary effects are effects that yield from the use of a drug after a short period of treatment 
as an indirect result of the primary action. For example, diarrhoea cases after treatment with 
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antibiotics because these drugs will change the gastrointestinal bacterial flora (Shah et al., 
2005). Acute watery diarrhoea and abdominal pain may result from treatment with 
clarithromycin (Namiki and Kobayashi, 2018). 
1.3.3.1.4 Drug Interactions. 
Drug-drug interactions are wanted or unwanted chemical, pharmacokinetic, or 
pharmacodynamic reactions, when two or more drugs or chemical substances are used for 
treatment and come together in the body (Chan et al., 2016). The interaction of drugs are 
very complex (Pai and Bertino, 2015). For example, that the second drug could influence the 
metabolism of the first drug or affect the drug's concentration in the bloodstream affecting 
it’s primary interaction with the pharmacological target (Brody, 2018). 
1.3.3.2 Type B reactions. (Idiosyncratic / off-target).  
This type of reaction is unpredictable, infrequent, and more or less doesn’t depend on the 
therapeutic dose and is not connected to the pharmacological effects of the drug. Type B 
reactions account for 10-15% of ADRs and the reaction mechanisms are more complex and 
less well understood than type A reactions. Most of these reactions are related to the 
activation of the host’s immune system by the drug and genetic effects influence 
susceptibility (Gomes and Demoly, 2005, Shah et al., 2005, Rawlins and Thompson, 1991). 
Type B reactions have a very complex burden on pharmaceutical manufacturers (Park et al., 
2011b). Type B reactions are also subdivided according to Rawlins and Thompson 
classification (Rawlins and Thompson, 1991), as immunological and non-immunological 
reactions. 
1.3.3.2.1 Non-Immunological Reactions. 
These reactions are further divided as following: 
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A. Intolerance: Mainly occurs due to a change in threshold for drug pharmacodynamics in 
some patients. When the threshold becomes very low, drugs will produce intolerance 
(Bennett et al., 2012). 
B. Pseudoallergic (Nonallergic Hypersensitivity): Pseudoallergy is a typical non-immune 
anaphylactic reaction. The responses are not dependent on antigen-specific immune 
responses. Pseudoallergy often emerges with the first dose of a medication, therefore this 
reaction is considered unpredictable and occasionally has a lethal consequence (Zhang et al., 
2018). Drugs directly react with inflammatory cells such as mast cells, eosinophils and 
basophils (Pichler et al., 2015). These reactions are similar to anaphylaxis symptoms but the 
mediator release mechanism from basophils and mast cells does not involve IgE antibodies 
(Zhang et al., 2018, Pichler, 2007). Some drugs have the ability to induce mast cell 
degranulation and alter enzymatic activity via an interaction with the MRGPRX2 receptor 
on mast cells, leading to IgE-independent mast cell degranulation (McNeil et al., 2015, 
Zhang et al., 2018). There are several drugs that are commonly associated with 
pseudoallergenic reactions, for instance, opioid drugs and nonsteroidal anti-inflammatory 
drugs (Zhang et al., 2018). 
C. Metabolic idiosyncratic drug reactions (mIDRs): Metabolic idiosyncratic drug 
reactions come from toxic metabolites followed by covalent binding to cellular proteins 
(Zuniga et al., 2012). These abnormal reactions to a drug do not occur in all patients. The 
adverse effects are not related to the pharmacological actions of the drug. They are usually 
mediated by reactive drug metabolites after the bioactivation in the liver by cytochrome P450 
enzymes (Larrey, 2002, Huang et al., 2002). The drug metabolites can be electrophilic 
chemicals or free radicals which promote a variety of chemical reactions, including depletion 
of reduced glutathione; covalent binding to proteins, lipids, or nucleic acids; or lipid 
peroxidation. All of these reaction’s produced by the metabolites have direct effects affects 
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on the biochemistry of the cells on organelles, such as mitochondria, the endoplasmic 
reticulum, the cytoskeleton, microtubules, or the nucleus (Kaplowitz, 2002). Drug effects 
could also be indirect on cellular organelles, which leads to activation and inhibition of 
signalling kinases, transcription factors, and gene-expression profiles. Both direct and 
indirect intracellular effects leads to cell stress and then cell death (apoptosis) or swelling 
and lysis (Kaplowitz, 2004, Kaplowitz, 2002). A well-known example of these reactions is 
acetaminophen (N-acetyl-p-aminophenol, paracetamol (APAP). APAP is the most common 
drug used as pain killer to remove and treat fever (Lee, 2017). APAP metabolism occurs 
within liver by three pathways. 90% of APAP is metabolized by phase II metabolic pathways 
through conjugation. 10% of APAP is funnelled by hepatic cytochrome CYP 2E1 to phase I 
oxidation, which produces a highly reactive and toxic metabolite, N-acetyl-para-benzo-
quinone imine (NAPQI). While phase III pathways include metabolite transport in the form 
of biliary excretion (Yoon et al., 2016). 
1.3.3.2.2 Immunological reactions (Drug Allergy). 
Drug allergy was orginally classified into four types by Gell and Coombs in 1963 (Table 
1.2) (Rajan, 2003, Baldo and Pham, 2013). 
 Type I hypersensitivity reactions. (IgE-mediated immediate hypersensitivity). These 
reactions are also called anaphylactic hypersensitivity. The reaction appears after 30-
60 min, but it may take place much more quickly after drug exposure. IgE antibodies 
are the mediators of immediate hypersensitivity reactions. Hypersensitivity develops 
when the allergen binds to the IgE on the surface of mast cells and basophils. This 
will lead to degranulation and the secretion of histamine, kinins, and prostaglandins. 
These substances act together to produce symptoms of immediate hypersensitivity 
such as increased vascular permeability, vasodilatation, smooth muscle contraction 
and oedema (Baldo and Pham, 2013, Grant et al., 2007). Chemical and lipid 
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mediators produce these immediate symptoms while cytokines will cause delayed 
symptoms (Rajan, 2003). These symptoms appear with cases of urticaria, 
anaphylactic shock and asthma (Bennett et al., 2012).  
 Type II hypersensitivity reactions. These reactions are known as antibody-dependent 
cytotoxicity (Baldo and Pham, 2013), or antigen-antibody interactions (Rajan, 2003). 
IgG or IgM antibodies are responsible for targeting membrane-associated antigens 
(Male et al., 2012, Beenhouwer, 2018). A sensitization phase leads to production of 
antibodies. The effector phase, occurs when the antibodies coat the target cells 
(Beenhouwer, 2018). This causes cell demolition and destruction by complement 
system activation or due to the cytotoxic effect of natural killer cells especially those 
with Fc-IgG receptors or by cells such as macrophages. Target cell lysis occurs by 
lysosomal enzymes and the cytolytic molecule perforin (Pichler et al., 2010).  
 Type III hypersensitivity reactions. These reactions are also known as immune 
complex hypersensitivity. These reactions occur due to soluble immune complexes 
which are formed by antigen-antibody interactions. IgG antibodies are mostly 
responsible for this type of hypersensitivity; however, sometimes IgM antibodies are 
involved. These antigen-antibody complexes will precipitate in tissues, producing 
tissue damage. This process initiates complement activation, which will initiate 
inflammatory and allergic processes such as mast cell degranulation, leukocyte 
chemotaxis, and lysosomal enzyme release (Baldo and Pham, 2013). The classical 
type III hypersensitivity reaction is  systemic lupus erythematosus (Male et al., 2012). 
 Type IV hypersensitivity reactions. Delayed-type or cell-mediated hypersensitivity. 
This type of reaction differs from the previous three types because T-cells bring about 
the adverse reaction (Beenhouwer, 2018). The reactions are so called because the 
development of clinical symptoms can take one or more weeks to develop (Male et 
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al., 2012). T-helper and T-cytotoxic cells are responsible for the generation of these 
reactions (Aronson, 2012, Adam et al., 2011). An interaction between T-cells, 
antigen presenting cells and a drug causes T-cell activation, proliferation and 
cytokine secretion (Actor, 2014). 
Type IV hypersensitivity reactions are divided into several subtypes based on cytokines 
secreted and the types of cells involved (Table 1.2) (Adam et al., 2011, Posadas and Pichler, 
2007).  
The subtypes of type IV hypersensitivity reactions are: 
 Type IVa 
When CD4+ Th1 cells encounter specific antigens, they will be activated and then cause 
macrophage stimulation by IFN-γ secretion. This leads to a sequence of immune events that 
sometimes involves CD8+ T-cell responses. 
 Type IVb 
In these reactions, CD4+ Th2 cells produce IL-4, IL-13 and IL-5 cytokines after exposure to 
drug antigens. Activated B-cells enhance secretion of IgE and IgG antibodies. This will 
reduce macrophage activity and promote mast cell and eosinophil responses. 
 Type IVc 
In this type of reaction, CD8+ T-cells act as effector cells. They move to the tissues and kill 
the host tissue cells. For example hepatocytes or keratinocytes are killed by CD8+ T-cells 
through secretion of several types of cytolitic molecules including perforin, granzyme B 
and/or FasL. 
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 Type IVd 
In this type of reaction, CD8+ cytotoxic T-cells are again the primary mediators. CXCL8 and 
GM-CSF producing T-cells will activate neutrophils and produce neutrophilic infiltrates, 
leading to pustular exanthema. This is a typical case of inflammation of the skin, in acute-
generalized exanthematous pustulosis (Adam et al., 2011, Warrington, 2012). CXCL8 
chemokins recruit neutrophils (Lyons et al., 2004) and GM-CSF prevents neutrophil 
apoptosis (Britschgi et al., 2001). 
Table 1-2 Gell and Coomb’s classification system adapted from (Pichler, 2007). 
 
1.4. Mechanisms of T-cell mediated drug hypersensitivity. 
Several hypotheses have been proposed to describe the development of drug allergy or drug 
hypersensitivity. These include hapten / prohapten and pharmacological interactions of drugs 
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with immune receptors (P-I) mechanisms (Pavlos et al., 2015). These are described in detail 
below. 
 1.4.1 The hapten/pro-hapten hypothesis. 
Certain drugs and/or their reactive metabolites have the ability to bind covalently to proteins. 
The hapten is a small molecule that interacts with a protein carrier to eventually form a stable 
hapten-peptide-complex on the MHC of the APCs (Budinger and Hertl, 2000, Naisbitt et al., 
2000, Schnyder and Pichler, 2009).  
 Landsteiner and Jacobs were the first to develop this hypothesis in 1935, when they noticed 
that it was not possible to activate an immune response by small molecules unless the 
molecules were chemically reactive and bound to a protein. They coined the term, “hapten”. 
This name comes from the Greek “hapten”, meaning “to fasten”. Haptens are low molecular 
weight (LMW) chemicals, they weigh less than (1000 daltons). This reactive molecule needs 
to bind to another molecule called a carrier. This binding makes hapten molecules antigenic 
(i.e. to have the ability to produce an immune response) (Figure 1.12 A) (Landsteiner and 
Jacobs, 1935). The β-lactam antibiotics are the best example for the haptenation phenomenon 
(Levine, 1960, Ariza et al., 2015, Whitaker et al., 2011). Formation of hapten-protein 
complexes with β-lactam antibiotics occurs following when the nucleophilic opening of the 
β-lactam ring. The haptenic structure then binds to protein and forms a drug-protein 
conjugate (Faulkner et al., 2014). Covalent bonds have energies ranging from 200 to 
420 kJ/mol compared to hydrophobic, dipolar, and ionic interactions with bond energies 
<50 kJ/mol. This type of binding energy enables covalent adducts to survive the intracellular 
antigen processing of the haptenated protein into short peptides for cell surface expression 
by MHC complexes (Chipinda et al., 2011). There are other types of binding between the 
hapten and carrier, such as disulphide exchange and coordinate covalent binding (Chipinda 
et al., 2011). After binding of a hapten to a carrier protein, the complexes are processed 
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inside APCs and presented as a stable hapten-peptide complex by the MHC on APCs in the 
lymph nodes and on APCs settled in the tissues, (See section 1.2.5). These complexes are 
recognised by naïve T-cells, stimulating clonal expansion (Naisbitt et al., 2000). After the 
first exposure, primed T-cells develop functionally to two subclasses; the effector T-cells 
(Teff) and the effector memory T-cells (Tem). These specific T-cells (Teff and Tem) will 
move to the place of hapten-carrier compound exposure at the time of primary sensitisation 
(Schnyder and Pichler, 2009, Ebert et al., 2005).  
Some drugs have characteristics that differ from haptens. Therefore, they induce sensitisation 
via a different pathway. These drugs do not bind to protein themselves but they need to be 
metabolised to a more active substance (via a bioactivation process). These drugs are called 
pro-haptens. After metabolism, they will have the ability to bind to proteins leading to 
formation of a prohapten-carrier complex, to induce an immune response (Figure 1.12 B). 
Unlike penicillin, sulfonamides must undergo metabolic transformation into chemically 
reactive metabolites before a drug-induced response is triggered. Sulfamethoxazole is the 
archetypal model of a prohapten. This drug does not bind to proteins directly but it is 
metabolised in the liver by the cytochrome CYP2C9 isoenzyme to a pro-reactive 
hydroxylamine metabolite (Cribb and Spielberg, 1992). This hydroxylamine metabolite is a 
more active substance than the parent drug and it will undergo spontaneous oxidation to 
produce nitroso-sulfamethoxazole (Naisbitt et al., 1999). The nitroso compound binds 
irreversibly to serum and cellular proteins (Naisbitt et al., 2002, Callan et al., 2009, 
Sanderson et al., 2007). Reactive drugs and metabolites also induce cell stress and this lead 
scientists to consider Matzingers Danger model in the context drug hypersensitivity 
(Williams et al., 2002, Pirmohamed et al., 2002). According to this model, the immune 
system does not care about self and non-self, but it just tries to protect the body against a 
dangerous environment (Matzinger, 1994, Matzinger, 2002). Pursuant to this hypothesis, for 
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any immune response to occur by hapten or prohapten-protein complex, it must be reinforced 
by another signal called a danger signal. In the absence of a danger signal the hapten complex 
will be ignored by the immune system (Curtsinger et al., 1999, Matzinger, 1994). Thus, it 
became clear that the adaptive immune response does not work in isolation from the innate 
immune system. The innate immune system seems to play a critical role in determining the 
type of immune response induced by T-cells and B-cells by sending various signals 
(Gruchalla, 2001). During the sensitization phase of cutaneous hypersensitivity the hapten 
will interact with keratinocytes, and dermal DCs. The hapten will produce a stress effect on 
keratinocytes, which leads to release of a group of cytokines and inflammatory molecules 
such as IL-1β, IL-18, TNFα, and GM-CSF. These molecules work as danger transmitter 
signals and they support the immune response. As discussed earlier, innate immunity is 
trigger through pattern recognition receptors such as TLRs. DC activation will produce 
migration the DCs to the draining lymph node where they mature and present hapten-antigen 
complexes to naïve T-cells (Erkes and Selvan, 2014, Honda et al., 2013). The first signal is 
the binding of TCRs on T-cells to MHC molecules on DCs and the second signal is called 
co‐stimulation. This involves the triggering of CD28 on the T-cell by CD80 and CD86 
molecules on the DC (or APCs) (See section 1.2.6.4) (Chen and Flies, 2013). Injured cells 
(stress, necrosis) or cells under infection stress, release danger/alarm signals which increases 
APCs stimulation, resulting in increased expression of costimulatory molecules. Polarizing 
cytokines are direct T‐cell differentiation factors that are often referred to as signal 3 (Figure 
1.12) (Corthay, 2006, Naisbitt et al., 2000, Li and Uetrecht, 2010). 
 
Chapter one                                                                        Introduction and Literature review 
55 
 
 
Figure 1-12 Hapten and prohapten hypothesis and the role of danger signals.  
 
1.4.2 The P-I hypothesis (Pharmacological Interaction with Immune 
Receptors). 
This idea came about because some drugs do not have hapten characteristics, therefore they 
bind directly and reversibly to proteins to stimulate the immune system. This concept is 
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referred to as the pharmacological interaction of drug with the immune system and gave a 
mechanistic explanation for many cases of drug hypersensitivity reaction. Moreover, it is 
based on comprehensive investigations of how T-cell clones from human patients interact 
with drugs. Pichler (2008) explains that when drugs bind to TCRs on the surface of T-cells 
this interaction will initiate a pharmacological stimulation. This theory gives an explanation 
to the appearance of symptoms very quickly in certain forms of hypersensitivities, without 
previous exposure to the same antigen. Sometimes the response is anarchist although the 
immune response is very organised (Pichler, 2008). This hypothesis to describe the 
interaction between small molecules and immune receptors is a new immunological concept 
and had been defined as the "direct pharmacological interaction of drugs with immune 
receptors, the interacting substance is a chemically inert drug that does not have the 
ability to bind covalently to peptides or proteins, but it can stimulate T-cells if it has 
affinity for T-cell receptors or MHC-molecules. This binding is reversible (Pichler, 
2013, Pichler et al., 2006, Pichler, 2002). Reversible binding interactions include Van der 
Waals interactions, electrostatic forces and/or hydrogen bonds.  The binding will occur with 
HLA or the TCR. Therefore, these drugs are less toxic in comparison to hapten drugs 
(Pichler, 2013, Adam et al., 2011).  
 According to the P-I hypothesis, there are 3 criteria for T-cells to generate an immune 
response with a drug; the first criteria is that the T-cells must express a specific TCR that 
can bind to the drug and induce a stimulatory signal. The second criteria is, the T-cells should 
have a low threshold for stimulation. The third criteria is that an additional binding of the 
TCR with the MHC on the APC should exist to increase the intensity of the immune response 
(Schnyder and Pichler, 2009, Ghosh et al., 2011).  
 
Chapter one                                                                        Introduction and Literature review 
57 
 
 There are two shapes of P-I interaction (Pichler, 2008).  
1.4.2.1 P-I TCR (Direct). 
In this type of reaction, the drug binds directly to the specific TCR molecule via non-covalent 
unstable bonds. This will lead the MHC molecule (of APC) to bind to the TCR and induce 
full activation (Figure 1.13) (Depta et al., 2004, Schmid et al., 2006). Activation of the T-
cell can be measured by many methods including, the immediate Ca2+ influx into specific 
T-cells, cytokine synthesis and proliferation (Pichler, 2013). The first examples of this type 
of interaction were sulfamethoxazole (SMX) and lidocaine. The T-cell clones were activated 
even if the peptide or the HLA-molecule was removed or replaced (Burkhart et al., 2002, 
Zanni et al., 1998b). Furthermore, clones responded to the drug in the presence of allogenic 
MHC alleles, which is referred to as the loss of HLA restriction (von Greyerz et al., 2001b). 
Moreover, structurally related sulfonamides may block the stimulation of T-cells with SMX. 
Docking studies have discovered that these blocking sulfonamides bind to the same location 
as the SMX (CDR3), but without a stimulation signal (Pichler, 2013). Interestingly, only 
SMX binds to CDR3 with its NH2 group pointing to the peptide-binding groove (Pichler et 
al., 2015). While other non-stimulatory sulfonamides point their NH2 group toward the TCR 
and they bind to the outside of peptide interacting site (Werner and Stephen, 2014).  
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Figure 1-13 P-I TCR (Direct). The drug binds directly to TCR on the surface of T-cell and then that 
complex binds to MHC molecule on the APC, to generate a comprehensive immune response.  
 
1.4.2.2 P-I HLA (Indirect). 
Chung and his group studied Stevens-Johnson Syndrome (SJS) induced by carbamazepine 
(CBZ), a drug prescribed for the treatment of seizures. SJS is a life-threatening reaction of 
the skin. Their study found a strong association between a genetic marker, the human 
leukocyte antigen HLA-B*15:02, and the SJS cases induced by CBZ (Chung et al., 2004a, 
Leckband et al., 2013). Furthermore, the drug was found to bind directly to the HLA 
molecule to activate the CD8+ T-cells involved in CBZ-induce SJS. Due to the strength of 
the HLA-B∗15:02 association with CBZ-induced SJS/association, the National Health 
Insurance in Taiwan has covered the cost of the genetic screening for HLA-B∗15:02 since 
2010, in people treated with CBZ. This test has contributed to the reduction of CBZ-induced 
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SJS /TEN to almost zero. The test has been used clinically in 23 hospitals in Taiwan (Chen 
et al., 2011).   
There are two models of P-I HLA binding 
 The Altered Peptide Model of P-I HLA (intracellular pathway). 
This model of binding between drugs and HLA was generated from a breakthrough in 
understanding of the type of connection between the crystallographic structure of the HLA-
B *57:01 molecule and abacavir (Ostrov et al., 2012, Norcross et al., 2012). When drugs 
such as abacavir enter a cell, and are transported to the cytoplasmic reticulum, they bind with 
endogenous HLA molecules. The drug attaches to a site below the peptide presented by the 
specific allele HLA-B*57:01, far from the loci peptide-TCR interaction (Figure 1.14 A) 
(Illing et al., 2012, Ostrov et al., 2012).  
Abacavir modifies the structure of HLA-B*57:01 and changes the nature of peptide-binding 
to HLA-B*57:01. Approximately 20% of the peptides presented by abacavir-modified HLA-
B*57:01 are made up novel peptide sequences (Illing et al., 2012). This alteration in the 
binding capacity of peptides by the new abacavir-modified HLA-B*57:01 will result in the 
activation of T-cells and hypersensitivity reactions in patients (Illing et al., 2013). 
 The Allo-Immune Model of P-I HLA (extracellular pathway). 
Comprehensive analysis of abacavir-specific T-cells has challenged the altered peptide 
concept. Further studies have resulted in a new  concept, i.e. that the exchange of the peptide  
is not necessary for immunogenicity, but changing the HLA-(self) allele without alteration 
the sequence of the peptide is sufficient for immunogenicity (Pichler, 2013). For example 
abacavir binds directly to the F9-pocket of the peptide-HLA-B*57:01 complexes which is 
presented on the cell surface. Drug binding occurs directly as a result of the flexibility of the 
peptide-HLA binding, which allows abacavir to enter the specific binding site below the 
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peptide,  to create (abacavir-peptide-HLA-B*57: 01) complexes without the need of peptide 
exchange (Figure 1.14 B) (Pichler et al., 2015, Yun et al., 2014). 
 
Figure 1-14 P-I HLA concept highlighting 2 possible senarios (A): Altered Peptide Model of P-I HLA 
(intracellular pathway) the drug enters into the cell and binds to an endogenous HLA, producing an alteration 
in the peptides bound to HLA molecule. (B): The Allo-Immune Model of P-I HLA (extracellular pathway) the 
drug such as abacavir binds to the peptide loaded on the HLA molecule. That binding would trigger an altered 
peptide-HLA complex configuration without a peptide change. In both senarios, the binding will make a change 
that would be sensed by the TCR as a new antigen that would incite an immune response. 
 
1.4.2.3 The need for co-stimulation signals (danger signals) in P-I 
reactions. 
The cofactors implicated in P-I TCR and P-I HLA may differ. Co-stimulation signals are not 
an absolute requirement in the P-I HLA activation model especially for abacavir. This is 
because abacavir-B*57:01 peptide complexes may act as an allo-allele and create a strong 
direct T-cell stimulation (Pichler et al., 2015). The innate immune system is not stimulated 
and B-cells are not involved. Therefore, there is no B-cell activation or IgE-mediated 
reaction confirmed for the P-I mechanism. So far, the drug interaction is limited to the TCR 
and/or HLA (Pichler, 2003, Yun et al., 2016). On the other hand, the, P-I TCR stimulation 
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models are different and some may require co-stimulatory factors.  For example, activation 
of T-cells may occur with a concomitant infection. This will lead to upregulation of adhesion 
molecules and secretion of cytokines, which perhaps lower the threshold of T-cell reactivity 
needed for hypersensitivity (Pichler et al., 2015). 
1.5 The role of HLA human leukocyte antigen in drug hypersensitivity 
drugs. 
Over the last decade many studies explored the specific relationship between drug 
hypersensitivity and HLA alleles. These studies have enriched and driven the knowledge 
toward understanding the immunopathogenesis (Pavlos et al., 2012). A strong genetic 
association between HLA allele and hypersensitivity reactions to certain drugs have been 
described (Chung et al., 2007). Table 1.3 summarizes some of the well-known examples for 
drug hypersensitivity cases and the culprit HLA alleles (Fan et al., 2017). 
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Table 1-3 Drug-induced ADRs and HLA allele associations, adopted from (Fan et al., 
2017). 
Drug HLA allele Phenotype Population 
Carbamazepine
  
B∗15:02 SJS/TEN Taiwanese, Han 
Chinese, Thai, 
Malaysian, Asian 
Carbamazepine A∗31:01 SJS/TEN
  
Han Chinese 
Caucasian  
Japanese 
Carbamazepine B∗15:11 SJS/TEN Japanese 
Allopurinol B∗58:01 SJS/TEN Han Chinese 
Caucasian, Thai 
Japanese 
Allopurinol  SCARS Taiwanese 
Phenytoin B∗15:02 SJS/TEN Han Chinese, Thai 
Lamotrigine B∗15:02 SJS/TEN Han Chinese 
Nevirapine DRB1∗01:01 DRESS Hispanics, African 
Sulphamethoxazole B∗38 SJS/TEN European 
Amoxicillin-
clavulanate 
DRB1∗15:01-DQB1∗06:02 DILI Caucasian 
Flucloxacillin B∗57:01 DILI Caucasian 
Lumiracoxib DRB1∗15:01 DILI Not available 
Ticlopidine A∗33:03 DILI Japanese 
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1.5.1 Human Leukocyte Antigen (HLA). 
The specific genetic loci implicated in immune responses is known as the major 
histocompatibility complex (MHC). This genetic locus MHC encodes for highly 
polymorphic cell surface molecules. In humans, the HLA (Human Leukocyte Antigen) 
system is a gene complex encoding the MHC. This genetic complex HLA is located on the 
short arm of chromosome 6. Human MHC is divided in three parts (Figure 1.5) (Choo, 2007, 
Boegel et al., 2018). As we explained before (in section 1.2.5.1, figure1-5) MHC I molecules 
are encoded by MHC-A, B and C, and these are expressed on all nucleated cells types but to 
different degrees. MHC-II molecules are encoded by MHC-DP, DQ and DR, which are 
expressed on APCs and on some endothelial tissue, thymic epithelial cells and B-cells 
(Degoot et al., 2018, Choo, 2007, Mosaad, 2015). Nomenclature for HLA has been generated 
by the Nomenclature Committee for Factors of the HLA System of the World Health 
Organization (WHO). They use separators to divide the group of alleles (Figure 1.15) (Torres 
and Moraes, 2011). 
 
Figure 1-15 Nomenclature system for the HLA system. 
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1.6 Clinical cases. 
Drug hypersensitivity can affect any organ but the skin, the liver and blood are the most 
important targets. Some drugs have a limited action on one organ, while, others drugs have 
a wide range of actions and affect several organs (Uetrecht and Naisbitt, 2013).  
1.6.1 Skin rashs or skin lesions. 
1.6.1.1 Maculopapular rash. 
Maculopapular or morbilliform rashes are a very common type of drug reaction, which 
results in skin lesions (drug-induced skin rash). This type of rash constitute approximately 
90% of all clinical cases of drug-reactions (Uetrecht and Naisbitt, 2013). Maculopapular 
rashes start 1-2 weeks after commencing treatment with a drug. This type of rash is not very 
dangerous and cytotoxic CD4+ T-cells are the dominant cell type for these reactions (Naisbitt, 
2004).  
After stimulation of CD4+ T-cells and their infiltration into cutaneous tissue, these cells will 
mediate skin inflammatory reactions by binding their chemoreceptor CCR10 to the skin-
associated chemokine CCL27. This interaction between CCL27 and CCR10 plays a vital 
role in T-cell recruitment and T-cell- mediated skin inflammation (Lee and Rosenberg, 2013, 
Homey et al., 2002). 
1.6.1.2 Urticaria. 
Urticaria is dermal oedema caused by vasodilatation, and perivascular nonnecrotising 
infiltrates; comprising primarily of mononuclear cells, predominantly CD4+ lymphocytes 
(Jain, 2014). These reactions are also called hives. Urticarial lesions are itchy (Levine and 
Price, 1964). Urticaria occurs mainly due to IgE-mediated allergic reactions. Penicillin 
reactions are examples of this type of adverse event. Sometimes, urticaria may not be a real 
allergic reaction because some people develop it when they feel cold or following exercise. 
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Urticaria is clinically characterised by large, raised, pruritic skin lesions that do not continue 
for more than 24 hrs (Uetrecht and Naisbitt, 2013). Some drugs such as opiates or codeine 
have the ability to activate mast cells. There are other drugs that produce pseudoallergic 
reactions that may include urticaria, such as angiotensin converting enzyme (ACE) 
inhibitors, aspirin and nonsteroidal anti-inflammatory drugs (NSAID). They may produce or 
exacerbate chronic urticaria by their pharmacological mechanisms which involves 
arachidonic acid metabolism (Mathelier-Fusade, 2006).  
1.6.1.3 Fixed Drug Eruption. 
This is a type of skin eruption is characterised by erythematous round lesions with 
oedematous plaques that are brown to dark purple or red in colour (Pal et al., 2014). The 
reaction is mediated by CD8+ memory T-cells that are limited to the site of the lesions. The 
site of the skin eruption is fixed. After re-exposure to the drug, the lesion will appear at the 
same place (Pal et al., 2014). Positive patch tests results are observed for this condition, if 
the test is applied on the site of the lesion (Uetrecht and Naisbitt, 2013). Co-trimoxazole is 
the most common example of this type of reaction (Miah et al., 2008).  
1.6.1.4 Drug reaction with eosinophilia and systemic symptoms (DRESS). 
DRESS syndrome is a serious life-threatening condition characterized by skin 
eruption, fever, haematologic abnormalities, and multi-organ involvement (Walsh and 
Creamer, 2011). The first detection of these cases was with anticonvulsants drugs. Therefore, 
these reactions were given the name of anticonvulsant hypersensitivity syndrome (Shear and 
Spielberg, 1988). Later these reactions were given another name, drug reaction with 
eosinophilia and systemic symptoms (DRESS) which is more commonly used nowadays 
(Uetrecht and Naisbitt, 2013). 
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This condition (DRESS) is characterised by a wide spectrum of clinical features, and the 
extended latency period, which leads to a delay in diagnosis. The main symptoms are fever, 
rashes, lymphadenopathy, and more severe symptoms resulting from hepatitis, nephritis, 
pneumonitis, carditis, thyroiditis, and hematologic illnesses such as (eosinophilia, atypical 
lymphocytes, thrombocytopenia, or leukopenia). However, skin signs and haematological 
abnormalities usually lead to the diagnosis of the case of hypersensitivity to the culprit drug 
(Walsh and Creamer, 2011, Uetrecht and Naisbitt, 2013, Um et al., 2010). Patients with 
DRESS syndrome present variable clinical and pathological features. Reactivation of viruses 
such as human herpesviruses (HHVs) is also a hallmark of DRESS (Cho et al., 2017). 
DRESS is possibly associated with proliferation of activated CD8+ T lymphocytes directed 
against viral antigens (Liang et al., 2018, Drago et al., 2016). Carbamazepine, phenobarbital, 
and sulfonamides are common examples of DRESS inducing drugs (Seishima et al., 2006). 
1.6.1.5 Steven Johnson syndrome (SJS) and toxic epidermal necrolysis 
(TEN). 
These lesions are more severe than any other type of skin reaction. SJS produces about 10% 
of epidermal detachment, while TEN about 30%. The clinical features start with fever and 
malaise. This is followed by a painful rash. Blisters are a classic sign which is known as 
Nikolsky’s sign; the tissue lesions histologically will show keratinocyte apoptosis with 
separation between the dermis and epidermis. The symptoms start in a much shorter time 
shorter than time DRESS (7-14 days). This could be even quicker if the patient was re-
exposed to the causative drug (Uetrecht and Naisbitt, 2013, Cote et al., 1995, Mustafa et al., 
2018). The mediators for these reactions are cytotoxic molecules (perforin, granzyme B, and 
granulysin), which are found in a high density in the lesions (Schlapbach et al., 2011, Posadas 
et al., 2002). Moreover, the cells in the skin lesions mainly consist of cytotoxic T 
lymphocytes and NK cells. Stimulation of the Fas ligand (Fas l) pathway will produce diffuse 
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keratinocyte apoptosis, followed by epithelial necrosis. Other inflammatory molecules like 
IFN-γ, TNFα, soluble Fas l, and NK-activating molecules, are found within the skin lesions 
(Mustafa et al., 2018, Ang et al., 2013). 
1.6.2 Idiosyncratic drug induced liver injury (iDILI). 
Idiosyncratic drug-induced liver injury (DILI) is an infrequent adverse drug reaction. It can 
produce jaundice, liver failure, or even death (Chalasani et al., 2014). iDILI is an important 
disease that occurs following drug use and it is very challenging for both clinicians and drug 
developers because the appearance of this reaction is determined by characteristics of the 
individual patients, and its incidence is very low (e.g., 1 in 10,000). However, its 
consequences are very severe. Patients may develop liver failure with the risk of death 
(Benesic et al., 2018). Age is one of the important factors influencing susceptibility. Patients 
with chronic hepatitis (Types A, B, or C), are more likely to develop iDILI  especially in 
patients treated with isoniazid and antiretroviral drugs (Yamashita et al., 2017). In a genetic 
study of iDILI causes, several HLA were found to be associated with iDILI. Examples 
include flucloxacillin, co-amoxiclav, ximelagatran, lapatinib, lumiracoxib. They found that 
several HLA haplotypes, B*57:01, DRB1*15:01, DRB1*07:01, DQA1*02:01 and 
DRB1*15:01 were risk factors in diverse ethnic of patient groups (Alfirevic et al., 2012). 
More recently, drug-specific T-cells have been detected in patients with flucloxacillin and 
co-amoxiclav-induced-iDILI (Cho and Uetrecht, 2017, Tailor et al., 2015). 
1.6.3 Hematologic Idiosyncratic Adverse Reactions. 
1.6.3.1 Drug-induced immune hemolytic anaemia (DIHA). 
It is not a common condition but still a dangerous type of ADRs. The mechanisms implicated 
in this condition are not fully understood. The reaction is thought to occur following 
oxidative damage to vulnerable erythrocytes. This happens when oxidative-stress-
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susceptible red blood cells face drug-induced oxidative damage, through the drug or its 
metabolites. Many drugs produce this reaction, especially antibiotics, but the reasons are 
considered to be very confounding (Bubp et al., 2015, Renard and Rosselet, 2017).  
1.6.3.2 Drug-induced thrombocytopenia. 
All idiosyncratic drug-induced thrombocytopenia reactions are thought to be immune 
mediated, but the mechanisms may differ (Uetrecht and Naisbitt, 2013). This condition is 
characterised by a decrease in the platelet count to below 150000 platelets/μL. If the platelet 
count drops below 10000 platelets/μL, the patient will be at risk of life-threatening 
haemorrhage (Aster, 2010). Heparin is a very well-known example of this condition. 
Antibodies against the heparin-platelet factor 4 complex have been detected in patients 
suffering from thrombocytopenia (Warkentin, 2003). 
1.6.3.3 Drug-induced agranulocytosis. 
Agranulocytosis is one of the lethal idiosyncratic reactions that occurs when neutrophil 
counts drop to less than 500 neutrophils/μL in the blood. This will produce dangerous and 
fatal symptoms. There is a large group of drugs that produce this condition, such as 
analgesics, antipsychotics, antithyroids and anticonvulsants (Andres et al., 2006). Clozapine 
is an antipsychotic drug used in treatment of refractory schizophrenia. This drug produces 
neutropenia and agranulocytosis in 0.8-3% of patients. Clozapine undergoes bioactivation to 
reactive metabolites by the cytochrome P450 and peroxidase enzymes (Pirmohamed et al., 
1995). This will cause neutrophil cytotoxicity. The mechanism of inducing the 
agranulocytosis by clozapine is not very clear (Pirmohamed and Park, 1997).  
1.7 Diagnostic tests. 
Drug hypersensitivity reactions are unpredictable, severe, and life threatening. Therefore, 
the diagnosis is a critical step to control and prevent it. These reactions are either fast and 
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start within 1-6 hrs after initiating the treatment with a causative drug (immediate reactions) 
or the reactions are delayed by several days or more (delayed reactions), for example, 
exanthematous eruptions (Brockow et al., 2015).  
There are two types of diagnostic test, either in the body of a living organism referred to as 
in vivo and / or in a test tube, which referred to as in vitro. Examples of in vivo diagnostic 
tests include skin tests and eosinophil count and the presence of autoantibodies. In vitro tests 
include the analysis and detection of drug-specific T-cells. Furthermore, in vitro tests can 
measure expression of certain cytokines that are produced from drug-stimulated PBMCs 
during the activation by drugs (Gómez et al., 2012).   
1.8 Treatment of Hepatitis C (HCV). 
Hepatitis C virus (HCV) is a serious and potentially life-threatening viral infection that 
affects an estimated 71 million individuals worldwide. Even though, a quarter of the infected 
patients effectively clear the virus (WHO, 2017), the majority of patients develop chronic 
HCV infection. Inflammation in the liver leads to severe liver sicknesses, including 
hepatocellular carcinoma, liver fibrosis and cirrhosis. Therefore, hepatitis C is the most 
common indicated condition for liver transplantation in the USA (Verna and Brown, 2006a). 
Chronic HCV infection is responsible for 300,000 to 400,000 deaths per year, due to cases 
of cirrhosis, end-stage liver disease and hepatocellular carcinoma (Hoofnagle, 2002). 
 HCV has traditionally been treated with a regimen of PEGylated IFN-α and ribavirin, which 
provides a sustained antiviral response in 40-50% of cases. In contrast, an updated triple 
treatment regimen including telaprevir (TVR, VX-950), increases the frequency of patients 
that achieve viral control up to 70% (Lang, 2007). TVR is an NS3.4.A protease inhibitor for 
use against HCV genotype 1 which prevents both the cleavage of viral proteins into active 
polypeptides and the deactivation of hepatic cellular proteins that are essential for mediating 
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the interferon cascade and mounting an viral response (Jesudian et al., 2012, Morikawa et 
al., 2011).  
While administered orally as a single S-configurated diastereomer, TVR spontaneously 
forms the corresponding R-diastereomer which is approximately 30-fold less active 
pharmacologically (Garg et al., 2012). Despite enhanced viral suppression, the triple regimen 
is associated with an increased risk of adverse cutaneous reactions, with triple TVR-
containing therapy causing severe rashes in 4.8% of patients, compared to just 0.4% of 
patients treated with the standard dual therapy. Of more concern is that a small subset of 
patients treated with TVR develop life-threatening cutaneous drug hypersensitivity reactions 
including DRESS and SJS (Roujeau et al., 2013a). This eventually lead to withdrawal of the 
drug. 
 Telaprevir (TVR). 
TVR was approved by the FDA in May 2011. The TVR dose is 750 mg which is taken three 
times per day together with peginterferon alfa and ribavirin (Bronson et al., 2012). 
There are many side effects related to TVR treatment, such as nausea/vomiting, tasting 
change, skin lesions including rashes, blisters and itching, skin and mouth sores and irritation 
of the eyes. Many studies confirmed that treatment with telaprevir in combination with other 
drugs produces severe skin lesions such as SJS, DRESS and TEN (Nicole Cutler, 2013). 
When taken orally, TVR has a high rate of absorption in the small intestine. Its plasma 
concentration reaches maximum after a single dose in 4-5 hrs. This drug is highly bound to 
plasma proteins (59-76% ), it especially binds to alpha 1-acid glycoprotein and albumin with 
an inverse concentration-dependent pattern (Vertex., 2013). Metabolism of TVR occurs 
mainly in the liver through reduction, oxidation and hydrolysis, which will produce various 
metabolites. Figure 1.16 show the structure of TVR and its alternative diastereomer. 
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       A                                                                B 
                 
      Figure 1-16 (A) Telaprevir (S-diastereomer) and (B) R-diastereomer (PubChem, 2018a).  
 
1.9 Treatment of autosomal dominant polycystic kidney disease (ADPKD). 
ADPKD is one of the most common monogenic defects of the kidney, it is widespreaded 
among different ethnic groups. It occurs in 1:400 to 1:1,000 patients. Tolvaptan as selective 
arginine vasopressin (AVP) a V2 receptor antagonist, it used in the treatment of ADPKD 
(Watkins et al., 2015a). The treatment with tolvaptan in ADPKD produces a slow increase 
in total kidney volume (Torres et al., 2012). The risk of liver failure has been reported in 
patients receiving long-term tolvaptan therapy, therefore patients who are treated with 
tolvaptan need continued monitoring through liver function tests (Watkins et al., 2015a).  
1.10 Hyponatremia 
Hyponatremia is an important and common clinical condition resulting from an electrolyte 
abnormality. This condition is characterised by a reduced serum sodium level below 135 
meq/l when the kidney doesn’t have the ability to excrete a water load or excess water intake 
(Sahay and Sahay, 2014, Eric, 2018). Tolvaptan has been approved by the FDA for 
management of hyponatremia. This drug is used orally, the dose is usually 15 mg/day. 
However, the dose may be increased to a maximum of 60 mg daily depending on sodium 
concentrations (Page, 2011). Tolvaptan is used also to treat hyponatremia because of its 
QA 
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ability to work as a selective arginine vasopressin (AVP) V2 receptor blocker (Dixon and 
Lien, 2008). 
 Tolvaptan. 
Tolvaptan can be given as single oral doses ranging 60 to 480 mg/day. After its 
administration orally it will be absorbed by the gastrointestinal tract and its bioavailability is 
50% after a 30 mg dose. Tolvaptan is mainly metabolised by cytochrome P450 3A and forms 
two types of metabolites; dehydrogenated and hydroxylated forms (Shoaf et al., 2012, Lu et 
al., 2016). The main two metabolites for tolvaptan are DM-4103 and DM-4107 (Figure 1.17),  
they are excreted in urine and feces, respectively (Lu et al., 2016). 
 
               
Figure 1-17 Tolvaptan and the main metabolites DM-4103 and DM-4107 (Wan et al., 2012). 
 
Mosedale et al studied the effect of tolvaptan on the liver. They found that the liver could be 
a target for an adaptive immune attack, which will lead to clinically significant liver injury. 
They suggested that iDILI starts when the drug induces hepatocyte stress, which will lead to 
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a release of danger signals and stimulation of the innate immune system. These steps are 
important for activation but they not enough to activate the adaptive immune response in the 
liver (Mosedale and Watkins, 2017, Mosedale et al., 2018). Since tolvaptan is metabolised 
in the liver by the CYP3A4 system (Dixon and Lien, 2008), the concentration will increase 
with any co-medication that inhibits CYP3A4 activity. Tolvaptan-induced exosomes are  
released by  primary human hepatocytes in patients in the absence of overt necrosis. The 
secreted exosomes are associated with mitochondrial-induced apoptosis and oxidative stress 
(Mosedale et al., 2018).  
1.11 Treatment of Leprosy. 
Leprosy is a disease that is characterised by chronic granulomatous lesions that occur due to  
infection with Mycobacterium leprae. The bacteria mainly infects the skin and nerves and 
this lead to immunological damage. The symptoms also include ulcerative lesions of  hands, 
feet and eyes as well as paralysis due to damage of the nerves (Walker et al., 2014). Dapsone 
is the main drug used in leprosy treatment. However, this drug is also used to treat cases of 
refractory skin lupus (Lahita, 2007).  
 Dapsone (DDS). 
DDS (4, 4-diaminodiphenylsulfone), is used as oral tablets in doses ranging from 25 mg to 
100 mg daily. DDS tablets have a different commercial name in different countries, for 
example, Dapsone® (Australia), Daps® (Argentina), Avlosulfon® (Canada), Dapson®, 
(Denmark, Egypt, the Netherlands, Norway), Dapson-Fatol® (Germany). DDS is used to 
treat leprosy usually with another anti-leprosy drugs (which are rifampicin and clofazimine 
(Venkatesan, 1997)). DDS it is also used in prophylaxis treatment against toxoplasmosis, in 
HIV and in treating acne vulgaris and other medical conditions. Moreover, DDS has been 
confirmed to be effective in different immune conditions and inflammatory diseases such as 
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recluse spider bites, dermatitis, leukocytoclastic vasculitis and rheumatoid arthritis (Bloom 
and Ryan, 2013). 
The mechanism of action of DDS is still not fully understood, but generally, DDS inhibits 
the synthesis of dihydrofolic acid by competing with para-aminobenzoate at the active loci 
of dihydropteroate synthetase. However, DDS may also inhibit neutrophil function through 
prevention of the respiratory burst and inhibition of adherence to the vascular endothelium. 
The peak serum level of DDS is reached after 2-8 hrs. DDS is highly bound to proteins (70-
90%) and it is distributed widely in the body. This drug has the ability to accumulate in the 
liver, kidneys, skin and muscles. It is mainly metabolised in the liver by acetylation, the 
dapsone metabolites are removed through the urine by formation of glucuronide conjugates 
(Bloom and Ryan, 2013). Figure 1.18 shows DDS and its metabolite nitroso (DDS-NO), 
which is formed through oxidative metabolism. 
Recent studies report that DDS induced hypersensitivity occurs in  0.5-3.6% of patients 
(Kosseifi et al., 2006). There are ongoing attempts to confirm if the parent drug or its nitroso 
metabolite are the culprits in hypersensitivity reactions (Vinod et al., 2013, Alzahrani et al., 
2017b). DDS hypersensitivity is a condition that is characterised by high fever, skin rash, 
lymphadenopathy, eosinophilia, hepatitis, acute pneumonitis, and other systemic features 
(Kosseifi et al., 2006). 
 
                           
Figure 1-18 A- dapsone structure (Pubchem, 2018b) B- nitroso dapsone (PubChem, 2018c) 
 
Chapter one                                                                        Introduction and Literature review 
75 
 
1.12 Aims of the thesis.  
The primary aim of this thesis is to investigate and discover the immunological aetiology of 
drug hypersensitivity reactions for 3 different drugs with different pharmacological 
mechanisms by utilising human blood samples from healthy donors and hypersensitive 
patients. We generated drug-specific T-cells clones, and utilised a battery of biological and 
functional assays to explore to chemical and cellular basis of hypersensitivity reaction to 
telaprevir, tolvaptan and dapsone. 
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 Chapter 2: Materials and Methods. 
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2.1 Reagents, drugs and chemicals. 
 Lymphoprep-source-Axis-Shield (Dundee, UK). 
 Magnets, magnetic columns, and antibody-conjugated magnetic bead kits for the 
isolation of cell subsets from PBMCs including CD14+, pan-T, CD25+, or CD45RO+ 
populations-source-Miltenyi Biotec (Surrey, UK). 
 A range of CD4 and CD8 conjugated fluorochromes for use in flow cytometry, along 
with CD1a-fluorescein isothiocyanate (FITC), CD11a-FITC, CD11c- phycoerythrin 
(PE), CD14-FITC, CD40-FITC, MHC class I-PE, MHC class II-FITC, PD-L1-PE, 
CD45RO-PerCP-Cy5, and the anti-mouse Ig/ negative control compensation 
particles set-source- BD Biosciences (Oxford, UK). 
 PD-1-PE, CTLA4-allophycocyanin (APC*), TIM-3-PE, CD80-FITC, CD1a-FITC, 
and CD86-FITC-source-Serotec (Kidlington, UK). 
  CD83-PE- source- R&D systems (Minneapolis, USA). 
  Galectin-9-APC*-source-Biolegend (Cambridge, UK). 
 Materials for blocking studies mouse anti-human HLA-ABC (isotype, IgG1; clone 
DX17), mouse anti-human HLA-DR/DP/DQ (isotype, IgG2a; clone, Tu39), mouse 
anti-human HLA-DR (isotype, IgG2a; clone G46-6), and mouse anti-human HLA-
DQ (isotype, IgG2a; clone, Tu169) monoclonal blocking antibodies and their 
respective isotype controls-source-BD Biosciences (Oxford, UK). 
 Anti-human HLA-DP blocking antibodies-source-Serotec (Kidlington, UK). LEAF 
purified (< 0.1 EU/μg endotoxin) mouse anti-human CD274 (PD-L1; isotype, IgG2b; 
clone, 29E.2A3), LEAF purified mouse anti-human CD273 (PD-L2; isotype, IgG1; 
clone, MIH18), LEAF purified mouse anti-human CD152 (CTLA4; isotype, IgG1; 
clone, L3D10), and LEAF purified mouse anti-human CD366 (TIM-3; isotype, IgG1; 
clone, F38-2E2) were azide-free and purchased from Biolegend (Cambridge, UK). 
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 ELIspot multiscreen filter plates-source-Millipore (Watford, UK),  
 The ELIspot kits containing coating and detection antibodies along with BCIP/NBT 
Plus liquid substrate solution for IFN-γ, IL-13, IL-17, IL-22, IL-5, granzyme B, and 
perforin-source-mabtech (Nacka Strand, Sweden).  
 The ELIspot kit for Fas ligand-source-Abcam (Cambridge, UK). 
 Recombinant human GM-CSF, recombinant human interleukin-2 (rhIL-2), and 
human IL-4-source-Peprotech (London, UK). 
  Foetal Bovine Serum (FBS) and Human AB Serum -source-Invitrogen (Paisley, UK) 
and Innovative Research (Michigan, USA), respectively.   
 The [3H]-methyl thymidine (5 Ci/mmol)-source-Moravek (California, USA) 
  Meltilex scintillator sheets, sample bags, and printed glass fibre filter mats for 
thymidine analysis-source-Perkin-Elmer (Waltham, USA).  
 Carboxyfluorescein diacetate succinimidyl ester (CFSE)-source-eBioscience (San 
Diego, USA). 
 Cell culture flasks and nunc 6-, 24-, 48-, and 96-well plates-source-Thermo Scientific 
(UK). 
  Purified tetanus toxoid (TT) -source-Statens seruminstitut (Copenhagen, Denmark). 
DNA-selective magnetic beads, protease, associated wash buffers and the Magnetic 
Separation Module-1 for the isolation of DNA-source-Chemagen (Baesweiler, 
Germany).  
 Cyclosporine-A-source-Fluka Analytical (Dorset, UK). 
 Dimethyl sulfoxide (DMSO), Roswell Park Memorial Institute (RPMI)-1640, 
penicillin and streptomycin, transferrin, 4-(2-hydroxyethyl)-1-
piperazineethanesulfonic acid (HEPES buffer), L-glutamine, Hanks balanced salt 
solution (HBSS), bovine serum albumin (BSA), ethylenediaminetetraacetic acid 
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(EDTA), sodium azide, and all other unlisted reagents were purchased from Sigma-
Aldrich (Dorset, UK). 
 Telaprevir and its metabolites - source- Janssen Pharmaceutica (Belgium). 
 Tolvaptan and its metabolites-source-Otsuka Pharmaceuticals (Japan). 
 Dapsone and its metabolites -source-Sigma (UK). 
2.2 Cell culture medium and Buffers. 
 Cell culture medium -R9 medium -500 mL RPMI 1640, 100 μg/mL penicillin, 100 
U/mL streptomycin, 100 mM L-glutamine, 25 μg/mL transferrin, 10% (v/v) human 
AB serum, 25 mM HEPES buffer. Used for T-cells clones. 
 Cell culture F1 medium-500 mL RPMI 1640, 100 μg/mL penicillin, 100 U/mL 
streptomycin, 10% (v/v) FBS, 25 mM HEPES buffer, 2mM L-glutamine. Used for 
Epstein-Barr virus (EBVs) culture. 
 MACS buffer (X 10)-50 mL HBSS, 50 μg/mL BSA, 20 mM EDTA. Used for 
magnetic bead isolation for cells. 
 FACS buffer -500 mL HBSS, 10% (v/v) FBS, 0.2 mg/mL sodium azide. Used for 
T-cells phenotyping. 
 Phosphate buffered saline (PBS; X 10) - NaCl (80g), Na2HPO4 (11.6 g), KH2PO4 
(2g), KCl (2g). Dilute to 1 litre with distilled water, further 1:10 dilution required 
before use, final pH: 7.0. Mainly used in ELIspot for washing plate. 
2.3 Human Subjects. 
Up to 120 mL venous blood was collected from healthy volunteers and from clinically 
diagnosed hypersensitive patients.  
The study was approved by the Liverpool local research Ethics Committee and informed 
written agreements/consents were obtained from all participating blood donors. 
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2.3.1 Generation of drug-specific T-cells clones from healthy volunteers 
and from hypersensitive patients by isolation of peripheral blood 
mononuclear cells (PBMCs). 
Blood was taken by venesection and collected in heparinised vacutainer tubes. Blood (25 
mL) was carefully layered on lymphoprep (25 mL) and spun at 2000 revolutions per minute 
(rpm) for 25 min with zero deceleration in a centrifuge at 25°C. Then the blood was separated 
to different layers that were visible from top to the bottom. They were easily identifiable by 
their individual colours; plasma (yellow), lymphocyte layer (cloudy white to grey), 
lymphoprep (transparent), erythrocytes (red). In the middle, the buffy coat layer containing 
the peripheral blood mononuclear cells (PBMCs) was carefully collected using a Pasteur 
pipette (Figure 2.1). PBMCs were placed in a new tube, and washed twice with Hanks 
balanced salt solution (HBSS). The ratio of dilution was 1:4 and then cells were centrifuged 
at 1800 rpm for 10 min. The supernatant was discarded and the cell pellet resuspended in 
HBSS. The tubes were then spun at 1500 rpm for 10 min and the cells resuspended in culture 
medium prior to counting.  
PBMCs (10 μL) were mixed with an equal volume of trypan blue (0.2 % w/v) and another 
(20 μL) of HBSS was added. Then (10 μL) of the mixture was placed on a Neubauer 
haemacytometer (Sigma-Aldrich) under a Leica DME microscope (Leica Microsystems, 
Milton Keynes). Dead cells were much darker than the live cells under the microscope. The 
percentage viability was calculated by the following equation: percentage viability=viable 
cells ÷ total cells x100. Percentage viability was ≥95% for all the PBMC isolations. Cells 
were then used in functional assays or frozen for later use by resuspending them in R9 
medium (10-20x106 cells/mL) and further diluting them 1:1 with “freezing mix” (80% 
human AB serum, 20% DMSO) in 1.8 mL cryovials (total volume, 1 mL; maximum cell 
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concentration per vial, 5x106/mL). Cryovials were placed in Mr. Frosty tubs and stored at -
80°C for 24-48 hrs before being transferred to -150°C for longer term storage. 
 
 
Figure 2-1 The procedure for separation of PBMCs. 
 
2.3.2 Detection of drug-specific PBMC responses using the lymphocyte 
transformation test (LTT). 
PBMCs (0.15x106 per well) were cultured in triplicate. The following reagents were added: 
 Diluted drug concentrations by serial dilution. 
 Tetanus toxoid (5 μg/mL) as a positive control. 
 Negative control (medium). 
The final volume inside the wells was 200 μL for all the conditions. The test plates were 
incubated for 6 days at 37°C and 5% CO2. [
3H]-thymidine was added for the last 16 hrs (0.5 
μCi/well). The cells were then harvested on to paper filter mats which were sealed with wax 
after drying using tomtec harvestor 96 (Receptor Technologies). Incorporated radioactive 
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wax was then read using a Microbeta Trilux 1450 LSC (Perkin-Elmer, UK) which 
interpreted the data as radioactive counts per minute (cpm), to measure the rate of [3H]-
thymidine uptake by the cells. This gives a quantitative measure of proliferation in counts 
per minute (cpm), Figure 2.2 illustrates the procedure with telaprevir. An SI ≥1.5 was 
considered as an indicator for the proliferation of T-cells with the culprit drug. 
 
 
Figure 2-2 Lymphocyte transformation assay (LTT) scheme. 
 
2.3.3 Generation of Epstein-Barr virus transformed B-cells. 
Antigen presenting cell lines (EBVs) were generated from healthy donors or hypersensitive 
patients (Neitzel, 1986, Naisbitt et al., 2003, von Knebel Doeberitz et al., 1983). 
Autologous EBVs are a fundamental requirement for the examination of T-cell clones. The 
marmoset cell line B9-58 acts as a source for the Epstein-Barr Virus (EBV), which is found 
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as circular episomal DNA inside the infected cells (5-800 copies/cell). This virus (EBV) 
selectively transforms human B-lymphocytes into an endlessly dividing, and immortalised 
lymphoblastoid cells (Neitzel, 1986). 
PBMCs (5x106) either from patients or from normal volunteers were cultured with (5 mL) 
of supernatant from the B9-58 cell line filtered using 0.45 μm syringe filter. After that, 
cyclosporine A (CSA, 1μg/mL) was added to prevent the proliferation of T-lymphocytes, 
and PBMCs were incubated at 37°C overnight under an atmosphere of 5% CO2. Cells were 
then spun at 1500 rpm for 5 min. The supernatant was discarded and the cells were 
resuspended in 2 mL of APC culture medium supplemented with (1 μg/mL) CSA. The cells 
were then transferred to new 24-well plates in a total volume 1 mL/well. Medium was 
replaced twice a week. CSA was stopped after a period of 3 weeks, and the cells transferred 
to cell culture flasks.  
2.3.4 Generation of drug-specific T-cell lines and T-cell clones from 
PBMCs. 
2.3.4.1 Drug-specific T-cell enrichment "bulk culture". 
PMBC (2x106 cells/well) were cultured in 48 well plates with the culprit drug, in the optimal 
dose for activating T-cells for 14 days, at 37 °C and 5% CO2. The cultures were fed on day 
6 and 9 with culture medium and IL-2 (60 IU/mL).  
2.3.4.2 Serial dilution of bulk cultures. 
Bulk culture PBMC were diluted serially to 96-well U-bottom plates at 3 densities: 0.3, 1 
and 3 cells/well, in culture medium supplemented with IL-2 (200 IU/mL),             
Phytohaemagglutinin (PHA) (5 μg/mL) and 45 Gy irradiated allogeneic PBMCs (as feeder 
cells). The serial dilution cultures were incubated for 2 weeks at 37 °C and 5% CO2 with 
feeding every 48 hrs with culture medium (25 μL/well) containing IL-2 (60 IU/mL).  
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The restimulation cocktail was prepared with irradiated, allogeneic PBMCs at a 
concentration of 5x105 cell/mL, IL-2 (400 IU/mL) and PHA (10 μg/mL). Serial dilution well 
volumes were reduced to 80 μL. Subsequently 50 μL was added to each well from the 
“restimulation cocktail”. The cultures were incubated at 37 °C and 5% CO2 for a further 14 
days, during this period cells were fed every 2 days with culture medium (25 μL/well) 
supplemented with IL-2 (200 IU/mL), and the plates were regularly checked for any clone 
growth. Any wells that contained a mature clone, in the cell pellet (about 2mm) was 
transferred to new 96-U bottomed plate and expanded into 2 wells and later into 4 wells. 
When the clones were split into 4 wells, they were tested for drug-specific T-cell 
proliferation. 
2.3.4.3 Proliferation of drug-specific T-cell clones using radioactive 
thymidine. 
Half of each picked clone was split to 4 wells (50 μL/well) in 96-well plates and tested for 
antigen specificity. Autologous EBV-transformed B-cells were centrifuged to remove the F1 
medium and resuspended in R9 medium. EBVs were irradiated for 20 min to stop cell 
proliferation but maintain their ability and process and present antigen. Irradiated EBVs were 
diluted to 104 cells/well and added (50 μL) to wells containing the clones. Two of the wells 
received 50 μL/well R9 medium as a negative control. The other two wells received 50 μL 
drug. Test plates were incubated for 48 hrs in a humidified atmosphere of 5% CO2 at 37°C. 
[3H]-thymidine (0.5 μCi) was added for the final 16 hrs. The tested clones were harvested 
on paper filter mats and read by the beta counter to measure the [3H]-thymidine uptake by 
T-cell clones. The extent of the proliferation of the cells with drugs was divided by the 
proliferation of the cells in medium, to calculate the stimulation index (SI). If the SI was ≥ 
2, it was accepted as a drug-specific T-cell. 
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2.3.4.4 Restimulation and expansion of drug-specific T-cell clones 
After detecting drug-specific T-cell clones, the remaining 2 wells were transferred to sterile 
3 mL tubes and centrifuged at 1500 rpm for 10 min at the room temperature. They were then 
resuspended in 330 μL R9 medium and added to one well of a 48-well culture plate. The 
restimulation cocktail consisting of irradiated allogeneic PBMCs which had been diluted to 
1.5x106/mL in R9 medium supplemented with IL-2 (400 IU/mL) and PHA (10 μg/mL) was 
then added to each well. Every two days clones were fed with 330 μL R9 medium 
supplemented with IL-2 (200 IU/mL).  
2.3.5 Quantitative assessment of the clone responses to drugs (dose-
response test).  
The drug-specific T-cell clones were subjected to quantitative assessment of drug doses. 
Drug-specific T-cell clones were cultured with irradiated autologous EBV and serially 
diluted drug doses. A wide range of concentrations were selected around the optimum dose 
(higher and lower). Test plates were incubated for 48 hrs in a humidified atmosphere of 5% 
CO2 at 37°C. [
3H]-thymidine (0.5 μCi) was added for the final 16 hrs. Tested clones were 
harvested on paper filter mats and read by the beta counter to measure the [3H]-thymidine 
uptake. 
2.3.6 Qualitative assessment of clone reactivity to drugs (cross-reactivity 
test). 
The general protocol for T-cell proliferation by uptake of thymidine was also used here, but 
with this experiment T-cell clones were cultured with different concentrations of structurally 
related drugs. 
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2.3.7 T-cells proliferative response with and without APC fixation. 
T-cell clones were harvested and suspended in HBSS (2 million/mL). Glutaraldehyde (1 μL 
/mL, 25%) was added to EBVs and the mixture was incubated at room temperature for 30s. 
The reaction was stopped by adding glycine (0.2M) for 45s. EBVs were washed with 3x25 
mL medium. An additional set of EBVs (without fixation) was prepared, as a control for the 
experiment. Both types of EBV were irradiated and used in a [3H]-thymidine uptake 
proliferation test (2.3.4.3). 
2.3.8 APC pulsing assay. 
Harvested EBVs were centrifuged to remove F1 medium and R9 medium was added. EBVs 
were incubated with the culprit drug for different periods with the same concentration of test 
drug in a 24 well plate for 1, 4, 16, 24 and 48 hrs. The time for pulsing was changed 
depending on the experiment. Harvested EBVs were washed, irradiated (60 Gy) and then 
incubated at (10000 cell/well/50 μL) in 96-well test plates. Other wells with non-pulsed 
irradiated (60 Gy) EBVs were added as controls. T-cells were prepared at a concentration of 
50000 cells/well/50 μL. The drug was added in double effective concentrations. Control 
wells without the drug contained 100 μL medium. The plate was incubated for 48 hrs at 37°C 
and 5% CO2. For the last 16 hrs [
3H]-thymidine (0.5 μCi)/well was added. The plate was 
harvested and read using a Beta counter (Figure 2.3). 
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Figure 2-3 Pulsing assay. This assay was divided into two parts. First, pulsed EBVs were treated with the drug 
for different periods of time. Secondly, unpulsed EBVs were treated with soluble drugs. This group was 
considered as a positive control. The treated EBVs were washed several times to remove the unbound drug. 
Both groups (the treated and non-treated EBVs) underwent radiation.  
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2.3.9 Measurement of cytokine secretion from T-cell clones using Enzyme-
linked immunospot assays (ELIspot). 
This test is used to quantify individual cytokines-secreting cells when they encounter a 
specific antigen. There are several steps to the procedure (Figure 2.4). The limit of detection 
can be as low as 1 cell in 100,000 (Mabtech, 2018). ELIspots assays are carried out according 
to the manufacturer’s instructions (Mabtech, Nacka Strand, Sweden). 
                         
Figure 2-4 Detection of cytokine secretion using ELIspot. A. The ELIspot plate is coated with cytokine-
specific coating antibody and is incubated overnight at 4°C. B. The plate was washed and the membrane was 
blocked with R9 medium. T-cells, APCs and drug were added and incubated for 48 hrs at 37°C. C, The plate 
was washed, and biotin-conjugated detection antibody was added and incubated at room temperature for 2 hrs. 
D. The plate was washed, streptavidin-bound enzyme (HRP or ALP) was added and incubated for 1 hr at room 
temperature. E. The plate was washed and substrate was added (BCIP-NBT or TMB). Spots start to appear 
during 15 min incubation in the dark. (F) The plate was washed and left to dry overnight, to be ready for reading 
by the ELIspot reader. 
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A. Coating the ELIspot plate: On day 0. 
Ethanol (20 μL, 35%) was added to each well of the ELIspot plate and left for one minute. 
The plate was washed 5x with sterile dH2O (200 μL/well). Coating antibody (100 μL/well) 
was added and incubated overnight at 4°C. The antibodies were diluted from the stock (IFN-
γ, diluted from 1 mg/mL to 15 μg/mL; IL-13, IL-22, IL-17, diluted from 0.5 mg/mL to 10 
μg/mL) in HBSS. 100 μL of coating antibody was added to each well and then incubated 
overnight at 4°C.  
B.  Cell Incubation: On day 1. 
The coated plate was washed 5x using 200 μL HBSS, to remove the excess antibody. The 
plate was blocked by adding culture medium (200 μL/well) for 30 min. After washing 5x 
with HBSS, 5x104/50 μL T-cells, 1x104 60 Gy irradiated EBVs/50 μL, medium (negative 
control), serial dilutions of culprit drug 100 μL/well, or PHA (5μg/μL) as a positive control, 
were added to the wells. The plate was wrapped in aluminium foil and incubated at 37 °C 
and 5% CO2 for 48 hrs. 
C.  Spot Detection: On day 4. 
On completion of the incubation the plate was washed 5x with 200 μL PBS. Detection 
antibody (100 μL/well) was added and incubated for 2 hrs at room temperature. The plate 
was washed 5x with 200 μL PBS. Streptavidin ALP (100 μL/well) was added and incubated 
for 1 hr at room temperature. The plate was washed 5x with 200 μL PBS and afterwards 100 
μL/well of detection substrate (BCIP/NBT) was added. The plate was kept in the dark at 
room temperature. The final step was waiting until the spots emerged (generally they 
appeared in 13-15 min). The reaction was stopped by washing the plate with tap water and 
then the plate was rinsed and kept in dark until it dried. The plate was then analysed using 
an AID ELIspot reader (Cadima Madical, Stourbridge, UK) to count the spots. 
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2.3.10 MHC restriction assay. 
MHC restriction assay was conducting using two methods, either by assessment proliferation 
or by ELIspot assay to detect cytokine secretion from T-cell clones. The method follows the 
previous protocols for proliferation and cytokine release. Autologous EBV-transformed B-
cell lines (1x104, 50 μL) were incubated with either MHC I or MHC II blocking antibodies 
at a concentration 5 μg/mL in a humidified atmosphere of 5% CO2 at 37°C for 30 min. The 
EBVs were then cultured with drug-specific T-cell clones (5x104, 50 μL) with or without a 
drug for 48 hrs. After the incubation period, [3H]-thymidine (0.5 μCi) was added for the final 
16 hrs and plates were harvested onto filter mats using a TomTec Harvester 96. Incorporated 
radioactivity was measured as described previously. Cytokine secretion profiles (IFN-γ, IL-
5, IL-13and granzyme-B) were determined by using ELIspot analysis using the procedure 
described on the previous page. 
2.3.11 Measurement of T-cell receptor and chemokine receptor expression 
using flow cytometry. 
Flow cytometry was created in the 1970s. It became a very important method for detection 
of the specific markers on the surface of cells and to measure single cell characteristics. Flow 
cytometry depends on the suspension of cells in a narrow liquid flow so that they pass in a 
single file through the path of multiple laser beams, with different wavelengths. Optical 
detectors transform fluorescent light emitted from each cell into an electrical signal (Figure 
2.5 A). Most of the cells are labelled with fluorescent antibodies that bind to specific 
membrane proteins. Depending on the density of signal emitted at various wavelengths, the 
cells are analysed one by one for various features, for example, size, granularity, and 
expression of membrane-bound proteins. By this method, thousands of single cells can be 
analysed per hour, for up to 18 protein markers (Figure 2.5 B, C) (Nassar et al., 2015). 
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A. Flow cytometry technique. 
 
    
B. Data analysis for types the cells.             C. Phenotyping for type cells.  
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D. The T-cells gate 
                      
 
Figure 2-5 A. The principle of phenotyping cells using flow cytometry. The figure is adapted from 
(Semrock, 2018).The cell populations are stained with fluorochrome-bound antibodies. To detect multiple 
markers, the individual fluorochromes must be associated with various wavelengths to help distinguishing 
them. After passing the cells through the flow cell tube as a single cell stream in fast flowing sheath fluid 
(hydrodynamic focusing), each individual cell will pass through the channel of the laser light. Fluorochromes 
bound to markers on the cell surface diffuse light at their particular wavelengths, and this will be detected with 
sensor specific for different wave-bands that have the ability to detect the emitted light. B. Data analysis 
depends on the differential refraction of the light based upon the cell size and granularity that is detected by 
the side scatter (SSC) - and forward scatter (FSC)-sensors to provide information indicative of particular cell 
populations. If the cells appear in the upper half that means the cells give high signals at the side scatter 
detectors, which means that cells are complex. If the cells appear in the left side that means the cells give low 
signals of forward light scatter, which means that cells are small. If the cells appear in the lower quarter that 
means the cells give low signals at the side scatter detectors, which means that the cells are simple. If the cells 
appear in the right half that means the cells give high signals of forward light scatter, which means that cells 
are large. C. Phenotyping. This gated population is analyses of the type of the cells depending on various kinds 
of specific proteins on the cell surface by using two different fluorescent stains such as CD4, CD8. D. The T-
cell population (lymphocytes) is gated on a dot plot of FSC and SSC. 
 
The protocol below describes a general method for flow cytometric analysis. 
Compensation Preparation: Due to the fact that this experiment contains multicolour 
staining, compensation should be performed. The compensation is used to prevent 
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interference of the fluorescent dyes signals. The compensation kit consists of 2 droppers, 
they contain beads which can be stained with the fluorochrome antibodies used in the 
analysis. The first step is that the FACS buffer (400 μL), is added to one non-sterile FACS 
tube. Then, one drop of each compensation bead is added to the tube. After shaking, (100 
μL) of the mixture is transferred to non-sterile FACS tubes. The number of compensation 
tubes equals the number of the colours of fluorescent antibodies used in the experiment, plus 
one extra tube for the control condition.  
Cell labelling: 50 μL of cells were transferred into a non-sterile FACS tube. The fluorescent 
stain bound antibodies were added into the FACS tube at a concentration determined by the 
manufacturer. Then, the tubes were incubated at 4°C for 20 min in the dark. After the 
incubation period, 500 μL of FACS buffer was added to each tube. Subsequently, they were 
centrifuged at 1500 rpm for 5 min. The supernatant was discarded and the cells were 
resuspended in 200 μL FACS buffer for immediate analysis by flow cytometry. In case of 
delayed the analysis, the cells were fixed in 4% paraformaldehyde (200 μL) and kept in the 
fridge at 4ºC. 
2.3.12 Migration of T-cell clones.   
A Corning Costar Transwell plate containing 12 wells and a pore size of 5µm was prepared 
by adding medium (3 mL) with chemokines (48 µL) to the lower chamber of the well. 
Specifically, CCL17, CCL27 and a mixture of CCL17 and CCL27 were used to identify the 
migration of drug-specific T-cell clones. Clones were added to the top chamber and their 
migration was assessed by counting the increase in number of cells in the bottom 
compartment at different time points (30 min, 2 hrs, 4 hrs, 16 hrs, and 24 hrs). 
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2.3.13 Isolation of cell subsets from whole PBMC using MACS magnetic 
bead columns and the priming of naïve T-cells from healthy donors.  
In this experiment different populations of cells were separated from total PBMCs using 
magnetic beads and columns in a sequence steps according to the manufacturers’ instructions 
(Miltenyi Biotec, Bisley, UK). The purified cells were utilized to perform tests which needed 
pure populations of CD14+ monocytes, CD45RO- CD45RA+ (naïve) T-cells, and CD45RO+ 
CD45RA- (memory) T-cells. During positive selection, antibodies specific for the required 
cell surface marker protiens were bound to 50 nm diameter, non-toxic, biodegradable, 
superparamagnetic particles to produce MACS microbeads. These MACS microbeads bind 
to the cell surface. The labelled cells could be easily separated from non-labelled cells by 
passing the total cell population through a magnetic field. The microbeads do not block all 
the epitope on each cell, thus allowing cells to maintain their functionality. The labelled cells 
bound to the magnetic beads are retained within the column. After that, the magnet is 
removed and the labelled cells are pushed out of the column by plunging the column with 
MACS buffer. The second type of selection is negative selection attributed to the use of the 
antibodies which select markers that are not found on the cell population of interest. 
Selections yield population purities of > 97% (Faulkner et al., 2012b).  
Procedure: A sample of blood would be taken from a volunteer and the PBMCs isolated. 
2.3.13.1 Positive selection of CD14+cells monocytes. 
All cells, microbeads and MACS buffer were kept on ice. PBMCs were centrifuged for 10 
min at 1500 rpm. The supernatant was removed, and the cells were resuspended in MACS 
buffer (800 μL per 108 PBMCs). CD14+ specific microbeads (200 μL per 108 cells) were 
added, then the cells were incubated at 4ºC for 15 min. 15 mL MACS buffer per 108 cells 
was added to the cells suspension, which was then centrifuged for 10 min, 1500 rpm at 4ºC. 
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The supernatant was removed and the cells resuspended in MACS buffer (500 μL per 108 
cells). A MACS LS column was added to the magnet and washed with MACS buffer, then 
the cell suspension was added directly to column. The column was washed  3x with 3 mL 
MACS buffer to ensure all unlabelled cells had passed through the column and been eluted. 
The collection tube contains the CD14- cell population, while the CD14+ population stick to 
the column. The column as then removed from the magnet, and placed over a new collection 
tube to collect the cells from the column by plunging 5 mL MACS buffer firmly through the 
column into a new collection tube. These were the CD14+ cells (Figure 2.6 A). MACS buffer 
(10 mL) then was added to the CD14+ and CD14- cells. Both of cells were counted, 
centrifuged and then resuspended in R9 medium. 500 μL of the cell suspension was taken to 
generate dendritic cells. The remaining cells were cryopreserved at 5-10x106 cells/cryovial. 
2.3.13.2 Negative selection of CD3+ T-cells. 
Further isolation was performed using the total T-cell population (Figure 2.6 B). Non-CD14 
cells were spun down and the supernatant was discarded, then they were resuspended in 
MACS buffer (400 μL per 108 cells). A pan T-cell antibody cocktail (100 μL per 108 cells) 
was added. This cocktail consisted of different types of antibodies prepared for selective 
markers that would not be found on T-cells to allow for later positive selection of these cells 
and for T-cells to pass through the column. The cells were mixed and incubated at 4°C for 
10 min. After the first incubation period was finished, more MACS buffer (300 μL per 108 
cells) was added as well as anti-biotin microbeads (200 μL per 108 cells). The cells were 
entered to a second incubation period at 4ºC for 15 min. Next, the cells were diluted in MACS 
buffer (1.5 mL per 107cells). Then they were centrifuged at 1500 rpm for 10 min at 4°C. The 
supernatant was removed and resuspended in the MACS buffer (500 μL per 108 cells) and 
passed through a new LS column as previously described in positive selection of CD14+ 
cells. The cells that travel into the collection tube were CD3+ cells. The volume of T-cells 
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(CD3+) was increased to 15 mL. The non-T-cells (CD3-) were also collected from the 
column. Both cell subsets were counted before centrifuging. Non-T-cells (CD3-) were frozen 
and stored for use in the setup of Epstein-Barr virus transformed B-cells (EBV) as discussed 
in section 2.3.3.   
2.3.13.3 Positive selection of CD25+ (regulatory) and CD45RO+ (memory) 
T-cell populations 
The T-cell population (CD3+) was then subject to two final positive selection processes. 
First, T-cells were resuspended in MACS buffer at a concentration of (900 μL per 108 cells) 
and CD25+ microbeads (100 μL per 108 cells). The cells were then incubated for 15 min at 
10ºC. After centrifugation the cells were resuspended in MACS buffer (500 μL per 108 cells), 
and pushed through a new LS column as previously described. The CD25- T-cells crossed 
the column to the collection tube. While the CD25+ T-cells were retained in the column. 
CD25+ T-cells were subsequently extracted from the column. In the second selection, the 
CD25- T-cells were resuspended in MACS buffer (800 μL per 108 cells) and CD45RO 
microbeads (200 μL per 108 cells), and the mixture was incubated for 15 min at 4ºC. After 
washing, the cells were resuspended in MACS buffer (500 μL per 108 cells), and passed 
through a new LS column as previously described. The CD45RO- T-cells passed directly 
through the column, while the CD45RO+ T-cells were retained. The CD45RO+ T-cells were 
subsequently eluted by force. The final step was that all the cells (CD25+ T regulatory cells, 
CD45RO+ memory T-cells, CD45RO- naïve T-cells), were counted, centrifuged and then 
frozen at a concentration of 5-10x106 cells per cryovial in a 1:1 mixture with “freezing mix”.  
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Figure 2-6 Magnetic bead-mediated isolation of various cell subsets from healthy donor PBMCs. (A) the 
first step was to add CD14 microbeads. The labelled PBMCs were then added to a column placed on a magnet. 
The CD14+ labelled cells stick in the column, whereas, the CD14- would wash through. Then the column was 
removed from the magnet and the CD14+ cells eluted. (B) Next, the CD14- cells were incubated with a 
biotinylated antibody cocktail which connects to a range of cell surface molecules not associated with T-cells. 
After that, anti-biotin microbeads were added to bind to these antibodies. When the cells were added to the 
column, T-cells were washed through. The non-T cells still binding in the column, therefore would be forcibly 
eluted from the column. Other steps for further separation, (C) First isolation of CD25+ cells by positive 
selection (Treg) (D) Second, separation were then performed of CD45RO+ cells from the CD25- cells was 
conducted. Finally, naïve (CD45RO-) T-cells were separated from their CD45RO+ (memory) T-counterparts. 
(C and D not found in the graph). 
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2.3.14 Generation of dendritic cells from CD14+ monocytes. 
CD14+cells (monocytes) can differentiate into dendritic cells (DCs). DCs act as APCs and 
are effective at priming of naïve T-cells (Guermonprez et al., 2002). 
To generate DCs, frozen CD14+ monocytes were thawed then transfered to a fresh tube of 
R9 medium. The thawed cells were centrifuged at 1500 rpm for 10 min. The supernatant was 
discarded and the cells resuspended in R9 medium for counting. The CD14+ cells were 
suspended in medium containing GM-CSF (800 IU/mL) and of IL-4 (800 IU/mL) and 
aliquoted into a 6 well plate. The cells were then incubated overnight in a humidified 
atmosphere containing 5% CO2 at 37°C (Faulkner et al., 2012a).  3 mL of the medium from 
each well (supernatant) was withdrawn and discarded. Then, 3 mL of the medium containing 
GM-CSF (800 IU/mL) and IL-4 (800 IU/mL) was added. The cells were fed as in day 4 the 
penultimate day before use on but with the addition of the maturation factors LPS (1 μg/mL; 
bacterial source reference, Escherichia Coli 0111:B4) and TNF-α (25 ng/mL).  
2.3.15 Activation of naïve T-cells with drugs. 
Activation of naïve and memory T-cells was studies in vitro (Figure 2.7). Autologous mature 
DCs were harvested from 6 wells plate, centrifuged and counted. The DCs were plated at a 
concentration of 0.8x105 per well, and cultured with naïve or memory CD3+ T-cells at a 
concentration of 2.5x106 per well; 24-well flat-bottomed plate. The volume in the wells was 
2 mL (Figure 2.7 F). The drugs and metabolites were prepared at on optimum doses and 
added the cells. The cells were incubated in conditions of 5% CO2 at 37°C for 8 days. During 
incubation period a second batch of mature DCs were generated from autologous CD14+ 
monocytes. 
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Figure 2-7 T-cell activation assay (in vitro).  Isolation of PBMCs from venous blood. A: first isolation for 
CD14+ cells. B: isolation the CD3+ T-cells by negative selection from CD14- population. C: isolation the types 
of T cells (CD25+ and CD25- T-cells). D: CD 25- isolated more to CD45RO+ cells (memory) and CD45RO- 
T-cells (naïve) and CD45RO+ T-cells (memory). E: culture the CD14+ monocytes to generate DC and then 
matured. F: Naïve or memory T-cells are cultured with mature DC and drug. G: after 1 week of culture T-cells 
were harvested and used for T-cell cloning, or H: collected with fresh mature DC and drug to study the features 
of T-cells. I: types of assays. 
 
2.3.16 Reactivity and specificity assays for T-cells.  
The aim of these experiments is to detect antigen-specific T-cell responses generated from 
naïve and memory T-cell cultures. 
A. [3H]-Thymidine incorporation to measure antigen-specific T-cell proliferation. 
Priming cultures were harvested, centrifuged, resuspended in R9 medium and counted. The 
desired concentration for the primed cells 1x106/mL. Mature DCs were harvested by cell 
scraping. The DCs were centrifuged, resuspended in R9 medium, counted and diluted to a 
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cell concentration of 0.8x105/mL (Figure 2.7 H). Primed T-cells (1x105/well) were cultured 
in 96 well test plates (100 μL) along with 4x103 mature DCs (50 μL) in triplicate cultures per 
condition. The drugs were prepared in non-toxic doses, alongside a positive 
(Phytohemagglutinin (PHA) 20 μg/mL) and negative control (R9 medium). The test plate 
was incubated in a humidified of 5% CO2 at 37°C for 48 hrs. [
3H]-thymidine (0.5 μCi/well) 
was added in last 16 hrs. The test plate was harvested onto filter mats and dried. The filter 
mats were then combined with hot wax and counted in a Micro Beta counter. After counting 
the ratio of proliferation compare to controls conditions was calculated. A stimulation index 
(SI; average cpm of drug-treated wells/average cpm of control wells) of ≥1.5 was accepted 
as a drug-specific T-cell response. 
B. IFN-γ, IL-13, IL-17, and IL-22 secretion to measure antigen-specific T-cell response. 
The ELIspot plate was coated prior to setting up the T-cell assays. Antibodies for IFN-γ, IL-
5 and IL-13 were used according to the procedure was described in section 2.3.9. The next 
day, primed T-cells (1x105; 100 μL) and 4x103 mature DCs (50 μL) were added to the plate. 
The drug was added in 50 μL R9 media alongside 50 μL R9 and PHA (20 μg/mL) as negative 
and positive controls, respectively. The cells were incubated in a humidified of 5% CO2 at 
37°C for 48 hrs. The ELIspot plates were washed and read using the procedure was described 
in section 2.3.9. 
2.3.17 Assessment of DC and T-cell phenotype using flow cytometry. 
The T-cell surface markers were detected during priming and following restimulation using 
the method discussed in section 2.3.11, to determine whether the primed cells are either 
CD4+ or CD8+. Furthermore, to detect the phenotype of the monocyte-derived mature DCs 
various antibodies including CD1a-FITC, CD11a-FITC, CD11c-PE, CD14-FITC, CD40-
FITC, CD80-FITC, CD83-PE and CD86-FITC were used. The cells were incubated with 
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antibodies in the dark  for 20 min,  washed with 1 mL FACS buffer, centrifuged (1500 rpm 
for 10 min at 4ºC), resuspended in 200 μL FACS buffer, then analysed using a FACS-Canto 
II flow cytometer.
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Chapter 3: Dapsone and Nitroso dapsone-specific activation of 
T-cells from hypersensitive patients expressing risk alleles HLA-
B*13:01. 
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3.1 Introduction 
Genome-wide association studies have identified strong associations between expression of 
single HLA alleles and susceptibility to different forms of drug hypersensitivity (Redwood 
et al., 2018). These ground-breaking data propose that drugs might bind selectively to the 
protein encoded by the HLA allele to activate the T-cells that participate in the adverse event. 
Molecular docking studies seem to support this concept, drugs can interact directly with T-
cells and HLA proteins (Teh et al., 2016, Van Den Driessche and Fourches, 2017). However, 
modelling data has to be interpreted with caution as the nature of the drug that interacts with 
the HLA protein and the requirement for a specific peptide in the binding groove has not 
been determined. The most robust genetic associations are between HLA class I alleles and 
abacavir hypersensitivity (Mallal et al., 2008), flucloxacillin liver injury (both HLA-
B*57:01) (Daly et al., 2009), carbamazepine-induced Stevens-Johnson syndrome (HLA-
B*15:02) (Chung et al., 2004b) and allopurinol hypersensitivity (HLA-B*58:01) (Hung et 
al., 2005). All mechanistic studies in these cases have shown that CD8+ T-cells are stimulated 
during the interaction between the drug and the relevant HLA protein (Monshi et al., 2013b, 
Yun et al., 2014, Illing et al., 2012, Ostrov et al., 2012, Ko et al., 2011). There are differences 
in the drug HLA binding such as for abacavir and carbamazepine, abacavir binds deep in the 
HLA peptide binding pocket, while carbamazepine binds to a site closer to the T-cell receptor 
interface. Despite this, both drugs interact with HLA proteins via a reversible interaction to 
stimulate T-cells. T-cells from patients with allopurinol hypersensitivity are activated with a 
stable metabolite, oxypurinol, via direct binding interaction with HLA. In contrast, 
flucloxacillin-specific T-cells from patients with liver injury are activated with drug-protein 
adducts, via a hapten mechanism involving protein processing. This brief discussion 
illustrates that rapid progress has been made in our understanding of the relationship between 
drug HLA binding and the activation of T-cells; however, reactive drug metabolites have 
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been ignored. This is primarily because of the absence of synthetic reactive metabolites for 
drugs associated with HLA allele-restricted forms of hypersensitivity. Recently, we 
synthesized the nitroso metabolite of dapsone and studied the priming of naïve T-cells from 
healthy donors (Alzahrani et al., 2017b). The chemical structure for dapsone (DDS) contains 
a sulfone group that links two aromatic amine moieties. Oxidative metabolism of the amine 
groups generates a hydroxylamine intermediate. The hydroxylamine undergoes spontaneous 
oxidation to form nitroso dapsone (DDS-NO), which binds covalently to dendritic cells and 
keratinocytes (Roychowdhury et al., 2007, Vyas et al., 2006a). Naïve CD4+ and CD8+ T-
cells which were generated from healthy donors expressing different HLA-B alleles were 
activated with the parent drug and nitroso metabolite when (1) Tregs were removed and (2) 
the compounds were presented to naïve T-cells by dendritic cells (Alzahrani et al., 2017b). 
These data confirm that the drug in both forms interacts with multiple HLA molecules and 
has the capacity to stimulate T-cells when regulatory pathways have been manipulated. 
 DDS is used in combination with other drugs for the treatment of various infectious diseases 
such as leprosy and malaria. Between 0.5-3.6% of treated patients develop a hypersensitivity 
syndrome characterized by fever, skin rash and internal organ involvement 4-6 weeks after 
treatment commences (Rao and Lakshmi, 2001). The culprit allele HLA-B*13:01, is 
associated with the development of DDS hypersensitivity in Chinese and Thai patients 
(Zhang et al., 2013, Tempark et al., 2017), and modelling data suggests that DDS may fit in 
the peptide recognition site of HLA-B*13:01 (Watanabe et al., 2017). DDS-treated cell lines 
expressing HLA-B*13:01 appeared to stimulate T-cells, while PBMC from 2/7 patients 
appeared to secrete high levels of the cytolytic molecule granulysin when stimulated with 
the drug (Chen et al., 2018). 
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Despite all these studies, a detailed analysis of the phenotype and function of DDS-specific 
T-cells from hypersensitive patients has not been performed. Moreover, the activation and 
generation of patient T-cells with DDS-NO has not been investigated. Thus, our study had 
three primary objectives: (1) to investigate whether DDS and/or DDS-NO activates CD4+ 
and CD8+ T-cells from hypersensitive patients; (2) to define the phenotype and function of 
drug-specific T-cells and (3) to explore whether HLA-B*13:01 is directly involved in the 
drug- / drug metabolite-specific T-cell response. 
3.2 Aims of the study. 
 Generation and characterization of DDS and DDS-NO-specific CD4+, CD8+ T-cell 
clones from patients with DDS hypersensitivity. 
 To investigate the individual roles of DDS and DDS-NO in activation the drug-
specific T-cell clones.  
 To explore the mechanisms of T-cell activation. 
 To determine the role of HLA-B*13:01 in the activation of DDS- and DDS-NO-
CD8+ T-cell clones. 
 To investigate the function, reaction and phenotypic characteristics of specific T-
cells clone.   
3.3 Methods.  
The methods used in this chapter are discussed in detail in chapter 2 with some changes in 
some materials to be suitable for DDS and DDS-NO study. 
3.3.1 Study approval.  
The study was approved by the Ethical Committee of the Shandong Provincial Institute of 
Dermatology and Venereology and informed written consent was received from participants 
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prior to inclusion in the study. A material transfer agreement was signed prior to shipment 
of cryopreserved PBMC to Liverpool. 
3.3.2 Human subjects and cell isolation/separation. 
In this study we used venous blood (50 mL) collected from six DDS hypersensitive patients. 
Table 3.1 summarizes the demographics of the patients and details the nature of the adverse 
events. Table 3.2 shows the results of HLA typing. HLA-B*13:01+ donors (n=4) with no 
history of DDS exposure were selected as a control group. PBMC were isolated and used for 
the lymphocyte transformation test, IFN- PBMC ELIspot, the generation of EBV-
transformed B-cells and T-cell cloning. Patch testing was conducted on the back of 
hypersensitive patients with DDS concentrations between 0.1-25%. The patch was removed 
after 48 hrs and the results were recorded 24 hrs later. 
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Table 3-1 Patient demographics and details of the hypersensitivity reaction. 
Patient 
ID 
Gender Age 
(years) 
Medication 
history 
Onset of 
symptoms 
(days) 
Clinical presentation Skin 
patch 
test 
1 Female 43 Dapsone, 
rifampin, and 
clofazimine 
3 Fever, rash, and 
abnormal liver 
function tests 
- 
3 Female 25 Dapsone, 
rifampin, and 
clofazimine 
28 Fever, rash, and 
abnormal liver 
function tests 
- 
5 Male 39 Dapsone, 
rifampin, and 
clofazimine 
30 Fever + 
6 Male  41 Dapsone, 
rifampin, and 
clofazimine. 
48 Fever, rash,  and 
lymphadenopathy 
+ 
7 Male  54 Dapsone, 
rifampin, and 
clofazimine 
16 Fever, rash, and 
abnormal liver 
function tests (AST 
47.7 U/L; ALP132.3 
U/L) 
- 
8 Female 27 Dapsone, 
rifampin, and 
clofazimine 
17 Fever and abnormal 
liver function tests 
(AST 56.3 U/L; ALP 
225.7 U/L; GGT 
184.8 U/L; TBIL 38.8 
umol/L; DBIL 21.3 
umol/L; IBIL 17.5) 
+ 
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Table 3-2 HLA typing of hypersensitive patients. 
 HLA-A
 HLA-B HLA-C HLA-DQB1 HLA-DRB1 
Patient 1 02:07 24:02 13:01 40:01 03:04 15:02 03:01 06:01 11:01 15:01 
Patient 5 02:07 11:01 13:01 40:01 03:04 07:02 06:01 06:01 08:03 15:01 
Patient 6 02:07 11:01 13:01 6:01 01:02 03:04 06:01 06:10 15:01 15:01 
Patient 7 11:01 11:01 13:01 15:32 03:04 12:03 03:01 03:01 11:06 13:12 
Patient 8 11:01 24:02 13:01 15:25 03:04 04:03 03:01 05:02 12:02 15:01 
1 Patient 3 PBMC were not available for HLA typing. 
 
3.3.3 Medium for T-cell culture and cloning.   
This medium has been described in detail in chapter 2 section 2.2. 
3.3.4 Lymphocyte transformation test and PBMC ELIspot. 
PBMC (1.5x105 cell/well) from hypersensitive patients and control donors were incubated 
with DDS (125-500 µM), DDS-NO (10-40 µM), rifampicin (10-100 µM), clofazimine (10-
100 µM) or tetanus toxoid (5μg/mL, as a positive control) in culture medium for 5 days. 
[3H]-thymidine was added for the final 16h of the experiment. IFN-γ secreting PBMC were 
visualized using ELIspot (MabTech, Nacka Strand, Sweden) by culturing PBMC (5x105 
cell/well) in medium with or without optimal concentrations of DDS or DDS-NO for 48 hrs. 
3.3.5 Generation of EBV-transformed B-cells. 
Epstein-Barr virus transformed B-cell lines were generated from PBMC and used as antigen 
presenting cells in experiments with T-cell clones (Wu et al., 2007). This method is described 
in chapter 2 section 2.3.3. 
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3.3.6 Generation of drug-specific T-cell clones.        
Isolation of PBMC (as described in chapter 2 section 2.3.1) and generation of drug-specific 
T-cell lines and T-cell clones from PBMC which derived from DDS hypersensitive patients’ 
blood samples are described in chapter 2 section 2.3.4. The cells were serially diluted 
(described in chapter 2 section 2.3.4.2). Initial proliferation tests were performed for picked 
clones using radioactive thymidine uptake assay.  
3.3.7 Phenotype and specificity testing of drug-specific T-cell clones. 
T-cell phenotyping was performed by flow cytometry (described briefly in chapter 2 section 
2.3.11). TCR Vβ expression was measured using the IOTest® Beta Mark by flow cytometry 
with characterization of chemokines receptors for DDS- and DDS-NO-specific T-cells 
clones (chapter 2 section 2.3.11). Dose-dependent proliferative responses and the profile of 
secreted cytokines (chapter 2 section 2.3.5 and section 2.3.9). 
DDS- and DDS-NO-responsive clones (5x104) were also cultured with non-toxic 
concentrations of structurally-related compounds (sulfamethoxazole, sulfamerazine, 
sulfadiazine, sulfachloropyridazine, sulfadoxin, sulphanilamide, 4, 4 thiodianiline, 4, 4 
oxyaniline, 3, 3 sulfonyldianiline and mono and diacetylated forms of dapsone) and antigen 
presenting cells (1x104; 200 µL) for 48 hrs. Proliferation was measured by the addition of 
[3H] thymidine followed by scintillation counting.    
3.3.8 Pathway of T-cell activation. 
To explore the pathway of CD4+ and CD8+ T-cell activation with DDS and DDS-NO, T-cell 
clones were subjected to a variety of experimental protocols, mentioned in details in chapter 
2. First, clones were cultured with optimal concentrations of DDS or DDS-NO in the 
presence or absence of antigen presenting cells (chapter 2 section 2.3.6). Second, MHC class 
I and class II restriction assay was performed (chapter 2 section 2.3.10). Third, clones were 
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cultured with DDS or DDS-NO and glutaraldehyde-fixed antigen presenting cells. Fixation 
blocks protein processing (chapter 2 section 2.3.7) (Zanni et al., 1998a). Fourth, antigen 
presenting cells pulsed with DDS or DDS-NO for 0.5-2 hrs were used to activate T-cells in 
the absence of soluble drug (chapter 2 section 2.3.8). Fifth, clones were cultured with DDS 
or DDS-NO and antigen presenting cells in the presence or absence of glutathione (1mM). 
Glutathione binds covalently to aromatic nitroso compounds, limiting their protein reactivity 
(Naisbitt et al., 1996b, Ellis et al., 1992). The stability of DDS and DDS-NO and the 
formation of dapsone glutathione adducts during the culture period were measured by mass 
spectrometry. Briefly, aliquots of cell culture supernatant (20 µL) and the calibration 
standards (20 µL) were diluted with LC-MS grade water (1:10 dilution) and deproteinized 
with acetonitrile. The extracts were evaporated to dryness in a Speed-Vac and reconstituted 
in 200 µL water. 5 µL samples and standards were analysed immediately by a Triple 
QuadTM  6500 mass spectrometer (AB Sciex,) coupled with a 1260 Infinity LC system 
(Agilent Technologies, Germany). The multiple reaction monitoring transitions for each 
analyte were as following: DDS 249.1/156.1 and 249.1/107.9; azoxy dapsone, 509.1/108.1 
and 509.1/156.1; dapsone-GSH (Bergström et al., 2007), 602.1/401.3, 602.1/156.1, and 
602.1/261.5. Other MS parameters, such as voltage potential and collision energy were 
optimised to achieve the greatest sensitivity. Data acquisition and quantification were 
performed using Analyst 1.5 software and Multi-Quant 3.0 (AB Sciex). 
3.3.9 The involvement of HLA-B*13:01 in the activation of CD8+ T-cell 
clones. 
To explore whether DDS and DDS-NO interact with HLA-B*13:01 to activate CD8+ T-cell 
clones, EBV-transformed B-cells were generated from 9 healthy donors expressing HLA 
alleles displaying at least 90% similarity to HLA-B*13:01 (Table 3.3). EBV-transformed B-
cells from one additional hypersensitive patient expressing HLA-B*13:01 itself were also 
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used. CD8+ T-cell clones were cultured with the different antigen presenting cells and DDS 
or DDS-NO for 48 hrs. Proliferation was measured by the addition of [3H]-thymidine 
followed by scintillation counting.       
Table 3-3 HLA typing of antigen presenting cells from healthy donors. 
 
1 Antigen presenting cells from hypersensitive patients 5, 6 or 8 were used. See Table 3.2 for 
HLA typing data.   
 
 
 
3.3.10 Statistics  
All statistical analysis (One-way ANOVA unless stated otherwise) was performed using 
SigmaPlot 12 software (*P<0.05). 
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3.4 Results. 
3.4.1 Patch testing of DDS hypersensitive patients. 
Patch testing was conducted on the back of 6 patients with DDS concentrations between 0.1-
25%. After 72 hrs drug exposure, 3 out of 6 patients displayed DDS concentration-dependent 
positive readings (Figure 3.1 A). 
3.4.2 PBMC from DDS hypersensitive patients proliferate and secrete IFN-
, following stimulation with DDS and DDS-NO. 
PBMC from all 3 patch test positive patients were stimulated to proliferate strongly in the 
presence of DDS and DDS-NO (Figure 3.1B). Maximally tolerated concentrations of DDS 
and DDS-NO were 250-500µM and 40-50 µM, respectively. Positive DDS-specific 
proliferative responses (SI ≥ 2 or above) and/or IFN- secretion were also detected with 
PBMC from the 3 patch test negative patients, while DDS-NO responses were detected in 2 
patients (Figures 3.1B-D). PBMC were not activated with the co-medications rifampicin and 
clofazimine (Figure 3.1D). Proliferative responses were also detected with the positive 
control phytohemagglutinin (results not shown).  
PBMC from drug naïve HLA-B*13:01+ controls proliferated in the presence of 
phytohemagglutinin, but not the test drugs (SI less than 1.5; results not shown).   
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Figure 3-1 Diagnosis of DDS hypersensitivity by skin testing and in vitro assays. (A) Skin patch test results 
for DDS hypersensitivity. Skin was exposed to DDS in polyethylene glycol 200 at dilutions of 0, 0.1, 0.5%, 1, 
5, 10, 15, 2%, and 25%. The patch tape was left to the skin for 48 hrs and the diagnosis was made 24 hrs later. 
(B and D) PBMC from patients were exposed to graded concentrations of DDS, DDS-NO, rifampicin and 
clofazimine. Proliferation was measured after 6 days by the addition of [3H] thymidine. Results are expressed 
as mean±SD cpm of triplicate cultures. A doubling of cpm in drug-treated cultures over vehicle control is 
considered positive. (C) PBMC from patients were exposed to optimal concentrations of DDS or DDS-NO and 
IFN- release was visualized by ELIspot. 
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3.4.3 DDS and DDS-NO activate CD4+ and CD8+ T-cell clones. 
A total of 1334 and 1374 CD4+ and CD8+ clones, respectively, were expanded from DDS 
and DDS-NO T-cell lines from patients 5, 6 and 8. Six hundred and twenty six CD4+ clones 
displayed reactivity against DDS or DDS-NO (Figure 3.2). DDS- and DDS-NO-specific 
CD8+ T-cell clones were generated in lower numbers; one hundred and sixty eight were 
activated with either the drug or drug metabolite. DDS- and DDS-NO-responsive CD4+ and 
CD8+ T-cell clones were detected in equal numbers (Table 3.4).  
 
 Chapter Three                                                               Dapsone and nitroso dapsone  
115 
 
 
Figure 3-2 Generation of DDS- and DDS-NO-responsive CD4+ and CD8+ T-cell clones. Clones were 
generated from DDS and DDS-NO CD4+ or CD8+ T-cell lines by serial dilution and repetitive mitogen 
stimulation. Well-growing clones were cultured with autologous antigen presenting cells and either DDS or 
DDS-NO in duplicate cultures for 48 hrs. Proliferative responses were measured by the addition of [3H]-
thymidine. Clones with a stimulation index (SI) of 2 or above were expanded further for phenotypic analysis 
and mechanistic studies. 
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Table 3-4 Phenotype and drug specificity of T-cell clones generated from dapsone 
hypersensitive patients. 
Phenotype & drug 
specificity 
Total Number 
of clones 
Number of drug-
specific  clones 
Percentage of 
responding clones 
(%) 
Patient 8 
CD4+, DDS+ 236 176 74.58 
CD8+, DDS+ 245 29 11.84 
CD4+, DDS-NO+ 384 210 54.69 
CD8+, DDS-NO+ 304 54 17.76 
Patient 6 
CD4+, DDS+ 177 76 42.94 
CD8+, DDS+ 178 14 7.87 
CD4+, DDS-NO+ 208 57 27.40 
CD8+, DDS-NO+ 285 15 5.26 
Patient 5 
CD4+, DDS+ 180 64 35.56 
CD8+, DDS+ 170 36 21.18 
CD4+, DDS-NO+ 149 43 28.86 
CD8+, DDS-NO+ 192 20 10.42 
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One hundred and two well-growing clones were selected for dose-response studies and the 
analysis of cytokine secretion. Proliferative responses were detected with 3 well tolerated 
concentrations of DDS (125-500 µM) and DDS-NO (5-20 µM) and drug treatment resulted 
in the secretion of Th1 (IFN), Th2 (IL-5, IL-13) and Th22 (IL-22) cytokines, alongside the 
cytolytic molecules perforin, granzyme B and FasL. CD4+ and CD8+ clones secreted similar 
levels of cytokines and cytolytic molecules (Figure 3.3). Table 3.5 shows the percentage of 
DDS- and DDS-NO-responsive CD4+ and CD8+ T-cell clones that secrete individual 
cytokines. 
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Figure 3-3 Dose-dependent proliferative response and cytokine release by DDS- and DDS-NO-responsive 
CD4+ and CD8+ T-cell clones. (A) One hundred and two CD4+ or CD8+ T-cell clones were incubated with 
autologous antigen presenting cells and either DDS (125-500 µM) or DDS-NO (5-20µM) in triplicate cultures 
for 48h. Proliferative responses were measured by the addition of [3H] thymidine. Results are expressed as 
mean±SD cpm of the indicated number of clones. (B) Detection of IFN-γ, IL-5, IL-13, IL-17, IL-22, granzyme 
B, perforin and Fas-ligand secretion by DDS- and DDS-NO-responsive CD4+ and CD8+ T-cell clones. Clones 
were incubated with autologous antigen presenting cells and either DDS or DDS-NO and cytokine release was 
visualized by ELIspot. (C) Representative ELIspot images showing the cytokines released by DDS and DDS-
NO-responsive CD8+ T-cell clones. 
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Table 3-5 Cytokine secretion from DDS and DDS-NO-responsive CD4+ and CD8+ T-cell 
clones. 
 
 IFN-γ IL-5 IL-13 IL-17 IL-22 
Per-
forin 
Granz-
yme B 
Fas L 
CD4 
DDS 
 
1001 88 82 0 100 94 94 92 
DDS
-NO 
80 100 60 0 100 60 80 92 
CD8 
DDS 
 
100 79 57 0 78 93 78 100 
DDS
-NO 
100 100 100 0 90 100 100 100 
1 Numbers refer to the percentage of clones with an increase of at least 50 sfu when the drug- 
and vehicle-treated wells were compared.  
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3.4.4 DDS- and DDS-NO-responsive CD4+ and CD8+ T-cell clones display 
three distinct patterns of reactivity. 
Sixty three DDS- and ninety eight- DDS-NO-responsive CD4+ and CD8+ T-cell clones were 
assayed for crossreactivity. When all of the DDS-responsive clones were assessed together, 
low levels of proliferation was observed with DDS-NO (Figure 3.4 A). It should be noted 
that the maximum concentration of DDS-NO used was over 10 times lower than the DDS 
concentration. Analysis of individual clones revealed three distinct crossreactivity patterns; 
DDS-specific, and weakly and strongly crossreactive with DDS-NO. Approximately 90% of 
the clones were DDS-specific or weakly crossreactive (Figure 3.4 B and C). 
DDS-NO CD4+ and CD8+ T-cell clones displayed a much higher level of crossreactivity 
(Figure 3.4 A). However, 3 patterns of crossreactivity were again observed with individual 
clones; DDS-NO-specific, and weakly and strongly crossreactive with DDS. In contrast to 
the DDS-responsive clones, approximately 90% of the DDS-NO-responsive clones were 
DDS-NO-specific or highly crossreactive (Figure 3.4 B and C).  
DDS- and DDS-NO-responsive clones were also stimulated to proliferate with DDS 
hydroxylamine; however, proliferative responses were not detected when clones were 
cultured with (1) DDS analogues with substitutions in the sulfone group, (2) DDS analogues 
with amine groups in different positions on the aromatic rings and (3) structurally distinct 
sulfonamide antimicrobials (Figure 3.5). 
The stability of DDS-NO in the 2 day proliferation assay was assessed. DDS-NO was 
converted rapidly to azoxy dimers and the parent compound. Both compounds were 
detectable within a 10 min incubation with antigen presenting cells and T-cell clones. After 
2 days, 50% of DDS-NO had been converted to DDS (Figure 3.4 D-E). 
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Figure 3-4 Crossreactivity of DDS- and DDS-NO-responsive T-cell clones. DDS- and DDS-NO-responsive 
CD4+ and CD8+ T-cell clones were cultured with irradiated autologous EBV-transformed B-cells and either 
DDS (100-500 µM) or the nitroso metabolite (5-20 µM) in triplicate cultures for 48h. T-cell proliferative 
responses were assessed through the addition of [3H]-thymidine. (A) Mean crossreactivity data for 153 clones 
divided according to the drug antigen PBMC were cultured with drug to generate clones and CD phenotype. 
(B) Pie charts showing a number of clones with a particular crossreactivity profile (compound specific, weekly 
crossreactive (crossreactive compound displaying 10-50% response detected with a comparator) and strongly 
crossreactive (crossreactive compound displaying greater than 50% response detected with a comparator). (C) 
Representative clones displaying each response profile. (D) Relative quantification of DDS and azoxy dimer 
in cultures containing DDS-NO (30 µM), autologous EBV-transformed B-cells and T-cell clones. (E) Absolute 
quantification of DDS formation in cultures containing DDS-NO (30 µM), autologous EBV-transformed B-
cells and T-cell clones. Left hand graph shows the standard curve for DDS (concentration range: 5nM-1µM). 
Right hand side graph shows the time-dependent formation of DDS.    
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Figure 3-5 Crossreactivity of DDS- and DDS-NO-responsive CD4+ and CD8+ T-cell clones with dapsone 
hydroxylamine, analogues and sulfonamide antimicrobials. (A) DDS- and DDS-NO-responsive CD4+ and 
CD8+ T-cell clones were cultured with irradiated autologous EBV-transformed B-cells and non-toxic 
concentrations of the test compounds in triplicate cultures for 48 hrs. T-cell proliferative responses were 
assessed through the addition of [3H]-thymidine. (B) Structure of the test compounds.   
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3.4.5 Crossreactive clones are activated with equivalent concentrations of 
DDS and DDS-NO. 
Six strong and weakly crossreactive clones were incubated with DDS and DDS-NO at 
concentrations of 0.1-100 µM to define the minimum stimulatory concentrations of the two 
compounds. Surprisingly, clones were stimulated to proliferate with equivalent 
concentrations of each compound (Figure 3.6). The line graphs in Figure 3.6 A and B show 
the level of DDS and DDS-NO-specific proliferation for each clone on the same scale. The 
same data is then reproduced as bar charts on different scales to show more clearly that the 
clones are activated at the same concentrations of drug and metabolite irrespective of the 
extent of crossreactivity. 
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Figure 3-6 DDS and DDS-NO activate T-cell clones at the same minimum concentration. (A) DDS- and 
(B) DDS-NO-responsive CD4+ and CD8+ T-cell clones were cultured with irradiated autologous EBV-
transformed B-cells and either DDS (0.1-100 µM) or the nitroso metabolite (0.1-100 µM) in triplicate cultures 
for 48 hrs. T-cell proliferative responses were assessed through the addition of [3H]-thymidine. Representative 
weakly and strongly cross-reactive DDS and DDS-NO-responsive clones are shown. Line graphs show 
proliferative responses to DDS and the nitroso metabolite on the same scale. Bar charts show the same data on 
different scales to compare minimum stimulatory concentrations. 
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3.4.6 DDS- and DDS-NO-responsive CD4+ and CD8+ T-cell clones 
expressing multiple TCR Vβ chains display distinct chemokine receptor 
profiles. 
DDS- and DDS-NO-responsive CD4+ and CD8+ T-cell clones expressed single, but variable 
TCR Vβ chains (Figure 3.7 A), with no clear differences discernible when CD4+ and CD8+ 
or DDS- and DDS-NO-responsive clones were compared. DDS- and DDS-NO-responsive 
CD4+ T-cell clones expressed high levels of the chemokine receptors CXCR3 and CCR4. 
The CD8+ T-cell clones expressed CXCR3 and CCR4 alongside CCR10, CCR9 and CCR6 
(Figure 3.7 B). 
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Figure 3-7 T-cell receptor V chains and chemokine receptors expressed on DDS- and DDS-NO-
responsive CD4+ and CD8+ T-cell clones. (A) TCR Vβ expression was measured with the IOTest® Beta 
Mark, TCR Vβ Repertoire Kit, which covers over 80% of the available TCRs, by flow cytometry. (B) 
Chemokine receptors were measured on resting clones by flow cytometry. The expression is presented as mean 
fluorescence intensity of the whole population of each clone.   
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3.4.7 HLA-restricted activation of DDS- and DDS-NO-responsive clones 
ensues via different mechanisms.   
Stimulation of DDS- and DDS-NO-responsive CD4+ and CD8+ T-cell clones were 
dependent on the presence of antigen presenting cells (i.e., irradiated autologous EBV-
transformed B-cells; Figure 3.8 A). Use of anti-HLA class I and II blocking antibodies 
revealed that CD4+ and CD8+ proliferative responses to DDS and DDS-NO were HLA class 
II and I restricted, respectively (Figure 3.8 B). Fixation of antigen presenting cells with 
glutaraldehyde, which inhibits antigen processing, had no effect on the activation of CD4+ 
or CD8+ T-cell clones with DDS. 
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Figure 3-8 Antigen presenting cells are required for the activation of DDS- and DDS-NO-responsive 
CD4+ and CD8+ T-cell clones. (A) DDS- and DDS-NO-responsive CD4+ and CD8+ T-cell clones were 
cultured with DDS (500 µM) or the nitroso metabolite (20 µM) in triplicate cultures for 48h either in the 
presence or absence of antigen presenting cells. (B) DDS- and DDS-NO-responsive CD4+ and CD8+ T-cell 
clones were cultured with antigen presenting cells and DDS (500 µM) or the nitroso metabolite (20 µM) in 
triplicate cultures for 48 hrs either in the presence or absence of anti-HLA class I and II blocking antibodies. 
[3H]-thymidine was added for 16hrs to measure drug-specific proliferative responses. 
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 In contrast, antigen presenting cell fixation reduced the extent of proliferation with the 
nitroso metabolite (Figure 3.9 A). The residual response detected with DDS-NO and fixed 
antigen presenting cells likely relates to the conversion of DDS-NO to DDS in culture 
medium.  
DDS-NO-responsive CD8+ clones were activated with antigen presenting cells pulsed with 
DDS-NO for 0.5-2 hrs; clones were not exposed to the soluble drug metabolite in this 
experiment (Figure 3.9 B). Two out of four DDS-NO-responsive CD4+ T-cell clones were 
also stimulated to proliferate with DDS-NO-pulsed antigen presenting cells. Antigen 
presenting cells pulsed with DDS for 0.5-2 hrs did not activate the DDS-responsive CD4+ or 
CD8+ T-cell clones.  
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Figure 3-9 DDS and DDS-NO activate T-cells via different pathways. (A) DDS- and DDS-NO-responsive 
CD4+ and CD8+ T-cell clones were cultured with DDS or the nitroso metabolite in the presence of either 
irradiated or glutaraldehyde-fixed autologous EBV-transformed B-cells in triplicate cultures for 48 hrs. 
Fixation blocks antigen processing. (B) DDS- and DDS-NO-responsive CD4+ and CD8+ T-cell clones were 
cultured with drug- or drug metabolite-pulsed (0.5-2 hrs) irradiated autologous EBV-transformed B-cells in the 
absence of soluble drug in triplicate cultures for 48hrs. T-cell proliferative responses were assessed through the 
addition of [3H] thymidine. 
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Glutathione was added to (1) DDS-NO-responsive clones in a standard 48 hrs proliferation 
assay containing antigen presenting cells and soluble DDS-NO and (2) antigen presenting 
cells pulsed with DDS-NO for 2 hrs. Glutathione blocks the reactivity of aromatic nitroso 
compounds through reduction and conjugation reactions (Naisbitt et al., 1996b, Ellis et al., 
1992). Figure 3.10 A compares the level of DDS-NO glutathione adducts formed naturally 
in the cell culture assay in the presence and absence of exogenous glutathione. Adducts were 
formed rapidly (within 2 hrs) and the level of adduct formation was several orders of 
magnitude higher in the presence of exogenous glutathione. Figure 3.11 contains traces 
showing how the adducts were quantified. The addition of glutathione to the T-cell assay 
containing soluble DDS-NO reduced the strength of the proliferative response, while the 
response to DDS-NO-pulsed antigen presenting cells was completely blocked (Figure 3.10 
B).      
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Figure 3-10 Glutathione inhibits the activation of T-cell clones with DDS-NO. (A) Semi-quantitative 
analysis of the levels of DDS-NO glutathione conjugate formed in incubations containing EBV-transformed 
B-cells in medium alone, medium containing DDS-NO or DDS-NO and glutathione (1mM). Figure 3.11 
contains the mass spectrometric images. (B) DDS-NO-responsive clones were cultured with (i) irradiated 
autologous EBV-transformed B-cells, soluble drug metabolite and glutathione, and (ii) drug metabolite-pulsed 
(2 hrs) irradiated autologous EBV-transformed B-cells (±glutathione) in triplicate cultures for 48hrs. 
Glutathione was added to cells before DDS-NO in both assays. T-cell proliferative responses were assessed 
through the addition of [3H]-thymidine. 
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Figure 3-11 Mass spectrometric analysis of the DDS-NO glutathione adduct formed in the culture 
medium. EBV-transformed B cells were cultured with either (A) medium only, (B) medium containing DDS-
NO or (C) DDS-NO in the presence of glutathione (1mM). 
 
3.4.8 DDS and DDS-NO bind with a degree of selectively to HLA-B*13:01-
dependent activation of CD8+ T-cell clones. 
EBV-transformed B-cells were generated from 9 healthy donors expressing HLA alleles with 
greater than 90% sequence homology to HLA-B*13:01. HLA typing of the healthy donors 
is shown in Table 3.3. The B-cell lines were used as antigen presenting cells in proliferation 
assays with DDS- and DDS-NO-responsive CD8+ T-cell clones to explore the requirement 
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for HLA-B*13:01 for T-cell activation. Autologous antigen presenting cells and antigen 
presenting from cells 1 additional patient (both expressing HLA-B*13:01) were used as 
comparators.  
As has been described previously for other drugs (von Greyerz et al., 2001a, Zanni et al., 
1998a) 30% of DDS and DDS-NO-responsive HLA-class I restricted CD8+ T-cell clones 
displayed proliferative responses with the drug or metabolite and antigen presenting cells 
expressing a wide variety of HLA alleles (Figure 3.12).  
 
Figure 3-12 DDS and DDS-NO bind to wide variety of HLA alleles to activate certain CD8+ T-cell clones. 
(A) DDS-NO- and (B) DDS-responsive CD8+ clones were cultured with drug or drug metabolite and irradiated 
EBV-transformed B-cells from 12 donors expressing different HLA-B alleles in triplicate cultures for 48hrs. 
The complete HLA type of the different donors is shown in Table 3.3. CD8+ T-cell clones were cultured with 
DDS or DDS-NO and irradiated EBV-transformed B-cells from 12 individuals expressing various HLA-B 
allele in triplicate cultures for 48hrs. T-cell proliferative responses were assessed through the addition of [3H] 
thymidine.  
 
 Chapter Three                                                               Dapsone and nitroso dapsone  
135 
 
Other clones were activated with the drug or metabolite only in the presence of autologous 
antigen presenting cells. Despite this, 30-40% of CD8+ clones displayed a degree of HLA-
B*13:01 allele restriction. Figure 3.13 A and B shows 3 clones (1 DDS- and 2 DDS-NO-
responsive) that were stimulated to proliferate exclusively in the presence of DDS or DDS-
NO and antigen presenting cells expressing HLA-B*13:01. Three additional clones (1 DDS- 
and 2 DDS-NO-responsive) are shown that were activated in the presence of antigen 
presenting cells expressing HLA-B*13:01 and either B*13:02, B*58:01 or B*51:01. 
The 2 DDS responsive CD8+ T-cell clones were expanded in sufficient numbers for us to 
conduct a proliferation assay using antigen presenting cells from the six hypersensitive 
patients that all express HLA-B*13:01. The clones were activated in the presence of DDS 
and antigen presenting cells from all of the patients (Figure 3.13 C).    
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Figure 3-13 DDS and DDS-NO bind with a degree of selectively to HLA-B*13:01 to activate certain CD8+ 
T-cell clones. (A) DDS-NO- and (B) DDS-responsive CD8+ T-cell clones were cultured with drug or drug 
metabolite and irradiated EBV-transformed B-cells from 10 donors expressing different HLA-B alleles in 
triplicate cultures for 48 hrs. The complete HLA type of the different donors is shown in Table 3.3. (C) DDS-
responsive CD8+ T-cell clones were cultured with DDS and irradiated EBV-transformed B-cells from 6 
hypersensitive patients expressing HLA-B*13:01 in triplicate cultures for 48 hrs. T-cell proliferative responses 
were assessed through the addition of [3H]-thymidine. 
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3.5 Discussion. 
Knowledge of the role drug metabolism plays in the generation of antigenic determinants 
that activate T-cells is limited. Circumstantial evidence supporting a role for drug 
metabolism includes (1) the identification of protein-reactive metabolites for many drugs 
associated with a high incidence of hypersensitivity and (2) the induction of toxicity in target 
tissue by reactive metabolites and hence the potential to disrupt immune regulatory pathways 
through the provision of danger signals (Uetrecht and Naisbitt, 2013). However, the most 
direct evidence linking drug metabolism to the development of hypersensitivity is the 
detection of halothane-specific antibodies in patients with liver failure (Kenna et al., 1993) 
and the observation that halothane protein adducts activate T-cells (You et al., 2010). 
Furthermore, halothane derivatives that form lower levels of reactive metabolite are 
associated with a decreased risk of liver injury (Park et al., 1998). To explore whether 
metabolites activate hypersensitive patient T-cells in vitro, co-culture strategies have been 
developed using microsomal metabolite generating systems (Bergström et al., 2007, Sachs 
et al., 2001). Enhanced drug-specific T-cell responses have been reported with drugs in the 
presence of a metabolising system; however, it is very difficult to delineate the disparate 
effects of the parent drug and metabolites. For this reason, we synthesized the reactive 
metabolite of sulfamethoxazole (Naisbitt et al., 1996a) which causes immune-mediated skin 
and liver reactions that are not linked to the expression of a specific HLA allele (Alfirevic et 
al., 2009). Working alongside other researchers in the field we have shown that PBMC and 
inflamed tissue from all hypersensitive patients contain T-cells that are activated with 
sulfamethoxazole and/or its reactive metabolite via different pathways (i.e., direct HLA 
binding and a hapten pathway, respectively) (Nassif et al., 2004a, Castrejon et al., 2010a, 
Schnyder et al., 2000). 
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In recent years, researchers studying hypersensitivity reactions strongly linked to the 
expression of specific HLA alleles have focussed exclusively on the interaction between 
parent drug and the HLA molecule. This is because the parent drug is, for the most part, the 
only reagent available for in vitro cell culture studies. The observation that T-cells from 
patients with hypersensitivity to drugs such as carbamazepine are activated with the parent 
drug (Ko et al., 2011), has lead researchers to hypothesize that reactive metabolites are not 
involved in the development of HLA allele-restricted forms of drug hypersensitivity. To 
investigate this hypothesis we now focused on DDS hypersensitivity in patients with leprosy. 
DDS is a model study drug as (1) hypersensitivity reactions in patients are strongly linked to 
the expression of HLA-B*13:01 (Zhang et al., 2013), (2) the reactive nitroso metabolite of 
dapsone has been synthesized in a stable form (Alzahrani et al., 2017b) and (3) patient 
samples are available for mechanistic studies. Utilizing PBMC from HLA-B*13:01+ 
patients we show CD4+ and CD8+ T-cell responses to dapsone and the nitroso metabolite. 
Furthermore, DDS and DDS-NO bind to HLA-B*13:01 to selectively activate certain CD8+ 
T-cell clones.  
Six HLA-B*13:01+ patients that developed hypersensitivity whilst receiving DDS in 
combination with rifampicin and clofazimine were recruited to the study. Three displayed a 
positive patch test response to DDS. PBMC from all six patients were stimulated to 
proliferate and/or secrete IFN- after stimulation with DDS or the nitroso metabolite. The 
strongest in vitro responses were seen in the patients with the positive patch test response 
and these patients were selected for serial dilution experiments to search for drug- and drug 
metabolite-responsive T-cell clones. CD4+ and CD8+ clones were purified prior to plating 
single cells in culture plates for the cloning procedure. DDS- and DDS-NO-responsive T-
cells were generated in almost equal numbers (DDS 395; DDS-NO 399). The ratio of DDS- 
or DDS-NO-responsive CD4+ and CD8+ T-cell clones was 4-5:1 in patients 6 and 8 and 2:1 
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in patient 5, which demonstrates that drug exposure results in a complete cellular immune 
response against the drug antigens. This is in stark contrast to the findings with abacavir 
where CD8+ T-cells are the only cells activated with the drug (Bell et al., 2013, Lucas et al., 
2015). The activation of CD4+ and CD8+ T-cell clones that expressed an array of TCR Vβ 
receptors, with DDS or DDS-NO, was HLA class II and class I restricted, respectively. This 
confirms our previous data with PBMC from healthy donors (Alzahrani et al., 2017b), which 
shows that both DDS and DDS-NO interact with HLA class I and class II molecules.    
The availability of cloned CD4+ and CD8+ T-cells permitted the detailed analysis of 
crossreactivity between DDS, DDS-NO and structurally-related compounds. The position of 
the amine groups on the aromatic rings and the availability of the sulfone group was found 
to be critical for the activation of the T-cell clones. A panel of sulfonamides, which contain 
one aromatic amine group did not activate the clones. Thus, both of dapsones’ aromatic 
amines and sulfone were required for T-cell activation.  
25-50% of CD4+ and CD8+ T-cell clones were classified as highly specific as they were only 
activated with one compound (either the parent drug or metabolite [Figure 3.4 B]). This 
confirms that T-cells recognize and respond selectively to the two different forms of the DDS 
antigen. DDS has an unusual structure in that the two aromatic amines connected to the 
sulfone group are identical. If the structure of a DDS-NO-modified HLA binding peptide is 
compared with DDS complexed to the same peptide, it is likely that similar conformations 
will be observed and as such the interaction with the T-cell receptor will be the same. Thus, 
our working hypothesis to explain the drug- or drug-metabolite-specific activation of certain 
clones is that the HLA binding peptides also participate in the TCR interaction and impart a 
degree of selectivity.  
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When using optimum concentrations of DDS (100-500 µM) and DDS-NO (5-20 µM) to 
activate CD4+ and CD8+ T-cells, clones displaying high (i.e., at least 50% of the response 
detected with the opposite compound) and low (i.e., 10-50% of the response of the response 
detected with the opposite compound) levels of crossreactivity were also detected. The 
majority of DDS-responsive, crossreactive CD4+ and CD8+ T-cell clones displayed low 
levels of crossreactivity with DDS-NO. Using quantitative mass spectrometry we were able 
to demonstrate that the nitroso metabolite is reduced to DDS in the 2 day proliferation assay. 
Thus, clones incubated with 30 µM DDS-NO were exposed to 2.5-15 µM of the parent drug, 
which stimulates a sub-optimal T-cell proliferative response. In contrast, the majority of 
crossreactive DDS-NO-responsive CD4+ and CD8+ T-cell clones displayed high levels of 
crossreactivity with 100-500 µM DDS. To investigate the response profiles further, a panel 
of crossreactive DDS- and DDS-NO-responsive clones were cultured with equal 
concentrations of the parent drug and metabolite (0.1-100 µM). Interestingly, weakly and 
strongly crossreactive clones were activated with the same concentrations of DDS and DDS-
NO with similar dose-response curves until nitroso metabolite-induced toxicity was 
detected. These data are in contrast to our earlier studies with sulfamethoxazole and its 
nitroso metabolite, where the parent drug activates T-cells at significantly higher 
concentrations (Castrejon et al., 2010a). It is reasonable to assume that HLA binding peptides 
play a less important role in the triggering of crossreactive TCR.  
Antigen presenting cells were required for the strong activation of CD4+ and CD8+ T-cell 
clones with DDS and the nitroso metabolite. Clones were activated with DDS in the presence 
of irradiated and glutaraldehyde-fixed antigen presenting cells. In contrast, fixation reduced 
the strength of the DDS-NO-specific T-cell proliferative response. As discussed above, the 
best explanation for the weak response of DDS-NO-responsive clones with soluble DDS-
NO and fixed antigen presenting cells is the formation of DDS in the proliferation assay. 
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Application of drug- or drug metabolite-pulsed antigen presenting cells instead of the soluble 
drug in T-cell assays provides a tool to differentiate between the effects of covalent and non-
covalent forms of drug (Schnyder et al., 2000, Castrejon et al., 2010b). DDS-responsive 
clones were not activated with DDS-pulsed antigen presenting cells. In contrast, six out of 
the eight DDS-NO-responsive clones tested were activated with DDS-NO-pulsed antigen 
presenting cells and the strength of the induced response was the same as that seen with the 
parent drug. Two of the DDS-NO-responsive clones were not activated with pulsed antigen 
presenting cells; interestingly, both of these clones crossreacted strongly with DDS.  
Glutathione is a tripeptide intracellular antioxidant that protects cells from exposure to 
aromatic nitroso compounds by acting as a reducing agent and through direct conjugation 
(Naisbitt et al., 1996a, Cribb et al., 1991, Ellis et al., 1992). The addition of glutathione to 
T-cell assays prevents the covalent binding of nitroso compounds and hence it is possible to 
explore whether T-cells are activated with drug metabolite-modified protein adducts 
(Burkhart et al., 2001). DDS-NO glutathione adducts were formed rapidly in cultures 
containing the drug metabolite, T-cells, antigen presenting cells and glutathione. Moreover, 
glutathione decreased the response of clones to soluble DDS-NO and blocked the response 
to DDS-NO-pulsed antigen presenting cells.            
In the next section of the project, antigen presenting cell were generated from healthy donors 
expressing HLA-B alleles with at least 90% sequence homology to HLA-B*13:01 (including 
an additional HLA-B*13:01+ donor) to investigate whether either DDS or DDS-NO interact 
with a degree of selectivity to the risk allele to activate CD8+ T cell clones. As described 
previously with other forms of drug hypersensitivity, several clones displayed HLA allele-
unrestricted drug recognition (i.e., DDS and DDS-NO stimulated a proliferative response in 
the presence of multiple antigens presenting cells expressing different B alleles) (von 
Greyerz et al., 2001a). Other clones were only activated in the presence of DDS-NO and 
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autologous antigen presenting cells. However, a panel of clones were selectively activated 
with DDS or DDS-NO in the presence of antigen presenting cells displaying HLA-B*13:01. 
This indicates that both the parent drug and reactive metabolite interacts with HLA-B*13:01 
to activate certain CD8+ T-cell clones. We are therefore synthesizing designer DDS-NO-
modified HLA-B*13:01 binding peptides and conducting structural analyses to compare the 
binding interaction of DDS and DDS-NO with HLA-B*13:01. 
CD4+ and CD8+ T-cell clones secreted the same panel of cytokines when stimulated with 
DDS or DDS-NO, but expressed distinct chemokine receptors. Clones secreted Th1, Th2 
and Th22 cytokines alongside the cytolytic molecules perforin, granzyme B and FasL; 
however, IL-17 was not detected. IL-22 secretion in the absence of IL-17 seems to be a 
common feature of drug-specific clones as this profile has now been detected with DDS, 
sulfamethoxazole and piperacillin (Sullivan et al., 2018, Gibson et al., 2014). The chemokine 
receptors displayed on DDS- or DDS-NO-responsive CD4+ T-cell clones was restricted to 
CXCR3 and CCR4. In contrast, CD8+ T-cell clones also expressed CCR6, 9 and 10. CCR4 
and CCR10 have been implicated in the migration of T-cells into skin (Xia et al., 2014, Zaid 
et al., 2017); thus, a more detailed investigation of migratory properties of CD4+ and CD8+ 
T-cells in patients with DDS hypersensitivity is warranted.          
In conclusion, our study shows that DDS- and DDS-NO-responsive CD4+ and CD8+ T-cells 
circulate in hypersensitive patients. T-cells were activated selectively with the parent drug 
and drug metabolite via direct HLA binding and a hapten mechanism, respectively. The 
detection of HLA-B*13:01-restricted DDS- and DDS-NO-responsive CD8+ T-cell clones 
indicates that DDS hypersensitivity should be used as an exemplar to explore the structural 
features of drug HLA binding and how this interaction results in an aberrant T-cell response.
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Chapter 4: Investigation of the immunological mechanisms 
relating to tolvaptan-induced liver injury. 
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4.1 Introduction. 
Adverse drug reactions represent an important clinical problem and a major impediment to 
the drug development process (Park et al., 2011a). Drug-induced liver (DILI) is of major 
concern both in the clinic and during drug development. Immunologically-mediated 
reactions are one of the most feared as they are difficult to predict and they show no simple 
dose-response relationship. We have previously undertaken a number of studies to 
demonstrate the presence of drug-responsive T-lymphocytes in blood and skin of patients 
with cutaneous reactions, thus providing direct evidence for their involvement in the disease 
pathogenesis (Castrejon et al., 2010a, El-Ghaiesh et al., 2011, Elsheikh et al., 2011, Nassif 
et al., 2004b, Pichler, 2005, Schnyder et al., 2000, Schnyder et al., 1997, Whitaker et al., 
2011, Wu et al., 2007, Wu et al., 2006). The role of T-cells in reactions targeting the liver is 
less well defined partly because of the lack of appropriate studies. In 1997, Maria and 
Victorino (Maria and Victorino, 1997) described lymphocyte responses to drugs in over 50% 
of patients with a drug-induced liver injury. More recently, histological examination of 
inflamed liver from a patient exposed to sulfasalazine revealed an infiltration of granzyme 
B secreting T-lymphocytes (Mennicke et al., 2009). In recent years, utilizing the 
experimental approach detailed in this proposal, we have detected and fully characterized 
drug-specific T-cells in patients with flucloxacillin, co-amoxiclav, isoniazid, ethanbutol and 
ticlopidine-induced liver injury (Usui et al., 2017b, Usui et al., 2018, Usui et al., 2016, 
Monshi, 2013). 
It is thought that to activate immune cells, a drug must bind to HLA molecules and in some 
way crosslink specific T-cell receptors. The hapten hypothesis, based on the studies of 
Landsteiner and Jacobs relating sensitization potential to protein reactivity states that a 
chemical (drug) must bind covalently to self-protein to break immune tolerance (Landsteiner 
and Jacobs, 1935). It is suggested that T-cells are subsequently stimulated by peptides 
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liberated from the modified protein following antigen processing. Drugs have also been 
shown to associate directly with HLA and/or HLA binding peptides to stimulate a T-cell 
response (Elsheikh et al., 2010, Naisbitt et al., 2003). An improved understanding of drug-
induced liver injury requires an integrated approach that relates drug disposition, drug 
antigenicity, drug immunogenicity, genetics and immune responses to clinical outcome. The 
recently described genetic associations between expression of particular HLA alleles and 
susceptibility to DILI (Chung et al., 2004b, Daly et al., 2009, Mallal et al., 2002) indicate 
that functional studies should be conducted with samples from HLA-typed individuals.  
For immunological drug induce liver injury disease status and host factors represent risk 
factors; however, such factors are often poorly predictive of toxicity. Recently, several strong 
associations between susceptibility to DILI and expression of HLA alleles have been 
identified (e.g., flucloxacillin (Daly et al., 2009), ximelagatran (Kindmark et al., 2008), 
lumiracoxib (Singer et al., 2010), and lapatinib (Spraggs et al., 2011), which imply a direct 
effect of the gene product on the disease pathogenesis. These findings suggest that a major 
susceptibility factor relates to the restriction of the fit of the causative antigen into particular 
immunological receptors in an appropriate chemical form. For certain drugs that cause 
cutaneous reactions (i.e., abacavir, carbamazepine and DDS in this thesis), it has been 
possible to relate the genetic association to mechanisms of disease by characterizing drug-
specific T-cell responses in volunteers carrying the appropriate HLA allele (Chessman et al., 
2008, Ko et al., 2011). In contrast, HLA-restricted T-cell responses in patients with DILI are 
less well described. We have recently shown that flucloxacillin preferentially activates 
cytotoxic CD8+ T-cells from patients with liver injury in an HLA risk allele (i.e., HLA-
B*57:01) restricted fashion (Kim et al., 2015, Monshi Manal et al., 2012). Using cells from 
healthy donors, it is also possible to prime naïve CD8+ T-cells to flucloxacillin with 
autologous dendritic cells expressing HLA-B*57:01 (Monshi et al., 2013b). In contrast to 
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the DILI patient cells that are activated via a hapten mechanism, T-cells from healthy donors 
can be activated via a direct binding interaction with HLA-B*57:01 (Faulkner et al., 2012b). 
Tolvaptan (TVP) an orally effective nonpeptide arginine vasopressin (AVP) V2-receptor 
antagonist is an example of a drug that causes serious liver injury in certain rare patients. 
The delayed nature of the liver injury that has been observed with TVP, the prompt 
recurrence of injury, which is sometimes observed on rechallenge with tolvaptan, and the 
very preliminary HLA associations suggested by genetic analyses already undertaken, 
support the idea that the final and critical event underlying the injury is an adaptive immune 
attack on the liver. Thus, a hypothesis for TVP-induced DILI is that the drug or a derived 
metabolic product(s) forms antigenic determinants with MHC molecules to activate T-cells.  
4.2 Aim of the study. 
 The purpose of this work is to detect, isolate, and characterize T-cells that are 
functionally responsive to tolvaptan-derived antigens from patients with tolvaptan-
induced liver injury. 
 The ultimate ambition is to define the role of T-cells in the aetiology of tolvaptan-
induced liver injury utilizing in vitro T-cell culture methods. 
4.3 Methods. 
4.3.1 Study approval. 
 Toxicity studies were performed utilising TVP, and TVP metabolites DM-4103 and 
DM-4107 on PBMCs from healthy donors obtained in Liverpool. Approval for sample 
collection was acquired from the Liverpool local research ethics committee and 
informed written consent was obtained. 
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 Patient blood samples: PBMC samples from a total of nine TVP-exposed patients who 
displayed signs of hepatic injury were collected from global sites with approval and 
consent obtained by Otsuka Pharmaceuticals. Cryopreserved PBMC were transferred 
to Liverpool for functional analysis.          
4.3.2 Human subjects and cell isolation/separation. 
In this study, we used PBMC samples from a total of 9 tolvaptan-exposed patients who 
displayed signs of hepatic injury. PBMC from each patient were counted and divided for 
various uses (5x106 for EBV-transformed B-cell generation (to act as an immortalised, 
autologous source of antigen presenting cell), minimum of 3.6x106 for the lymphocyte 
transformation test, 3x106 for bulk cultures, excess to be frozen). An LTT was performed 
whereby patient PBMC (1.5x105/well) were cultured for 5 days with a range of drug-antigen 
doses within and up to the limits of the non-toxic dose range established by the previously 
described toxicity assays.  
4.3.3 Medium for T-cell culture and cloning. 
The medium used is described in chapter 2 section 2.2. 
4.3.4 Identifying the drugs optimal dose (Toxicity assay). 
Blood samples were collected from healthy donors, PBMCs were isolated and toxicity 
studies were performed utilising TVP, DM-4103, and DM-4107. PBMCs were exposed to 
each drug over an initially broad dose range, typically 0.01-1000 µM, in which the likely 
toxicity range to the vast majority of drugs can be detected for a PBMC population. After 72 
hrs, PHA was added to non-specifically stimulate the proliferation of T-cells.  
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4.3.5 Lymphocyte Transformation Test (LTT). 
LTT assay was performed on PBMC isolated from TVP DILI patients using an established 
protocol. Briefly, PBMC (1.5x105 cells) were cultured in a 96-well U-bottom cell culture 
plate in triplicate with either TVP or one of the metabolites and incubated at 37°C, 5% CO2 
for 6 days. In this assay tetanus toxoid (TT) 5 μg/mL was used as a positive control while 
culture medium was the negative control. 16 hrs prior to harvesting [3H]-thymidine (0.5 
µCi/well) was added and lymphocyte proliferation was assessed as counts per minute (cpm) 
using scintillation counter (Wallac microbeta trilux, PerkinElmer, Cambridge, UK) (Figure 
4.1). Proliferative responses (counts per minute [cpm]) were converted to a stimulation index 
(SI) representing the cpm in drug treated cultures divided by the cpm in medium control. 
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Figure 4-1 A. Toxicity assay to identify the optimal doses for TVP and the metabolites. PBMCs from 
healthy donors were cultured with a wide range of drug doses for 72 hrs then PHA was added for 24 hrs. [3H]-
Thymidine (0.5 µCi/well) was finally added to the culture plate. 
B: LTT assay. In this test the PBMC isolated from TVP DILI patients were cultured in triplicate with either 
TVP or one of the metabolites. Plates were incubated at 37°C, 5% CO2 for 6 days. In this assay tetanus toxoid 
(TT) 5 μg/mL was used as a positive control while the culture medium was the negative control. 16 hrs prior 
to harvesting [3H]-thymidine (0.5 µCi/well) was added and lymphocyte proliferation was assessed as counts 
per minute (cpm) using scintillation counter. 
 
4.3.6 Generation of EBV-transformed B-cells. 
Epstein-Barr virus transformed B-cell lines were generated from PBMC and used as antigen 
presenting cells in experiments with T-cell clones. The protocol is described in chapter 2 
section 2.3.3. 
4.3.7 Generation of drug-specific T-cell lines and T-cell clones from 
PBMCs isolated from tolvaptan DILI patients. 
T-cell lines were generated by the bulk method described in chapter 2 section 2.3.4. Briefly, 
PBMC (1x106 /mL) were plated into 48 well plates with an optimal concentration of TVP 
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(30 µM), DM-4103 (40 µM), or DM-4107 (150 µM) and incubated for 14 days. Cultures 
were fed with R9 medium supplemented with IL-2 (200 IU/mL) on days 6 and 9. On day 14, 
a sample of these cultures was frozen, while other cells were subject to serial dilution and 
mitogen-driven expansion using previously described methods in chapter 2 section 2.3.4.2. 
T-cell clones were then maintained in medium containing IL-2. IL-2, PHA and irradiated 
allogeneic PBMC were added every 2 weeks to restimulate the clones (Figure 4.2). 
 
Figure 4-2 T-cell cloning from tolvaptan patients. Scheme depicts the sequence for the events starting with 
blood collection, generation of single specific T-cells clones, to specific assays to detect the characteristics of 
the clones.  
 
4.3.8 Initial testing of drug-specific T-cell clones antigen specificity using 
[3H]-thymidine uptake assay. 
After 28 days, picked clones from PBMC treated with TVP, DM-4103 or DM-4107 were 
expanded to approximately 5x104 cells. These clones cultured with TVP (30 µM), DM-4103 
 Chapter Four                                                             Tolvaptan-induced liver injury 
151 
 
(40 µM) or DM-4107 (150 µM) and irradiated EBV-transformed B-cells (1x104 cells/well) 
for 48 hrs in two conditions: one containing drug and the other the negative control 
(medium). 
Proliferation was measured by the addition of [3H]-thymidine for 16 hrs followed by 
scintillation counting. Clones with a stimulation index (SI) (mean cpm drug-treated 
wells/mean cpm in control wells) equal to or higher than 1.5 were expended for further 
analysis. 
4.3.9 Quantitative and Qualitative assessment of the T-cell clones 
displaying reactivity to drugs (dose response and cross-reactivity test). 
 T-cell clones were incubated with irradiated APCs and a range of concentrations of 
TVP (10-30 µM), DM-4103 (10-40 µM) and DM-4107 (50-250 µM) for 48 hrs. 
Proliferation was detected by the addition of [3H]-thymidine. 
 The same proliferation protocol was used for assessment of cross-reactivity. 
However, in this experiment, clones were incubated with TVP and the TVP 
metabolites. The assays contained a negative (medium) and positive (PHA) controls. 
4.3.10 Measurement of cytokine secretion from T-cell clones using 
ELIspot. 
ELIspot analysis for various cytokines was conducted using the protocol described in chapter 
2 section 2.3.9 after clones were cultured with irradiated EBV-transformed B-cells and either 
TVP, DM-4103 or DM-4107. 
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4.3.11 Characterisation of the phenotypic profile of drug-specific T-cell 
clones. 
Flow cytometry was used to detect expression of specific markers on the surface of T-cells. 
Phenotypic profiling of T-cell clones followed the same protocol described in chapter 2 
section 2.3.11.  
4.3.13 Generation of CD8+ T-cells clones. 
Previous experience with other drugs, such as flucloxacillin, have highlighted the importance 
of CD8+ T-cells in the aetiology of drug-induced liver injury, but also the difficulty in 
generating drug-specific CD8+ T-cell clones as they tend to be less abundant than the CD4+ 
population. To try and characterise the CD8+ T-cell response, and focussing on DM-4107 as 
our most promising target to date, we thawed DM-4107 patient 2, 4, 5, 6 bulks and isolated 
the CD8+ T-cell population using a CD8+ magnetic bead separation kit (miltenyi biotec) and 
conducted serial dilution experiments. 
4.4 Results. 
4.4.1. Toxicity test results. 
For all three drugs toxicity was observed (Figure 4.3). A sharp reduction in the proliferative 
response induced by PHA was due to the drug-specific induction of T-cell death. Further, 
toxicity assays were then performed with more limited dose ranges around the proposed 
toxic threshold to provide a more defined safe-dose limit. Tolvaptan and DM-4103 induced 
T-cell death upwards from 40 µM and 50 µM, respectively. DM-4107 was far less toxic, 
only resulting in toxicity from 400 µM.  
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Figure 4-3 Toxicity assay. Healthy donor PBMCs were cultured with drug antigens at varying concentrations 
for 72 hrs. PHA was then added to stimulate PBMC growth prior to measuring cell death using [3H]-thymidine 
incorporation. Cells with medium or non-toxic drug doses should proliferate due to PHA, while toxic doses 
should kill cells and thus have a low proliferative response. 
  
4.4.2 LTT test results. 
For all patients, no significant increase in PBMC proliferation was identified in response to 
TVP, DM-4103, or DM-4107 (Figure 4.4). In contrast, proliferation was observed in 
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response to the addition of tetanus toxoid (TT; positive control). No TT response was 
detected for patient 7. While this could have indicated a lack of viable cells, the lack of TT 
response could also represent a previous lack of exposure to TT through vaccination, which 
is necessary for TT to function as a positive control. Despite our inability to validate the 
viability of the PBMCs isolated from patient 7, we did not remove patient 7 from the study 
and continued to expose PBMCs to drug-antigens in bulk cultures. While for most donors 
we received a more than an adequate number of viable PBMC (12.4-33.6x106), we were only 
able to recover 2x106 PBMC from patient 9. To perform all of our standard cultures we 
require a minimum 12x106, so in order not to waste the sample we created an altered method 
to utilise the smaller sample. For this sample we separated 1x106 PBMC for the LTT 
(6.6x104/well), 1x106 for bulk cultures (3.3x104/well), and 0.5x106 for EBV-transformed B-
cell generation (1x105/well; 96-well U-bottomed plate). 
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Figure 4-4 TVP-derived antigen-induced proliferation of hypersensitive patient PBMCs. Hypersensitive 
patient PBMCs (1.5x105/well) were cultured  for 5 days with non-toxic concentrations of tolvaptan (1-60 µM), 
DM-4103 (5-90 µM), DM-4107 (10-500 µM), or tetanus toxoid (TT; positive control). [3H]-thymidine (0.5 
µCi/well) was added and incubated for 16 hrs. Data presented as radioactive counts per minute (cpm) ± SD of 
triplicate cultures. 
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4.4.3 Generation of drug-specific T-cell clones. 
A handful of clones surpassing the 1.5 stimulation index threshold could be identified 
(Figure 4.5). The majority of which were responsive to TVP-metabolites rather than 
tolvaptan itself. For patients 7 and 9, no clones were found to be responsive to any antigen. 
Patient 7 was the patient whose PBMCs failed to respond to TT in the LTT and thus both 
assays together indicate low cell viability, while patient 9 was the sample that we recovered 
a very low number of PBMC from to begin with and thus the lack of response may be due 
to the lower propensity to discover a low frequency population in a smaller PBMC sample. 
Additionally, this analysis was unable to be performed for Patient 8 as on multiple occasions, 
using fresh vials of frozen PBMCs, cultures to generate EBV-transformed B cells for use in 
antigen-presentation developed infections. We had been made previously aware that there 
had been sampling processing issues for this patient before transport to Liverpool. After three 
failed attempts to generate healthy cell lines we had exhausted the frozen PBMC stock and 
thus were forced to abandon a further investigation of this patient’s response. 
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Figure 4-5 Identification of TVP-derived antigen-responsive T-cell clones from hypersensitive patients. 
T-cell clones (5x104/well) derived from PBMC cultures with tolvaptan-derived antigens were cultured for 48 
hrs with autologous EBV-transformed B-cells (1x104/well) and the antigen to which they were initially exposed 
(TVP, 20 µM; DM-4103, 40 µM; DM-4107, 150 µM) or medium alone (negative control). Cells from all 
patients, apart from patient 8, were subject to duplicate cultures before calculating the stimulation index using 
average proliferative counts (stimulation index = average of drug-treated wells / average of control treated 
wells). 
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4.4.4 Detection of the response of drug-antigen-specific T-cell clones. 
Clones which had been deemed antigen responsive in test 1 and expanded were then subject 
to a more detailed proliferation assay using triplicate cultures to (1) validate the response 
observed in test 1, (2) to determine dose response using multiple antigen concentrations, and 
(3) assess cross-reactivity between TVP-derived antigens. For the majority of test 1-
responsive clones, test 2 did not show a proliferative response to any drug antigen, (patient 
1 figure 4.6), (patient 5 and patient 6 figure 4.7). All clones proliferated strongly in response 
to PHA (positive control) validating the presence of live cells within each culture. For clones 
which had expanded more than others after test 1 restimulation, test 2 was also performed 
using ELIspot to detect secretion of IFN-γ and/or IL-13 in response to antigen. For the 
majority of clones, the secretion of these cytokines was not enhanced by culture with 
tolvaptan-derived antigens but was induced by the presence of PHA (Figure 4.8).  
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Figure 4-6 Antigen-specific proliferation of TVP and TVP metabolites with cross reactivity for each 
drug. The specific clones were cultured with irradiated autologus EBVs transformed B cells with drug (TVP, 
DM-4103 and DM4107) and control condition (without drugs only medium). After culture for 48 hrs in similar 
conditions as before, proliferation was measured by adding [3H]-thymidine (0.5 μCi/well) for a final 16 hrs 
incubation. Data representative donors shows the mean ± SD of triplicate cultures.  
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Figure 4-7 Antigen-specific proliferation for the drug-specific clones from patient 5 and 6. The specific 
clones were cultured with irradiated autologus EBVs transformed B cells with drug (TVP, DM-4103 and 
DM4107) and control condition (without drugs only medium). After culture for 48 hrs in similar conditions as 
before, proliferation was measured by adding [3H]-thymidine (0.5 μCi/well) for a final 16 hrs incubation. Data 
representative donors shows the mean ± SD of triplicate cultures. 
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Figure 4-8 Cytokine secretion assay using T-cell clones derived from TVP patients. ELIspot plates were 
coated with IFN-γ and IL-13 capture antibody and incubated at 4°C overnight. (A) TVP, DM-4103 and DM-
4107 specific T-cell clones (5x104/well; total volume, 200 μL; 96-well ELIspot plate) were cultured with drugs 
and autologous irradiated EBV-transformed B-cells (1x104/well) in an atmosphere of 5% CO2 /37°C for 48 hrs. 
The ELIspot plates were washed and developed in concordance with the manufacturer’s instructions. Images 
and SFU counts were analysed from dry wells using an ELIspot reader.  
 
In contrast, a handful of T-cell clones displayed antigen-specific proliferation and/or 
cytokine secretion. Clone 120, derived from patient 4 bulk cultures with DM-4107 
proliferated in response to DM-4107 (50-150 µM) during tests 1 and 2 (Figure 4.9).  
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Figure 4-9 [3H]-thymidine proliferation assay for DM-4107-specific T-cell clone 120. T-cell clone (no. 
120) was incubated with irradiated autologous EBVs and DM-4107 (50, 100 and 150 µM) in 1st test and the 
doses were increased in the 2nd test (in range from 100- 250 µM) with added two conditions for TVP 30 µM in 
1st test which increased in next one to two doses (20 and 30 µM) and DM-4103 40 µM, in 1st test which 
increased to 20 and 40 µM in 2nd test. The incubation period for 48 hrs. In the last 16 hrs, [3H]-thymidine was 
added which was followed by harvesting and reading plate with beta counter. The clone shows a dose-
dependent response with both of the proliferation tests. (CPM) represents the count per minute. 
 
Although weak cross-reactivity was indicated with both TVP and DM-4103 in test 1, an IL-
13 ELIspot which was simultaneously performed during test 2 clearly indicated strong DM-
4107-specific cytokine secretion, alongside a clear lack of cross-reactivity (Figure 4.10 A 
and B). After restimulation, confirmatory proliferative and cytokine secretion analyses were 
performed for this clone in test 3. DM-4107 (100-250 µM) induced the proliferation of T-
cells, which showed little cross-reactivity to alternate TVP-antigens (Figure 4.10 C). Due to 
the increased expansion of T-cells, a broader panel of cytokines (IL-13, IFN-γ, IL-22) and 
cytolytic molecule (GB; granzyme B) were able to be investigated by ELIspot (Figure 4.10 
C). DM-4107 (100-250 µM) induced the DM-4107-specific secretion of IFN-γ and GB 
alongside IL-13. Cross-reactivity with TVP or DM-4103 was not detected, nor was enhanced 
secretion of IL-22 in response to any TVP-antigen (Figure 4.10 C). 
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Figure 4-10 (A, B and C): DM-4107 clone 120: initially test for IL-13 secretion using ELIspot. IL-13 
secretion in response to both 100 and 200 µM DM4107 was detected with no cross-reactivity to TVP and DM-
4103. After this response, a broader range of cytokines were selected (IFN-γ, IL-22, GB and IL-13 again) and 
the cytolytic molecule granzyme B. DM-4107 exposure resulted in the secretion of IFN-γ, GB and IL-13. 
 Chapter Four                                                             Tolvaptan-induced liver injury 
164 
 
Patient 5 clones 158 and clone 104 which were derived from TVP appeared to show a weak 
response to the parent drug and the metabolites in the proliferation test (Figure 4.11). 
Moreover, clone 104 (but not 158) showed low levels of granzyme B secretion in the 
presence of TVP (Figure 4.13 B). 
Clone 52 from patient 5, derived from DM-4107 bulk cultures, also proliferated in response 
to DM-4107 exposure (100-200 µM) and did not display cross-reactivity (Figure 4.11). 
Unfortunately, restimulation was unsuccessful and we were therefore unable to generate 
further data from these clones.  
 
Figure 4-11 Patient 5 proliferation test for TVP and DM-4107. TVP specific (clone 158 and 104) and DM-
4107 specific clones (5x104/well; 96w plate) were cultured with autologous EBV-transformed B-cells 
(1x104/well) and an antigen for 48 hrs. [3H]-thymidine was then incorporated cultured for a further 16 hrs 
before harvesting for analysis of cellular proliferation. 
 
ELIspot assays were performed for a range of patient 5 clones derived from DM-4107 
cultures that proliferated in test 1 but not in test 2. A handful of clones secreting low levels 
of IFN-γ and IL-13 were identified (Figure 4.12 and Figure 4.13). This indicates that T-cell 
clones responsive to tolvaptan-derived antigens may be more likely to respond by way of 
cytokine secretion than proliferation. It may well be that the threshold of activation for a 
proliferative response is set higher than that of cytokine secretion, and only the most sensitive 
T-cells will mount a proliferative response. 
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Figure 4-12 A. Identification of cytokine secretion from patient 5 T-cell clones. T-cell clones derived from 
DM-4107 bulk cultures that did not display a proliferative response during test 2 were subsequently assessed 
for IFN-γ, IL-13, and granzyme B secretion in response to DM-4107-stimulation (100-200 µM) using ELIspot. 
T-cell clones (5x104/well; 96w plate) were cultured on pre-coated ELIspot plates with autologous EBV-
transformed B-cells (1x104/well) and an antigen for 48 hrs. Convincing secretion above baseline is highlighted 
in red, spot counts are shown for all wells. *TNTC (Too Numerous To Count). Clone phenotype was 
determined by flow cytometry. 
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Figure 4-13 Identification of cytokine secretion from patient 5 T-cell clones. T-cell clones derived from 
TVP and DM-4103 bulk cultures were subsequently assessed for IFN-γ, IL-13, and granzyme B secretion in 
response to TVP (20-30 µM) and DM-4103 (20-40 µM) stimulation using ELIspot. T-cell clones (5x104/well; 
96w plate) were cultured on pre-coated ELIspot plates with autologous EBV-transformed B-cells (1x104/well) 
and an antigen for 48 hrs. Convincing secretion above baseline is highlighted in red, spot counts are shown for 
all wells. Clone phenotype was determined by flow cytometry. 
 
4.4.5 Detection of antigen-specific CD8+ DM-4107 T-cell clones. 
CD8+ T-cell clones were generated from patient 2, 4, 5 and 6 DM-4107 PBMC bulk. The 
vast majority of clones were not stimulated to proliferate with DM-4107 (Figure 4.14). The 
small number of clones displaying DM-4107 proliferative responses in test 1 were expended 
and assessed in dose-response studies using proliferation and cytokines release assays. 
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Figure 4-14 Proliferative stimulation of hypersensitive patient CD8+ T-cell clones, derived from DM-
4107 treated PBMC. PBMCs (1x106/well; 48w plate) were bulk cultured with DM-4107 (150 µM) for 2 weeks 
before magnetic bead separation of CD8+ T-cells. The CD8+ population was then subject to serial dilution and 
mitogen-driven expansion to seed and expand an individual T-cell per well. Individual T-cell clones 
(5x104/well; 96w plate) were cultured with autologous EBV-transformed B-cells (1x104/well) and an antigen 
for 48 hrs. [3H]-thymidine was then incorporated and cells cultured for a further 16 hrs before harvesting for 
analysis of cellular proliferation. Cells were subject to duplicate cultures before calculating the stimulation 
index using average proliferative counts (stimulation index= average of drug treated wells / average of control 
treated wells). 
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High levels of proliferation or cytokine release was not detected in the dose-response studies. 
Representative INF-γ and IL-13 ELIspot data for patient 5 and patient 6 are shown in figure 
4.15. 
  
Figure 4-15 Cytokine secretion from patient 5 and patient 6 T-cell clones. T-cell clones (5x104/well; 96w 
plate) were cultured on pre-coated ELIspot plates with autologous EBV-transformed B-cells (1x104/well) and 
antigen for 48 hrs. In an atmosphere of 5% CO2 / 37°C. The ELIspot plates were washed and developed in 
concordance with the manufacturer’s instructions. Images and SFU counts were analysed from dry wells using 
an ELIspot reader. 
 
However, a small number of clones displayed weak responses to DM-4107. Patient 4 T-cell 
clone 16 secreted IFN-γ after exposure to DM-4107, DM-4103 and the parent drug (Figure 
4.16 A, B). A similar response was observed with patient 5 clone 106 (Figure 4.17 A, B). 
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Figure 4-16 Cytokine secretion (IFN-γ) from the DM-4107-specific CD8+ T-cell clone from patient 4. T-
cell clones (5x104/well; 96w plate) were cultured on pre-coated ELIspot plates with autologous EBV-
transformed B-cells (1x104/well) and antigen for 48 hrs. In an atmosphere of 5% CO2 / 37°C. The ELIspot 
plates were washed and developed in concordance with the manufacturer’s instructions. Images and SFU 
counts were analysed from dry wells using an ELIspot reader. 
 
 
                                        
Figure 4-17 Cytokine secretion (IFN-γ) from the DM-4107-specific CD8+ T-cell clone from patient 5. T-
cell clones (5x104/well; 96w plate) were cultured on pre-coated ELIspot plates with autologous EBV-
transformed B-cells (1x104/well) and antigen for 48 hrs. In an atmosphere of 5% CO2 / 37°C. The ELIspot 
plates were washed and developed in concordance with the manufacturer’s instructions. Images and SFU 
counts were analysed from dry wells using an ELIspot reader. 
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4.5. Discussion. 
Delayed-type drug hypersensitivity reactions are mediated by the activation of drug-
responsive T-cells, which have been isolated from the blood, skin, and reaction-induced 
blister fluid of patients with reactions in the skin. Indeed, the role of T-cells in the 
development of cutaneous drug hypersensitivities are well-defined, however the similar 
characterisation of those that induce liver reactions has been more difficult, partly due to the 
comparative inaccessibility to the diseased tissue. Although the skin is the major organ 
affected by delayed drug hypersensitivity reactions, the liver is the primary internal organ 
targeted by drug-responsive T-cells, responsible for >9% of ADRs (Lazarou et al., 1998). 
For many drugs that induce liver reactions, the onset of toxicity has now been associated 
with the expression of a particular HLA allele (e.g., ximelagatran and HLA-DRB1*07:01 
(Monshi et al., 2013c), and nevirapine and efavirenz with HLA-DRB1*01 (Vitezica et al., 
2008). Further, flucloxacillin-induced liver injury is associated with HLA-B*57:01, which 
although not 100% predictive, narrows the affected population to 1 in 500-1000 individuals 
(Andrews et al., 2010). Importantly, HLA-B*57:01-restricted CD8+ cytotoxic T-cell clones 
have been identified and characterised from the peripheral blood of patients with 
flucloxacillin-induced liver injury (Monshi et al., 2013b) providing the foundation for the 
similar characterisation of T-cells responsive to alternative drugs such as the nonpeptide 
vasopressin V2-receptor antagonist tolvaptan.  
Tolvaptan is used to treat autosomal dominant polycystic kidney disease (AKPKD), the most 
common monogenic kidney disease and fourth leading cause of end-stage kidney disease in 
adults worldwide (Torres, 2018). It represents the first pharmaceutical agent to be approved 
in Europe for delaying the progression of ADPKD in adults with stage 1-3 chronic kidney 
disease (Blair and Keating, 2015). However, alongside a variety of mild adverse events, it is 
associated with idiosyncratic elevations of liver enzymes, which are reversible on 
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discontinuation of the drug. Furthermore, the elevations in liver enzymes progresses to 
potentially fatal liver injury in a minority of patients. Of interest, DILI only occurs within 
the AD-PKD patient group and not others treated for alternative indications including 
cirrhosis, congestive HF, or hyponatraemia, implicating disease pathophysiology in the onset 
of toxicity (Watkins et al., 2015a). However, injury is hypothesised to occur as a result of an 
adaptive immune attack on the liver founded on the basis of a rapid recurrence of reactions 
upon rechallenge, the delayed nature of the initial reaction, and very preliminary associations 
with HLA alleles.  However, T-cells responsive to tolvaptan-derived antigens have yet to be 
identified. Utilising the peripheral blood of nine patients with suspected tolvaptan-induced 
liver injury, we sought to identify and characterise T-cells responsive to tolvaptan, or its two 
major metabolites, DM-4103 and DM4107.  
While the lymphocyte transformation test was performed to characterize tolvaptan-specific 
stimulation of PBMC from patients with liver injury, both drug metabolites (DM-4103, DM-
4107) as well as tolvaptan itself failed to induce a proliferative response. Previous studies 
have shown similar results with drugs associated with T-cell hypersensitivity reactions, 
where the low frequency of drug antigen-specific responder cells within the peripheral 
lymphocyte population equates to an undetectable proliferative response within the relatively 
short term, in vitro culture framework of the lymphocyte transformation test (Monshi et al., 
2013b). After responder T-cell expansion in bulk cultures with antigen for two weeks, we 
were able to identify individual T-cell clones that proliferated and secreted cytokines (IFN-
γ, IL-13) and the cytotoxic marker granzyme B in response to DM-4107. Importantly this 
phenotype indicates that these T-cells are pro-inflammatory and capable of inducing cell 
death through the release of key cytotoxic mediators that may be culpable for damage within 
the liver. Furthermore, and in agreement with the liver-specific targeting of this reaction, 
responsive T-cell clones failed to secrete IL-22 which is thought to be important for the 
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development of cutaneous reactions after release from Th17 and Th22 populations (Eyerich 
et al., 2010, Akdis et al., 2012, Cavani et al., 2012). Initially only CD4+ T-cells were 
identified, likely due to the known superior proliferation of these cells over the CD8+ 
population meaning that when generating clones from bulk cultures, the CD4+ population is 
more readily expanded. Thus, bulk cultures were revisited and the identification of CD8+ T-
cell clones was only achieved after magnetic bead separation of CD8+ T-cells from original 
bulk cultures. In the CD8+ T-cells, responses were more readily detectable using ELISpot 
opposed to analysis of cellular proliferation by [3H]-thymidine incorporation. This again 
corroborates with the reduced likelihood of CD8+ T-cells to proliferate vigorously, when 
their main objective is to kill the target cells through the secretion of inflammatory and 
cytotoxic mediators. Interestingly, the DM-4107-specific response lacked cross-reactivity 
with either DM-4103 or tolvaptan implicating DM-4107 as the immunogenic antigen.  
In this study, for the first time we have been successful in identifying and characterising T-
cell clones responsive to tolvaptan-derived antigens. T-cell clones were responsive to the 
DM-4107 major metabolite and lacked cross-reactivity with the parent drug or other major 
metabolite, DM-4103. However, while well-defined, the metabolism of tolvaptan is 
extensive with the formation of multiple other metabolites and intermediaries. Thus, while 
data from this study identifies the capacity of tolvaptan-derived antigens to activate T-cells 
in patients with associated DILI and provides credence to the original hypothesis that injury 
is due to an adaptive immune response, it will be the interest of future studies to pinpoint the 
exact nature of the immunogenic antigen. 
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Chapter 5: Characterisation of healthy donor-derived T-cell 
responses specific to telaprevir diastereomers. 
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5.1 Introduction. 
Hepatitis C (HCV) is a serious, potentially life-threatening viral infection that affects an 
estimated 71 million individuals worldwide (Organization, 2017). Although up to a quarter 
of infected patients effectively clear the virus (Organization, 2017), the vast majority develop 
chronic HCV infection. The associated inflammation ultimately leads to severe liver disease, 
including hepatocellular carcinoma, liver fibrosis and cirrhosis, due to which hepatitis C is 
the most common indication for liver transplantation in the US (Verna and Brown, 2006b). 
HCV has been traditionally treated with a dual regimen of PEGylated IFN-α and ribavirin 
which provide a sustained antiviral response (<10 IU/mL) in just 39% of patients. In contrast, 
an updated triple treatment regimen including telaprevir (TVR, VX-950), increases the 
frequency of patients that achieve viral control to 70% (Lang, 2007). Telaprevir is an 
NS3/4.A protease inhibitor for use against HCV genotype 1 which prevents both the 
cleavage of viral proteins into active polypeptides for viral assembly, and the deactivation of 
hepatic cellular proteins essential for mediating the interferon cascade and mounting a viral 
response (Jesudian et al., 2012, Morikawa et al., 2011, Smith et al., 2011). While 
administered orally as a single S-configurated diastereomer, telaprevir spontaneously forms 
the corresponding R-diastereomer (Figure 5.1 A, B), which is approximately 30-fold less 
pharmacologically active (Garg et al., 2012). 
Despite enhanced viral suppression, the triple regimen is associated with an increased risk 
of adverse cutaneous reactions, with triple telaprevir-containing therapy causing a severe 
rash in 4.8% of patients compared to just 0.4% with the standard dual therapy. Of more 
concern, a small subset of patients treated with telaprevir develops life-threatening cutaneous 
drug hypersensitivity reactions including drug rash with eosinophilia and systemic 
symptoms (DRESS) and Stevens-Johnson syndrome (SJS) (Pavlos et al., 2012, Roujeau, 
2005, Roujeau et al., 2013a). These clinical diagnoses, alongside the lack of correlation 
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between the severity of telaprevir-induced cutaneous reactions and drug plasma 
concentration, as well as the delayed onset (median 15 days) and slow resolution (median 44 
days) after drug discontinuation, are indicative of a type IV hypersensitivity reaction 
(Roujeau et al., 2013a). Such delayed drug hypersensitivity reactions are thought to be 
mediated by the activation and subsequent cytotoxic action of drug-specific T-cells, which 
have been previously isolated from patients with hypersensitivity to a diverse array of drugs 
(Kim et al., 2015, Lichtenfels et al., 2014, Meng et al., 2017, Usui et al., 2017a). Despite a 
reported correlation between the level of the T-cell-derived cytotoxic mediator granulysin 
release and the severity of telaprevir-induced skin reactions (Suda et al., 2015), telaprevir-
specific T-cells have not been identified. Furthermore, no specific HLA alleles are associated 
with telaprevir-induced skin reactions of any severity.  
To circumnavigate the inability of animal models to predict hypersensitivity, in vitro models 
that utilise T-cells from healthy human donors have been developed that are successful at 
generating and characterising drug-specific T-cells (Bell et al., 2013, Gibson et al., 2017, 
Monshi et al., 2013a, Sullivan et al., 2018). Critically, these assays enable the modulation of 
reported susceptibility factors and the identification of the antigen, whether parent compound 
or metabolic derivative, responsible for the initial, highly-regulated activation of T-cells. 
telaprevir undergoes extensive hepatic metabolism and forms a range of metabolites, 
including M11, which was identified as potentially immunogenic due to the induction of a 
positive guinea-pig maximization test (Figure 5.1C) (Garg et al., 2012). In order to provide 
an understanding of telaprevir immunogenicity, we utilised in vitro peripheral blood 
mononuclear cell (PBMC) drug bulk cultures to assess the propensity for telaprevir-derived 
antigens to activate T-cells isolated from drug-naïve healthy human donors. 
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Figure 5-1 Chemical structures of the (A) S- (therapeutic form) and (B) R-diastereomers of telaprevir 
and (C) the M11 metabolite. 
5.2 Materials and methods. 
5.2.1 Isolation of PBMC from drug-naïve healthy human donors:  
Venous blood samples (120 mL) were taken from seven telaprevir-naïve healthy human 
donors who had provided informed written consent as directed by the Liverpool local 
research ethics committee. A density gradient separation technique was performed to isolate 
the PBMC population from whole venous blood using lymphoprep (Axis-shield, Dundee).  
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5.2.2 PBMC bulk culture. 
PBMCs (1x106/well; 48-well plate; 660 µL total) were cultured for 14 days with either the 
S- or R-diastereomer of telaprevir (5-20 µM), or the M11 metabolite (20 µM). Cultures were 
fed with R9 medium (RPMI 1640, 100 µg/mL penicillin, 100 IU/mL streptomycin, 25 
µg/mL transferrin, 10% human AB serum [Innovative Research], 25 mM HEPES buffer, 2 
mM L-glutamine) supplemented with IL-2 on days 6 and 9. On day 14, cultures for the same 
antigen but of differing concentrations were harvested and pooled. A sample of PBMCs were 
frozen for later use at 10-20x106 cells/mL at 1:1 ratio of R9 medium to 80% human AB 
serum, 20% DMSO (total volume, 1 mL). Cryovials were stored at -80°C for 24-48 hrs 
before transfer to -150°C for longer term storage. Any remaining PBMCs were used for 
functional studies. Briefly, 1x105/well antigen-exposed PBMCs were re-exposed in 
duplicate wells (96-well plate, 200µL total) to either the S- or R-diastereomer of telaprevir 
for 48 hrs (37°C/5% CO2). Antigen re-exposed cultures were then pulsed with [
3H] 
thymidine (0.5 µCi/well) and subject to a further 16 hrs incubation before analysis of 
incorporated radioactivity as a measure of drug-specific proliferation using a Microbeta 
Trilux 1450 LSC beta counter (PerkinElmer, Cambridge, U.K.). 
5.2.2 Serial dilution and T-cell cloning.  
T-cell clones were generated from PBMC bulk cultures using serial dilution and mitogen-
driven expansion (Mauri-Hellweg et al., 1995). Briefly, cells were plated at 1, 3, 0.3 cell/well 
(96 well U-bottomed plate) in a restimulation cocktail (5x104 irradiated allogeneic 
PBMC/well, 10µL/mL PHA, 5µL/mL IL-2) and cultured for 14 days (37°C/5% CO2). 
Cultures were fed on day 5 and then every two days subsequently with R9 medium 
supplemented with IL-2. Additionally, autologous EBV-transformed B-cells (EBV) were 
generated from PBMC to function as an immortalised antigen presenting cell line.  
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To probe for antigen-specificity, expanded T-cell clones (5x104/well; 96 well plate; total 
volume, 200 µL) were cultured (37°C/5% CO2) in duplicate per experimental condition with 
irradiated autologous EBVs (1x104/well) ± the S- or R-diastereomer of telaprevir (10 µM) 
or the M11 metabolite (20 µM). After 48 hrs, [3H] thymidine was added before a further 16 
h culture prior to analysis of cellular proliferation by scintillation counting. T-cell clones 
with a stimulation index (mean cpm drug-treated wells/mean cpm of control wells) of >1.5 
were repetitively stimulated with allogeneic PBMCs (5x104/well; 96 well plate; total 
volume, 200 µL) in R9 medium supplemented with PHA (10 µg/mL) and IL-2 (400 IU/mL) 
for further expansion. 
5.2.3 T-cell clone characterisation assays. 
Those clones that responded to telaprevir-derived antigens in a second confirmatory 
proliferation assay were further expanded and characterised. To define cross-reactivity 
between telaprevir diastereomers and the M11 metabolite, T-cell clones (5x104/well; 96 well 
plate; total volume, 200 µL) were cultured (37°C/5% CO2) in triplicate with autologous 
irradiated EBVs (1x104/well) and either diastereomer (5-20 µM) or M11 (20 µM) for 48 hrs 
prior to proliferative analysis as described above. In order to explore the requirement for 
antigen uptake and processing, EBVs were pulsed with telaprevir for 1-16 hrs. After the 
allotted exposure period, drug-exposed EBVs were washed in PBS and used to restimulate 
cells as above in the absence of soluble drug. Alternatively, to determine whether antigen 
was presented in the context of MHC, EBVs were first pre-cultured with either MHC class 
I or II blocking antibodies or their corresponding isotype controls (5µL; BD Biosciences, 
Oxford, UK) for 30min. MHC blocked EBVs were then washed and included in the 
proliferation assay. 
ELIspot was used to characterise the drug-specific release of specific cytokines and cytolytic 
molecules from T-cell clones. The release of IFN-γ, IL-13, IL-22, and granzyme B in 
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response to telaprevir-derived antigens was visualised by the ELIspot procedure discussed 
in chapter 2 section 2.3.9 (Mabtech, Nacka Strand, Sweden). Flow cytometry was utilised to 
characterise T-cell clone phenotype, including clone CD4+ or CD8+ coreceptor expression, 
to assess the expression profile for a defined chemokine receptor panel (CCR1, CCR2, 
CCR3, CCR4, CCR5, CCR6, CCR8, CCR9, CCR10, E-cadherin, CLA, CXCR3, CXCR6), 
and to determine TCR Vβ protein expression using the IOTest Beta Mark TCR Vβ repertoire 
kit (Immunotech, Beckman Coulter, UK). Briefly, aliquots of T-cells were stained with 
fluorescence-conjugated antibodies before incubation on ice in the dark for 20 min. Cells 
were then washed with PBS and resuspended in 200 µL 10% FBS/PBS prior to data 
acquisition (minimum 5x104 events) using a FACS CANTO II flow cytometer. Data was 
analysed using FACS DIVA or Cyflogic software (CyFlo Ltd., Finland). 
5.3 Results. 
5.3.1 Weak telaprevir-specific proliferative response from healthy donor-
derived T-cell cultures.  
PBMC bulk cultures established with either the S- or R-diastereomer of telaprevir were 
restimulated every 2-3 weeks to promote further expansion of antigen-specific T-cells. 
Cultures with high cell recovery were tested for antigen specificity before being subject to 
serial dilution for T-cell cloning. While responses to the model drug immunogen nitroso 
sulfamethoxazole (SMX-NO) were clearly detectable from PBMC bulk cultures (Figure 5.2) 
in all donors, the majority of cultures exposed to telaprevir diastereomers failed to proliferate 
(Figure 5.2 i and ii; representative donors 1-3). However, T-cells from donor 2 responded 
weakly in response to the R-diastereomer. 
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Figure 5-2 Healthy donor T-cell responses from PBMC bulk cultures with the telaprevir (i) S- 
diastereomer (ii) R-diastereomer (5-20 µM), or (iii) SMX-NO (25-50 µM; model drug-derived 
immunogen). PBMCs (1x106/well; 48-well plate; 660 µL total) were directly cultured with antigen for 14 days 
prior assessment of drug specificity. [3H] thymidine (0.5 µCi/well) was added for the final 16 hrs of the 
incubation and then incorporated radioactivity was measured. Data shown as proliferative stimulation index 
(SI; average of drug-exposed wells/average of control wells). Error bars indicate standard deviation for the 
average of replicate cultures. 
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5.3.2 Identification of CD4+ and CD8+ telaprevir antigen-specific T-cells.  
To explore whether telaprevir-specific T-cells are present below the limit of detection in the 
PBMC assay, T-cell cloning was performed on cells derived from all seven telaprevir-
exposed cultures. Initial testing identified the drug-specific proliferation (SI >1.5) of T-cell 
clones from 3/7 donors (Figure 5.3).  
 
Figure 5-3 Generation of telaprevir-responsive T-cell clones. Telaprevir diastereomer-exposed T-cells from 
PBMC bulk cultures were subject to serial dilution and mitogen-driven expansion. Individual T-cell clones 
(5x104/well; 96 well plate; total volume, 200 µL) were cultured (37°C/5% CO2) in duplicate per experimental 
condition with irradiated autologous EBVs (1x104/well) ± the drug antigen. After 48 hrs, [3H]-thymidine was 
added before a further 16 hrs culture prior to analysis of cellular proliferation by scintillation counting. T-cell 
clones with a stimulation index (mean cpm drug-treated wells/mean cpm of control wells) of >1.5 were selected 
as drug-responsive and subject to further expansion and investigation. 
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After expansion, a further triplicate proliferation culture confirmed the presence of 
telaprevir-responsive T-cell clones. Five and thirty five T-cell clones derived from PBMC 
cultures containing the S- and R-diastereomer respectively remained drug-responsive during 
repetitive mitogen-driven expansions and were used for the mechanistic studies described 
below. 
Irrespective of the antigen used for initial culture, all clones proliferated in the presence of 
either diastereomer to a similar extent at similar concentrations (Figure 5.4). Flow cytometry 
determined that all telaprevir diastereomer-responsive T-cell clones from donor 3 were CD8+ 
T-cells, while a mixed phenotype was observed from the 13 suitable for analysis from donor 
2, with 10 CD4+ (76.9%) and 3 CD8+ (23.1%) T-cell clones identified (Figure 5.5). 
In stark contrast, cloning performed on PBMC bulk cultures with the M11 metabolite from 
three healthy donors failed to identify M11-responsive T-cell clones.  
 
 
 Chapter Five                                                           Telaprevir diastereomers 
183 
 
 
 
Figure 5-4 Cross-reactivity between telaprevir-diastereomers. Drug-responsive T-cell clones (5x104/well; 
96 well plate; total volume, 200 µL) generated from initial cultures with either the R- or S-diastereomers were 
cultured (37°C/5% CO2) in triplicate with autologous irradiated EBV-transformed B-cells (1x104/well) and 
either diastereomer (5-20 µM) for 48 hrs prior to pulsing with [3H]-thymidine (0.5 µCi/well). After a further 
16 hrs incubation, incorporated radioactivity was counted as a measure of proliferation. Data presented as 
radioactive counts per minute (cpm); error bars indicate the standard deviation for the average of triplicate 
cultures. 
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Figure 5-5 Flow cytometry analysis of telaprevir-specific T-cell clones. T-cell clones were generated from 
2 healthy donors and stained with CD4 and CD8 fluorochrome antibodies to determine the phenotype. A. shows 
a dot plot representation of CD8+ telaprevir diastereomer responsive specific T-cell clone phenotypes for donor 
3. B. shows a dot plot representation of CD4+ telaprevir specific T-cell clones phenotypes for donor 3. 
 
5.3.3 Telaprevir-responsive T-cells secrete cytotoxic and pro-
inflammatory mediators. 
 ELIspot was utilized to probe for the telaprevir-induced secretion of cytokines and cytolytic 
molecules from the CD8+ T-cell clones. All clones secreted IFN-γ to a similar degree upon 
exposure to either telaprevir diastereomer (Figure 5.6). Average spot count across 7 clones 
shown: IFN-γ; medium, 81 ± 47.9; 10 µM S-diastereomer, 282 ± 77.4; 10 µM R-
diastereomer, 288 ± 53). Drug-induced secretion of IL-13 and the cytotoxic mediator 
granzyme B was similarly observed. In stark comparison, none of the aforementioned 
mediators were secreted when telaprevir-responsive T-cell clones were exposed to the M11 
metabolite (Figure 5.7 A). The lack of cross-reactivity was further confirmed by a negative 
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proliferative response to the M11 metabolite in these clones (Figure 5.7 B). Secretion of IL-
22 was not detected in response to telaprevir diastereomers, despite its reported involvement 
in inflammatory skin conditions (Figures 5.6 and 5.7). 
 
 
Figure 5-6 Cytokine and cytolytic molecule secretion from telaprevir-responsive T-cell clones. ELIspot 
plates were coated with IFN-γ, IL-13, IL-22, or granzyme B (GB) capture antibody and incubated at 4°C 
overnight. Wells were then washed and blocked with R9 medium. T-cell clones (5x104/well; total volume, 200 
µL, 96-well U-bottomed ELIspot plate) were cultured with the S- (5-10 µM) or R-diastereomer of telaprevir 
and autologous irradiated EBV-transformed B-cells (1x104/well). After a 48 hrs incubation, the plates were 
washed and developed in concordance with the manufacturer’s instructions. Spot forming units (SFU) counts 
were analysed from dry wells using an ELIspot reader.* the red box refers to the wells treated with (5-10 µM) 
S-diastereomer to detect secretion ability for IFN-γ, GB, IL-13, IL-22 respectively.* the black box refers to the 
wells treated with 10 µM R-diastereomer to detect secretion ability for IFN-γ, GB, IL-13, IL-22 respectively. 
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Figure 5-7 The ability of the M11 metabolite to induce (A) cytokine or cytolytic molecule secretion or (B) 
a proliferative response in telaprevir-responsive T-cell clones. ELIspot plates were coated with IFN-γ, IL-
13, IL-22, or granzyme B capture antibody and incubated at 4°C overnight. Wells were then washed and 
blocked with R9 medium.  For both proliferation and ELIspot assays, T-cell clones (5x104/well; total volume, 
200 µL, 96-well plate) were then cultured with telaprevir (10 µM) or the M11 metabolite (20 µM) and 
autologous irradiated EBV-transformed B-cells (1x104/well). After a 48 hrs incubation, the ELIspot plates were 
washed and developed in concordance with the manufacturer’s instructions. SFU counts were analysed from 
dry wells using an ELIspot reader. Alternatively, plates for proliferation analysis were pulsed with [3H] 
thymidine (0.5 µCi/well) and subject to a further 16 hrs incubation before measurement of incorporated 
radioactivity. Data presented as radioactive counts per minute (cpm), error bars indicate the standard deviation 
for the average of triplicate cultures. * The red box refers to the wells treated with (10 µM) S-diastereomer 
(telaprevir)-specific T-cell clones to detect secretion ability for IFN-γ, GB, IL-13, IL-22 respectively.* the 
black box refers to the wells treated with (20 µM) M11 metabolite to detect secretion ability for IFN-G, GB, 
IL-13, IL-22 respectively. 
 Chapter Five                                                           Telaprevir diastereomers 
187 
 
5.3.4 Telaprevir-induced T-cell responses are MHC restricted and occur 
independent of antigen presenting cell processing.  
To assess the presentation of telaprevir to T-cells, telaprevir-specific T-cell clones were first 
cultured with telaprevir-pulsed autologous irradiated EBV-transformed B-cells free of 
soluble drug. While T-cells strongly proliferated in response to the soluble drug, they were 
not stimulated by drug-pulsed antigen presenting cells at either time point (1 or 16 hrs; Figure 
5.8 A). Further investigation using HLA blocking antibodies focussed on the requirement 
for HLA in the activation of T-cells. The telaprevir-induced CD8+ T-cell proliferative 
response was diminished by blocking HLA class I molecules (Figure 5.8 B), but not the 
corresponding isotype control. These data indicate that telaprevir is directly presented on 
HLA class I molecules to passing CD8+ T-cells, without a need for antigen uptake and 
processing. 
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Figure 5-8 Requirement for (A) antigen uptake and (B) HLA alleles for T-cell activation. Autologous 
EBV were either (A) pulsed with the soluble drug for 1-16 hrs prior to washing to remove free drug, or (B) 
cultured with HLA blocking antibodies or their respective isotype controls for 30 min. T-cell clones 
(5x104/well; total volume, 200 µL, 96-well plate) were then cultured with telaprevir(S-diastereomer) (10-
20µM) and pre-conditioned autologous irradiated EBV-transformed B-cells (1x104/well). After a 48 hrs 
incubation, cultures were pulsed with [3H]-thymidine (0.5 µCi/well) and subject to a further 16 hrs incubation 
before measurement of incorporated radioactivity. Data presented as radioactive counts per minute (cpm), error 
bars indicate the standard deviation for the average of triplicate cultures. 
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5.3.5 Telaprevir responsive T-cells express distinct TCR Vβ and 
chemokine receptors.  
To induce keratinocyte death, telaprevir-responsive T-cells must express specific homing 
receptors to promote migration to the skin. The expression of a diverse array of tissue-
homing chemokine receptors was analysed on the drug-responsive T-cell clones, which 
expressed the T-cell activation marker CD69. Of the 13 migratory markers assessed, 
telaprevir-responsive T-cells most highly expressed CCR4 (skin homing; mean fluorescence 
intensity [MFI]: 3.40 ± 1.04) and CXCR3 (migration to peripheral tissue; MFI: 3.16 ± 1.52). 
Further T-cell surface expression analysis revealed a restricted pattern of TCR-Vβ 
expression, in which there was a high expression of TCR-Vβ 22 (n=6, 46%), with fewer 
clones expressing TCR-Vβ 2 (n=5, 38%) and TCR-Vβ 5.1 (n=1, 8%). Of note, one clone 
expressed no identifiable TCR Vβ covered by the kit, which recognises 24 specificities that 
account for 70% of the total repertoire. Thus, it is likely this T-cell clone expressed another 
alternative rare TCR-Vβ (Figure 5.9). 
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Figure 5-9 TCR Vβ and chemokine profile of telaprevir-responsive T-cell clones. T-cell clones (5x104) 
were washed and stained with (A) individual Fluorochrome-conjugated antibodies specific for chemokine 
receptors or (B) combined Fluorochrome-conjugated antibodies specific for TCR Vβ specificities. Samples 
were left in the dark for 20 min at 4°C to aid antibody binding. After which samples were washed to remove 
unbound antibody and fixed in 4% PFA prior to analysis using a BD FACS CANTO II flow cytometer. Data 
analysis was performed using cyflogic software. 
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5.4 Discussion. 
As the acute stage of HCV is largely asymptomatic, the majority of patients develop a 
chronic infection that leads to long term, life threatening liver complications. An adaptation 
of the standardised dual therapy, by co-administration of telaprevir, led to >30% increase in 
therapeutic response rate. However, telaprevir also enhanced the incidence of mild skin 
reactions and led to a number of patients developing life threatening hypersensitivity 
reactions including DRESS and SJS. The appearance of new drugs with improved safety 
profile resulted in telaprevir being withdrawn from the market. 
Drug-specific T-cells have been isolated from the blood and blister fluid of patients with 
other forms of severe hypersensitivity reaction, and these T-cells are thought to mediate 
tissue destruction. However, as yet telaprevir-responsive T-cells have not been identified. 
While samples from hypersensitive patients are informative for clinical diagnosis (as 
detected in chapter 3 with dapsone), they represent a memory T-cell response and give no 
indication regarding the ability of the antigen to activate the more highly regulated naïve 
population. Thus, using PBMC drug bulk cultures we probed the immunogenicity of the 
telaprevir S- and R-diastereomers. 
Telaprevir-responsive T-cell clones were generated from 3 out of 7 healthy volunteers; 
however, the frequency of identifiable drug-responsive T-cell clones was low. Although 
administered as the S-diastereomer, telaprevir spontaneously converts to the R-diastereomer 
in vivo. A study on Japanese HCV patients showed that the mean Cmax for telaprevir was 5.4 
µM at steady state (Yamada et al., 2012), where maximal plasma concentrations of the R-
diastereomer were almost equivalent to those of the S-diastereomer (Nakada et al., 2014). In 
our study, T-cell clones were derived from PBMC cultured with both the S- and R-
diastereomer. In contrast to the diastereomer-specific actions of telaprevir at its 
pharmacological target, the hepatitis C viral enzyme NS3/4A serine protease, a high degree 
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of T-cell cross reactivity was observed with both diastereomers. In fact, the same 
concentrations of S- and R-diastereomer were capable of inducing proliferate responses to a 
similar degree. While these data imply the parent compound is responsible for T-cell 
activation, the formation of a metabolite after internalisation by antigen presenting cells and 
subsequent presentation on HLA to passing T-cells is a possibility. One potentially 
immunogenic metabolite is M11, as it has previously been reported to induce a positive T-
cell response in experimental animals. Telaprevir-responsive T-cell clones failed to respond 
to M11, and moreover, cloning directly using the M11 metabolite was unsuccessful in 3 
donors, including the donors who provided the most clones responsive towards the parent 
compound. While this inter-species differential response may relate to the small number of 
animals or humans tested between the two studies, it nonetheless stresses the importance of 
assessing antigenicity and immunogenicity using human models.  
Telaprevir is a reversible covalent binding inhibitor of its pharmacological target. The drug 
interacts with a high degree of specificity with serine in position 139, which resides in the 
catalytic area of the protease enzyme. Dissociation of the covalently bound drug has a half-
life of 58 min (Fowell and Nash, 2010a). 
To investigate whether the telaprevir-responsive T-cells were activated through the 
formation of protein adducts by a hapten mechanism or through direct HLA binding, antigen 
presenting cell pulsing experiments were conducted. Haptenic drugs bind irreversibly to 
antigen presenting cells in the pulsing assay and stimulate T-cells after repeated washing to 
remove the non-covalently-bound drug. In contrast, drugs that bind directly to HLA through 
a reversible bond yield a negative result (Alzahrani et al., 2017b, Castrejon et al., 2010a, 
Schnyder et al., 2000). While the telaprevir-specific T-cell response was MHC restricted, the 
T-cells were only activated in the presence of the soluble drug, highlighting that formation 
of a covalent adduct, antigen-uptake and processing by antigen presenting cells is not a 
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requirement for T-cell activation. These data indicate that telaprevir may be able to activate 
T-cells expressing distinct TCR Vβs via a direct HLA binding interaction. Interestingly, 
telaprevir is relatively large, with a molecular weight of 680 Da. This equates to the over 
50% of the mass of a typical HLA class I binding peptide (assuming an average amino acid 
mass of 130 Da and 9-10 amino acids in the peptide sequence). Thus, it will be intriguing to 
discover the structure of the telaprevir HLA peptide binding interaction. It seems unlikely 
that telaprevir will fit into a binding pocket under an HLA binding peptide. The only other 
possibilities are that telaprevir (1) interacts with the HLA binding peptide and projects from 
the HLA molecule, (2) replaces the requirement for an HLA binding peptide and (3) binds 
elsewhere on the HLA molecule altering the structure of the HLA binding cleft. 
CD8+ T-cells are designed to inflict damage and thus are the most likely mediators of 
keratinocyte death in patients with telaprevir hypersensitivity. Thus, CD8+ T-cells were 
analysed for their cytokine secretion profile and the secretion of cytolytic molecules using 
ELIspot. Previously, Suda et al reported a correlation between the level of the cytotoxic 
mediator granulysin and the severity of telaprevir-induced skin reactions. Moreover, they 
describe an early rise in serum granulysin levels with the onset of severe symptoms which 
fades within 6 days and therefore concluded that granulysin can be utilized as an early 
predictive marker for telaprevir-induced skin reactions (Suda et al., 2015). In agreement with 
the induction of a cytotoxic response, telaprevir-responsive CD8+ T-cell clones not only 
secreted IFN-γ and IL-13, but also the cytotoxic mediator granzyme B in response to culture 
with either diastereomer. Upon release from cytotoxic T-cell granules, granzyme B enters 
target tissue to cleave caspases and initiate apoptosis. The secretion of IL-22 was additionally 
monitored due to its proposed role in inflammatory skin conditions, including psoriasis. 
Furthermore, IL-22-secreting cells have been identified in patients with allergic contact 
dermatitis and β-lactam hypersensitivity reactions (Akdis et al., 2012, Cavani et al., 2012, 
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Eyerich et al., 2010, Sullivan et al., 2018). IL-22 was not secreted by telaprevir-responsive 
T-cells in this study. 
Chemokine receptor pattern analysis on telaprevir-responsive T-cell clones detected a 
population with a skin-homing phenotype. While the skin homing receptor CCR10 was 
present, CCR4 and CXCR3 were also highly expressed. CXCR3 is predominantly expressed 
by Th1 T-cells while CCR4 is expressed by Th2 T-cells (Kim et al., 2001a). These findings, 
along with the antigen-specific secretion of IFN-γ (Th1) and IL-13 (Th2), suggest the 
presence of a mixed Th1/2 T-cell population. CCR9, characterised as a gut homing receptor 
for T-cells with a role in intestinal inflammation (Agace, 2008, Bekker et al., 2015), was also 
relatively highly expressed in comparison to other chemokine receptors. Interestingly, 
adverse intestinal effects with telaprevir hypersensitivity is very common ranging from 
diarrhoea to haemorrhoids in 25% and 12% of patients, respectively. As yet, the underlying 
mechanism of intestinal disruption is not defined, but this data indicates the migration of T-
cells may play a role. 
This study identifies and characterises the telaprevir-induced activation of T-cells from 3 out 
of 7 healthy drug-naïve donors that develop into skin-homing, cytotoxic T-cells, which are 
activated by an HLA-restricted, but processing-independent mechanism. Drug-specific T-
cells responded to either telaprevir diastereomer and expressed varied TCRs. Drug-
responsive T-cells were induced using cultures from drug-naïve healthy donors and so define 
the utility of in vitro human platforms to explore the requirements for T-cell activation. As 
studies have previously failed to associate telaprevir hypersensitivity with HLA risk alleles 
(Roujeau et al., 2013b), the development of in vitro human assays to allow (a) modulation 
of other immune parameters and (b) inclusion of autologous keratinocytes will be key to 
understand the inter-individual skin-specific targeting by the immune system
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1.6 General Discussion. 
Drugs are critical for the treatment and prevention of diseases in modern medicine, but they 
can also cause significant unwanted adverse drug reactions. Adverse drug reactions 
contribute toward increased hospitalization and are a major burden on health care services 
throughout the world. Many reactions are self-limiting through drug withdrawal or a dose 
reduction. However, a small number of adverse drug reactions develop into life-threatening 
conditions. The majority of these are thought to involve the adaptive immune system; 
however, the mechanisms of drug-specific immune cell activation and factors that determine 
individual susceptibility are not well defined. Since the disease pathogenesis is not defined, 
it has not been possible to generate sensitive and specific assays for use by industry to predict 
intrinsic immunogenicity of new chemical entities or the National Health Service to diagnose 
culprit drugs in patients with reactions.  
Adverse reactions that involve the drug-specific activation of the adaptive immune system 
are often referred to as hypersensitivity or allergy. The onset of clinical symptoms may 
involve the production of antibodies by B-cells; however, the most severe and most 
unpredictable involve T-cells. Many forms of T-cell-mediated drug hypersensitivity reaction 
targeting skin, liver and blood have been shown to develop more frequently in individuals 
expressing a single HLA class I or class II allele (Daly and Day, 2012, Pirmohamed et al., 
2015, Redwood et al., 2018). These data suggest that the protein encoded by the HLA allele 
is directly involved in presenting the drug antigen to the T-cells that bring about the clinical 
symptoms of the hypersensitivity reaction. Drugs can interact directly with HLA alleles via 
a reversible pharmacological interaction to promote T-cell activation (Pichler et al., 2011). 
The drug abacavir interacts with HLA B*57:01 deep within the peptide binding cleft (Illing 
et al., 2012, Ostrov et al., 2012). Abacavir binding alters the peptide repertoire displayed on 
the surface of antigen presenting cells by HLA-B*57:01. It has been proposed that these 
Chapter six                                                                                         General Discussion  
197 
 
altered peptide sequences are responsible for CD8+ T-cell activation in patients with abacavir 
hypersensitivity; however, the nature of the peptides that stimulate the T-cell response are 
yet to be defined. For other drug reactions associated with expression of a specific HLA 
allele, the nature of the drug HLA binding interaction is less well defined. Drugs such as 
allopurinol and carbamazepine are thought to bind directly to the linked HLA molecules 
(Yun et al., 2014, Wei et al., 2012). The binding could take place in the peptide binding cleft 
similar to abacavir; however, it is also feasible that the drugs interact with HLA bound 
peptides above the binding cleft or the HLA molecule itself at a site distal to the peptide 
binding interaction. Other drugs such as flucloxacillin and amoxicillin do not interact directly 
with HLA molecules expressed by patients with drug-induced liver injury (Monshi et al., 
2013b, Yaseen et al., 2015, Kim et al., 2015). Instead, the drugs bind covalently to non-HLA 
associated protein generating neo-epitopes. These modified proteins are naturally processed 
by antigen presenting cells. This liberates HLA binding peptides that contain the drug moiety 
bound to specific amino acid residues. Although the nature of the naturally eluted drug-
modified peptides that activate T-cells has not been defined, synthesis of designer drug 
modified peptides containing amino acids that interact with specific HLA molecules has 
shown that patient T-cells display specificity for the peptide sequence and the drug molecule 
bound to specific locations in the peptide sequence (Padovan et al., 1996). Importantly, to 
date, studies have not been conducted to define the binding interaction of reactive drug 
metabolites with HLA molecules linked to specific forms of drug hypersensitivity. Thus, the 
aim of this thesis was to focus on three forms of drug hypersensitivity to explore (1) the role 
of drug-specific T-cells and (2) the nature of the drug HLA binding interaction that leads to 
T-cell activation. Telaprevir and tolvaptan have recently been associated with skin and liver 
reactions with a delayed onset (Fowell and Nash, 2010b, Watkins et al., 2015b). Specific 
HLA alleles are not linked to telaprevir reactions (Roujeau et al., 2013b), whereas genetic 
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studies to explore the association between expression of HLA alleles and development of 
tolvaptan-induced liver injury have not been performed. Furthermore, with both reactions, 
the role of the adaptive immune system in the disease pathogenesis has not been defined. 
Dapsone is an older drug that has been associated with severe skin and liver reactions for 
many years. Recently the development of dapsone-induced DRESS in patients of Chinese 
ancestry was found to be strongly associated with expression of the class I HLA allele 
B*13:01 (Zhang et al., 2013). Dapsone is metabolized to a hydroxylamine intermediate that 
undergoes spontaneous oxidation to generate nitroso dapsone. Nitroso dapsone is highly 
reactive and binds covalently to cysteine residues on proteins (Vyas et al., 2006b, Vyas et 
al., 2006c). Before arriving for my PhD studies, researchers in Liverpool synthesized nitroso 
dapsone in a stable form (Alzahrani et al., 2017a). This allowed an assessment of the 
immunogenicity of dapsone and nitroso dapsone in patients that developed DRESS.  
For the dapsone project we collaborated with the authors of the original genetic association 
study to recruit HLA-B*13:01+ patients with dapsone-mediated DRESS syndrome. Patient 
PBMC were activated with the parent drug and the nitroso metabolite. These data provided 
the framework to clone T-cells to characterize the cellular pathophysiology of the reaction, 
to explore the nature of the antigen that activated T-cells and to define crossreactivity with 
the parent drug, metabolites and closely related structures. Dapsone and nitroso dapsone 
activated CD4+ and CD8+ T-cells that secreted a similar panel of cytokines. Three patterns 
of reactivity were detected with dapsone- and nitroso dapsone-responsive clones. Certain 
clones were highly specific and were only activated with one compound the drug or 
metabolite. Others displayed high and low levels of cross reactivity. Activation of the clones 
with the parent drug occurred in an HLA-restricted manner through a direct binding of the 
drug with HLA and the T-cell receptor. In contrast, clones displaying reactivity against the 
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nitroso metabolite were activated via a hapten mechanism involving the formation of a drug 
protein adduct.  
Through the generation of a panel of antigen presenting cells expressing defined, but 
differing HLA B alleles we demonstrated that the drug and drug metabolite antigen could 
interact selectively with HLA-B*13:01, the HLA allele identified in the genetic association 
studies, to stimulate certain CD8+ T-cell clones. These data provide the framework for future 
studies to identify the nature of the drug and drug metabolite binding interaction with HLA-
B*13:01. In ongoing experiments, designer HLA-B*13:01 binding peptides containing 
modifiable cysteine residues are being synthesized and cultured with nitroso dapsone to 
generate adducts. These will be then assessed for their ability to activate patient T-cells. 
Alongside these experiments, peptides naturally eluted from dapsone- and nitroso dapsone-
treated antigen presenting cells are being assessed by mass spectrometry to identify 
drug(metabolite)-induced changes in the immunopeptidome and the nature of drug-modified 
HLA B*13:01 binding peptides. We are working alongside collaborators in China, America 
and Australia to attempt to solve the X-ray crystal structure of nitroso dapsone-modified 
peptides associated with HLA-B*13:01 and specific T-cell receptors. Scheme 6.1 shows the 
study plan and the team of investigators assembled to meet the study objectives.     
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To recruit patients with tolvaptan-induced liver injury, we collaborated with Otsuka 
Pharmaceuticals, who market the drug. Patients from Asia, America and Europe were 
identified and recruited to the study. Blood samples were isolated and viable PBMC 
cryopreserved at various clinical centres for Liverpool to explore whether tolvaptan or the 
major metabolites of tolvaptan activate T-cells. In contrast to the patients with dapsone-
induced DRESS, PBMC from patients with tolvaptan-induced liver injury were not 
stimulated to proliferate with tolvaptan or its metabolite. Despite this, cloning experiments 
were conducted by serial dilution of drug-treated PBMC and repetitive mitogen-driven 
expansion. On initial testing for drug- or drug metabolite-specific proliferation, a small 
number of responsive clones were detected. These clones were expanded further so that each 
clone could be assessed for proliferative responses and cytokine secretion after drug 
stimulation. The majority of clones yielded negative results in both proliferation and 
cytokine release assays on repeated testing. However, a small number of clones displayed 
CDSS
Clinical  
diagnosis & 
phenotype
Synthesis and 
testing of 
drug-modified 
peptides
Structural 
analysis of 
dapsone-
peptide MHC-
TCR binding
Immuno-
peptidomics
CD4+ & CD8+ 
clones to 
define HLA 
allele 
restriction
David Ostrov
Florida, 
USA
Furen Zhang
Shandong, China
Control
Clone 91: activated with peptide 
modified in position 2
IL13 
Elispot
Unmodified 
peptide
Modified 
peptide
S
e
q
u
e
n
ce AX
A A A A A EE L FA IKAc
Tony Purcell
Monash,
Australia
Characterization of designer & naturally processed drug-modified peptides to 
ascertain those structures responsible for eliciting T-cell reactions.
A Q D A C E A A L
DAP
HLA-B*13:01 Anchors
Dapsone
Modification
Naisbitt
team
Clinical  
diagnosis & 
phenotype
Synthesis and 
testing of 
drug-modified 
peptides
Structural 
analysis of 
dapsone-
peptide MHC-
TCR binding
Immuno-
peptidomics
CD4+ & CD8+ 
clones to 
define HLA 
allele 
restriction
Chapter six                                                                                         General Discussion  
201 
 
concentration-dependent responses, mainly in the presence of the tolvaptan metabolite DM-
4107. It was difficult to expand these clones in great numbers, thus, it was impossible to 
perform a detailed analysis of cellular phenotype or function. Thus, in a new project initiated 
after completion of the patient study, large numbers of tolvaptan antigen-responsive T-cell 
clones have been generated from drug-naïve healthy donors after regulatory T-cells were 
removed. The vast majority of these clones were responsive to DM-4107 and not the parent 
drug. The reason why it was so difficult to clone T-cells from patients with tolvaptan-induced 
liver injury is not clear. It may be that the frequency of drug-specific T-cells that circulate in 
the periphery of patients is very low. However, it could also relate the fact that the PBMC 
were isolated and cryopreserved in several different countries. Although cells from most 
patients retained adequate viability, it is possible that they were functionally impaired.    
Telaprevir, a drug developed for use in combination with pegylated interferon and ribavirin 
to treat Hepatitis C, was the final study drug. Telaprevir increases the incidence of cutaneous 
reactions seen in patients when compared with pegylated interferon and ribavirin treatment 
alone. Moreover, several cases of Stevens Johnson syndrome were observed in patients 
receiving the triple therapy. The appearance of the severe cutaneous reactions and the 
development of newer equally efficacious drugs eventually lead to the withdrawal of 
telaprevir. As patients with telaprevir-induced skin reactions were not readily available, 
PBMC from healthy drug-naïve donors were used to explore the telaprevir immunogenicity. 
This was possible as telaprevir reactions are not associated with expression of a specific 
HLA allele (Roujeau et al., 2013b). T-cells cloned from the peripheral blood of certain 
donors displayed reactivity against telaprevir. As telaprevir exists in different isomeric 
forms, with only one form showing pharmacological activity, PBMC were cultured with 
both isomers of the drug to generate clones. Clones displaying reactivity against both isomers 
were detected and importantly all responsive clones were stimulated to proliferate and 
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secrete cytokines to a similar extent with the same concentrations of the isomers. 
Mechanistic studies revealed that telaprevir and its alternative isomer interacts directly with 
HLA molecules to stimulate the clones. These data highlight an important difference in the 
binding interaction of telaprevir with its desired pharmacological and unwanted 
immunological target. If PBMC from patients were available it would be interesting to see 
whether our findings are replicated and whether the phenotype of drugs-specific T-cells are 
the same or different. 
To conclude, the data presented in this thesis shows that drug-specific T-cells participate in 
hypersensitivity reactions that target skin and liver. Furthermore, it is possible to utilize 
PBMC from healthy donors to model the T-cell responses that develop in patients. In the 
long term these mechanistic studies should feed into attempts to develop predictive T-cells 
assays for industry to predict immunogenicity of new chemical entities and diagnostic T-cell 
assays to improve management of hypersensitive patients.     
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